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Abstract 
Background: The American Heart Association (AHA) and the American Diabetes 
Association (ADA) recommend at least two servings of oily fish a week to promote 
cardiovascular health.  Oily fish is rich in the long-chain omega-3 polyunsaturated fatty 
acids (PUFAs) docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA).  These, 
along with the vegetable-derived omega-3 PUFA alpha-linolenic acid (ALA), play major 
roles in normal physiological processes.  The aim of this dissertation was to consider 
associations of fish, fish-derived omega-3 PUFAs DHA and EPA, and vegetable-derived 
omega-3 PUFA ALA with cardiovascular and glycemia outcomes, presented in three 
related manuscripts. 
Methods: All analyses utilized data from the Atherosclerosis Risk in Communities (ARIC) 
Study, a multi-center prospective study designed to investigate the etiology and natural 
history of cardiovascular disease.  There have been five visits: the baseline in 1987–89 
(visit 1) and four follow-up visits in 1990–92, 1993–95, 1996–98 and 2011–13.  Data 
from visits 1 through 4 were used in this dissertation.  Dietary data were collected at 
visits 1 and 3 via food frequency questionnaire (FFQ).  Paper 1: We studied the 
association of consumption of seafood, EPA, DHA, and ALA with fasting blood glucose 
(FBG) (n=13,173), HbA1c (n=11,575), and incident type 2 diabetes (T2D) (n=11,874).  
FBG and HbA1c were obtained using blood samples collected during study visits and 
diabetes status was identified through self-report and lab values.  To estimate 
differences across exposure categories, linear regression was used for continuous 
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outcomes (FBG, HbA1c), adjusting for repeated measures as appropriate; Cox 
proportional hazards regression with time varying covariates was used for the incident 
T2D outcome. Paper 2: We studied the association of consumption of seafood, EPA, 
DHA, and ALA with J-point height and heart rate-corrected (QTc) interval (n = 12,611). 
QTc interval and J-point height were measured using ECGs obtained during study visits.  
To estimate differences across exposure categories, generalized estimating equations 
were used to estimate odds ratios of prolonged QTc and J-point elevation and 
differences in continuous measures of QTc interval and J-point height.  Paper 3: One 
ARIC field center collected plasma biomarker values from participants at visit 1, and 
these data were used to augment self-report dietary data obtained via FFQ.  We 
imputed biomarker values for other participants using multiple imputation for chained 
equations and investigated the associations of plasma phospholipid measures of ALA, 
DHA, and EPA with prolonged QTc, HbA1c, and incident T2D. 
Results: Paper 1: In multivariable analyses, intake of seafood and DHA+EPA was 
favorably associated with FBG and HbA1c in non-diabetic participants, although the 
magnitude of the associations was small.  ALA was not associated with FBG or HbA1c in 
non-diabetic participants.  Among diabetic participants, intake of seafood, DHA+EPA, 
and ALA were adversely associated with FBG and HbA1c, with differential effects for 
seafood by sex and race.  Finally, higher intake of ALA was associated with higher risk of 
incident T2D in normoglycemics, while seafood and DHA+EPA were not.  Paper 2:  
Higher intakes of ALA+DHA+EPA and ALA were associated with a shorter QTc interval.  
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None of the exposures were associated with prolonged QTc, J-point elevation, or J-point 
height.  Paper 3:  In the full cohort (imputed) and the Minnesota (observed) populations, 
none of the exposures was significantly associated with prolonged QTc, HbA1c, or 
incident T2D.  Point estimates in both populations were similar across different 
covariate adjustments, and confidence intervals were narrower in the full cohort 
population than in the observed plasma population. 
Conclusions: Considering the dietary recommendations of the ADA and AHA, this 
dissertation examined the associations of dietary omega-3 PUFAs with cardiovascular 
and glycemia outcomes while also considering the implications of measurement error in 
the exposure of interest.  Taken together, these results suggest that consumption of 
omega-3 PUFAs are not associated with certain cardiovascular outcomes in healthy 
individuals, and may be associated with deleterious glucose homeostasis in those with 
diabetes. 
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1 BACKGROUND 
1.1 INTRODUCTION 
Cardiovascular disease (CVD) is a major public health problem. The American 
Heart Association (AHA) estimates that, in 2014, more than 30% of all deaths in the 
United States were due to CVD [1]. Similarly, diabetes, a major risk factor for CVD, is 
highly prevalent, with approximately 9% of the adult population being diagnosed with 
this condition [1]. Lifestyle factors constitute an important component of preventive 
strategies to improve cardiovascular health in the population – key among those factors 
is diet [1, 2]. 
Fish consumption has been frequently included in dietary guidelines for the 
prevention of CVD and its risk factors. Both the AHA and the American Diabetes 
Association (ADA) recommend at least two servings of oily fish a week to promote 
cardiovascular health [3, 4].  Oily fish is rich in the long-chain omega-3 polyunsaturated 
fatty acids (PUFAs) docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA).  
These, along with the vegetable-derived omega-3 PUFA alpha-linolenic acid (ALA), play 
major roles in normal physiological processes [5].   
With respect to studies considering nutrient intakes and CVD outcomes, few 
nutrients have been studied more than omega-3 PUFAs [6]. Consumption of fish and the 
fish-derived omega-3 PUFAs DHA and EPA has been associated with lower risk of 
coronary heart disease (CHD) mortality [6-8], particularly sudden cardiac death (SCD) [6, 
9].  Additionally, intake has been found to be associated with decreased levels of 
triglycerides in both non-diabetics [10-12] and persons with type 2 diabetes (T2D) [13-
15] – a finding of great importance given the propensity for elevated triglycerides in 
those with T2D. 
Even with all this evidence, the scientific picture is far from complete.  For 
example, many different studies have evaluated the association between omega-3 
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PUFAs and measures of glucose metabolism, as a major cardiovascular risk factor, but 
their results have been mixed. 
Additionally, there is scant literature regarding the mechanism by which omega-
3 PUFAs could prevent SCD. 
Thus, the existing recommendations from two large professional health 
associations to “eat more oily fish” and the existing gaps in the literature mentioned in 
the prior paragraph motivated the following three questions: 
1. Given that the ADA recommends intake of oily fish, what is the 
association between dietary intake of DHA, EPA, and ALA and various 
measures of glucose metabolism? 
2. Given that fish-derived omega-3 PUFAs are associated with lower 
incidence of SCD, can the association be elucidated by showing DHA, EPA 
and/or ALA are associated with electrocardiographic predictors of SCD? 
3. Since assessment of dietary exposures is subject to measurement error, 
does calibrating reported omega-3 PUFA exposure values using 
measurement error correction techniques alter the associations observed 
in questions 1 and 2? 
The rest of the background section will provide greater detail on the following: 
(1) the omega-3 PUFAs DHA, EPA, and ALA; (2) the physiological effects of omega-3 
PUFAs; (3) description of disorders of glucose metabolism; (4) description of SCD and 
electrocardiogram (ECG) predictors of SCD; (6) literature on the relationship between 
omega-3 PUFAs and CVD – specifically glucose metabolism and ECG predictors of SCD; 
and (7) how dietary measurement error can affect measures of association for 
outcomes where dietary data are used as the exposures (e.g., omega-3 PUFAs).  
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1.2 TYPES OF OMEGA-3 POLYUNSATURATED FATTY ACIDS 
The three types of long-chain omega-3 PUFAs most abundant in our diet and 
commonly described in epidemiological literature are ALA, EPA, and DHA.  Those PUFAs 
along with the EPA metabolite docosapentaenoic acid (DPA) can be seen in Figure 1-1.  
 
Figure 1-1. Structure of Omega-3 PUFAs. Adapted from Mozaffarian and Wu. [6] 
ALA is a plant-derived omega-3 PUFA while DHA and EPA are fish-derived.  ALA is 
an essential fatty acid – that is, the body cannot synthesize it – and dietary sources 
include flaxseed oil and walnuts. Biochemical pathways exist that allow for the 
conversion of ALA to EPA and ALA to DHA, however these metabolic conversions 
contribute very little to the body’s concentration of these fatty acids [5]. Only 0.2-0.8% 
of ALA is converted to EPA and 0-4% of ALA is converted to DHA.  Thus the primary 
dietary source of DHA and EPA are fish and shellfish [6]. Oily fish like sardines, 
swordfish, anchovies and salmon provide the richest concentration of DHA and EPA 
while white fish such as cod, haddock, tilapia, and catfish contain lower amounts of 
these fatty acids [6]. 
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1.3 PHYSIOLOGICAL EFFECTS OF OMEGA-3 PUFAS 
Figure 1-2 summarizes the effects of omega-3 PUFAs on various organs and 
tissues suggested through human (in vitro and in vivo) and animal research. The rest of 
this section will provide details on these effects.  Greater detail regarding the 
biochemical mechanism for the potential effect of omega-3 PUFAs on glucose 
metabolism and SCD will be provided in Sections 3 and 4 (Manuscripts 1 and 2). 
 
Figure 1-2. Physiological Effects of Omega-3 PUFAs. Adapted from Mozaffarian and Wu. [6] 
1.3.1 OMEGA-3 PUFAS AND THE LIVER 
Studies have suggested two effects of omega-3 PUFAs on the liver: (1) 
triglyceride lowering and (2) glucose release via gluconeogenesis.  The triglyceride 
lowering properties of fish-derived omega-3 PUFAs has been well-established [16]. 
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Studies have suggested that omega-3 PUFAs directly regulate hepatic genes decreasing 
de novo lipogenesis [16-21]. Results from randomized clinical trials (RCTs) and 
observational studies have shown that reductions are modest with typical dietary intake 
versus the more clinically significant impact of fish oil supplements [6].  
This triglyceride lowering effect is hypothesized to affect gluconeogenesis as 
well.  The carbohydrates no longer being used for triglyceride production could instead 
be used for glucose production which would raise fasting blood glucose (FBG) [6]. 
1.3.2 OMEGA-3 PUFAS AND THE HEART 
Studies have also investigated the effect of omega-3 PUFAs on the heart.  Results 
suggest that omega-3 PUFAs are associated with (1) heart rate; (2) arrhythmia risk; (3) 
myocardial efficiency; (4) left ventricular diastolic filling; and (5) autonomic 
function/vagal tone. 
Omega-3 PUFA consumption is associated with reduced heart rate [22] and this 
reduction is hypothesized to be a result of several mechanisms including the effect of 
omega-3 PUFAs on cardiac electrophysiological pathways [6] such as the accumulation 
of DHA in myocardial cell membranes [23], slowing of the heart rate, shortening of the 
QT-interval, reduction of left ventricular systolic pressure, and prolongation of the 
electrocardiographic atrial-ventricular conduction time (P-R interval) [24]. 
It is these same pathways that are hypothesized to effect risk of arrhythmias, 
although studies in animals and humans have been inconsistent [6].  Animal 
experiments and human studies show that fish oil increased myocardial efficiency. 
Hearts from rats fed a diet high in omega-3 PUFAs did not need as much oxygen during 
high cardiac demand compared to rats fed other types of fat [25]. Fish oil 
supplementation in human cyclists reduced amount of oxygen needed during exercise 
[26]. Omega-3 PUFA consumption has also been shown to be associated with more 
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favorable measures of left ventricular cardiac filling [27-29], left ventricular ejection 
fraction [27, 30], and vagal tone [31]. 
1.3.3 OMEGA-3 PUFAS AND COAGULATION 
Studies investigating the effect of omega-3 PUFAs on thrombolytic particles 
found no association with platelet aggregation or coagulation factors [12, 32-34] and no 
excess bleeding risk in RCTs investigating fish or fish oil supplementation – even in 
patients taking aspirin or warfarin [35-37]. There were associations, however, with 
decreased production of the pro-inflammatory, pro-thrombotic arachidonic acid-derived 
eicosanoids and increased production of potentially beneficial omega-3 PUFA 
metabolites such as plasma oxylipins [38]. 
1.3.4 OMEGA-3 PUFAS AND HUMAN 
VASCULATURE 
Studies have shown that omega-3 PUFA consumption is associated with lower 
blood pressure [34, 39]. This may be due to improved flow-mediated arterial dilation 
[40-44], a marker of endothelial health.  ALA may lower blood pressure through the 
creation of eicosanoids, leading to the production of prostaglandins and leukotrienes 
that can reduce vascular tone [45]. 
1.4 OMEGA-3 PUFAS AND CARDIOVASCULAR DISEASE 
As mentioned above, both observational studies and RCTs have shown fish, fish 
oil supplements, and intake of ALA are associated with more favorable measures of 
some cardiovascular risk factors including lower plasma triglycerides [6, 16, 34], reduced 
heart rate and blood pressure [6, 34, 46], improved endothelial and autonomic 
functions [40-44, 47-49], improved cardiac filling [6, 27-29, 50], greater myocardial 
efficiency [6, 25, 26], reduced inflammation [6, 34], and anti-arrhythmic effects [6]. 
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As for fatal endpoints, observational studies have demonstrated that higher 
consumption of fish, fish-derived omega-3 PUFAs, and ALA (compared to lower) is 
associated with lower CHD mortality [6-8], particularly SCD [6, 51, 52].  ALA has been 
shown to be associated with lower incidence of CHD and stroke [34].  In 2004, a meta-
analysis of 11 published manuscripts utilizing 13 cohort studies found that eating fish at 
least once a week was associated with lower CHD mortality [7].  Additionally, a report 
from the US Physicians Health Study showed that a fish meal at least once per week was 
associated with lower incidence of SCD compared to men who consumed less than one 
fish meal a month [52]. 
1.4.1 GAPS IN DATA REGARDING THE 
RELATIONSHIP OF OMEGA-3 PUFAS 
AND CVD 
Evidence has been mixed regarding the association between omega-3 fatty acid 
consumption (ALA, DHA, and EPA) and insulin resistance and diabetes, which some 
consider CHD risk equivalents [53], although evidence has been mixed [54-56].  Section 
3 (Manuscript 1) will provide greater detail. 
1.5 CLINICAL AND EPIDEMIOLOGICAL ASPECTS OF GLUCOSE 
METABOLISM AND TYPE 2 DIABETES 
1.5.1 MEASURES OF GLUCOSE METABOLISM 
Glucose metabolism indicators can be measured in several ways.  The following 
are measures that will be used in the proposed studies. 
1.5.1.1 Glucose Concentration in Blood 
Measuring glucose levels in the blood are done internationally in terms of the 
glucose molar concentration and are measured in mmol/L (millimoles per liter). In the 
United States, measurements are done using glucose concentration mass and are 
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measured in mg/dL (milligrams per deciliter).  FBG is a measurement of blood glucose in 
plasma and is performed after the subject has been fasting, generally for 8-10 hours.  In 
contrast, a random blood glucose measurement is a measurement of blood glucose in 
plasma and is performed at any time and not based on postprandial timeframes.  
1.5.1.2 Hemoglobin A1c 
Hemoglobin A1c (HbA1c) is a measurement of type A hemoglobin subtype and 
does not vary based on time since food was last consumed.  Hemoglobin is found in red 
blood cells, and the cells’ exposure to glucose in blood plasma causes the hemoglobin to 
glycate.  The extent of the glycation gives an estimate of the average blood glucose 
levels over the past 6-8 weeks. 
1.5.2 NORMAL GLUCOSE METABOLISM 
Normal levels of blood glucose are between 70 and 110 mg/dL.  When blood 
glucose is low the pancreas decreases its secretion of insulin and releases glucagon.  
Glucagon causes the liver to convert stored glycogen into glucose [57]. 
Postprandially, the digestive system converts food into glucose, amino acids, 
fatty acids, and other nutrients that are released into the bloodstream.  This results in 
blood glucose levels that are higher than the typical range.  Insulin is released allowing 
the glucose to leave the bloodstream and fuel the body’s cells [57]. 
Glucose homeostasis is dependent on normal insulin production and normal 
insulin sensitivity.  If the body does not make enough insulin then there are not 
sufficient amounts to get blood glucose into cells.  But, even if insulin production is not 
compromised, if the body’s cells are not sensitive to insulin (i.e., there is insulin 
resistance) the glucose still cannot be utilized by cells, sometimes even if higher than 
normal amounts of insulin are secreted.  These metabolic defects result in elevated 
blood glucose.  It is thought that nutrient overload (e.g., eating too much) can lead to 
insulin resistance [58]. 
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1.5.3 DEFINITION OF DIABETES 
The generic term “diabetes mellitus” encompasses a group of metabolic diseases 
characterized by hyperglycemia. This elevated glucose state can result from defects in 
insulin secretion, insulin action, or both [59]. 
Several pathogenic processes are involved in the development of diabetes.  Type 
1 diabetes mellitus (T1D) is characterized by autoimmune destruction of the beta-cells 
of the pancreas, which produce insulin, and generally onset is in childhood or 
adolescence, although it can manifest at any age [59].  T2D represents 90-95% of all 
cases of diabetes mellitus and characterized by insulin deficiency and/or insulin 
resistance [59]. 
Diagnosis with diabetes, as defined by ADA, requires one of the following four 
criteria to be met: fasting plasma (blood) glucose (FPG) ≥ 126 mg/l (7.0 mmol/L) after a 
minimum of eight hours with no caloric intake; symptoms of hyperglycemia and a casual 
(random) plasma glucose ≥ 200 mg/dL (11.1 mmol/L); or two-hour plasma glucose ≥ 200 
mg/dl (11.1 mmol/L) during a 75-gram oral glucose tolerance test (OGTT) [60].  In 2015 
the ADA added HbA1c criteria similar to those introduced in 2011 by the World Health 
Organization (WHO) where an HbA1c cut-point 6.5% was recommended [61].  The ADA 
noted that age, race, and other clinical factors should be considered before making an 
HbA1c-related diagnosis [60].  
1.5.4 DESCRIPTIVE AND CLINICAL 
EPIDEMIOLOGY OF DIABETES 
1.5.4.1 Prevalence 
According to the National Health and Nutrition Examination Survey (NHANES) 
data from 2011-2014, diabetes affects 31.0 million Americans – 9% of the U.S. 
Population.  This number includes 23.4 million with diagnosed diabetes and 7.6 million 
with undiagnosed diabetes [59, 62].  
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Using data from NHANES and National Center for Health Statistics (NCHS) 
collected between 1984 and 2004, the total prevalence of diabetes is expected to more 
than double in the United States between 2005 and 2050 (from 5.6% to 12.0%) [1]. This 
increase will occur in all age, sex, and race/ ethnicity groups, but are projected to be 
largest in the oldest (e.g., a four-fold increase among those 75 years of age and older) 
[1].  The group with the largest increase in prevalence is projected to be blacks aged 75 
or older – a 606% increase [1]. 
1.5.4.2 Incidence 
In 2012 there were approximately 1.7 million Americans aged 20 and older that 
were newly diagnosed with diabetes [63]. Incidence varies by race, with rates higher in 
blacks (9.5%) than whites (6.3%) [1]. 
1.5.4.3 Mortality 
Diabetes is the seventh leading cause of death in the United States [62]. 
Furthermore, the risk for death among people with diabetes is about twice that of 
people of similar age but without diabetes [62]. In 2014 there were 245,016 deaths in 
the United States where diabetes was the primary or secondary cause of death [1]. 
Death rates per 100,000 people were 23.4 for white males, 43.9 for black males, 14.6 for 
white females, and 34.0 for black females [1]. 
1.5.5 POPULATIONS AT INCREASED RISK FOR 
TYPE 2 DIABETES 
Prediabetes (Pre-T2D) is a condition in which individuals have abnormal glucose 
metabolism not yet severe enough to be classified as diabetes [1, 62].  An individual is 
considered prediabetic if at least one of the following are present: (1) impaired fasting 
glucose (IFG), (2) impaired glucose tolerance (IGT), or (3) elevated HbA1c. 
IFG is a condition in which an individual’s fasting (>8 hours) blood glucose value 
is greater than 100 mg/dl but less than 126 mg/dl.  IGT is diagnosed when an individual 
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fails at least two OGTTs – i.e., the 2-hour blood glucose value is greater than 140 mg/dL 
(but below 200 mg/dl).  Finally, Pre-T2D can be established using HbA1c values. An 
HbA1c value between 6 and 6.5% is considered prediabetic.  
People with Pre-T2D have an increased risk of developing T2D, heart disease, 
and stroke [59, 62, 64] and approximately 33.9% percent of US adults (81.6 Million) 
have prediabetes [1]. NHANES data from 2005-2008 showed 35% of U.S. adults aged 20 
years or older had Pre-T2D, with half of identified individuals aged 65 years or older 
[62]. 
These prediabetic populations are of interest as studying individuals at higher 
risk may provide insight into methods to delay or prevent transition to clinical diabetes 
and to better understand the pathophysiology of the disease. 
1.5.6 OMEGA-3 PUFAS AND TYPE 2 
DIABETES 
Intake of the vegetable-derived omega-3 fatty acid ALA and the fish-derived 
omega-3 PUFAs DHA and EPA may also affect risk of T2D and markers of glucose 
homeostasis such as fasting blood glucose levels and HbA1c. 
1.5.6.1 Biological Mechanisms 
There are data to support the biological plausibility of fish-derived omega-3 
PUFAs DHA and EPA affecting glucose homeostasis in those with T2D.  
Omega-3 PUFA may favorably affect glucose homeostasis. A pro-inflammatory 
state interferes with insulin signaling and inhibits insulin action on adipocytes [58], Fish-
derived omega-3 PUFAs have anti-inflammatory properties, and inhibit the production 
of pro-inflammatory cytokines [65] and increase insulin sensitivity [66].  Furthermore, 
omega-3 PUFAs are incorporated into cell membranes where they may modify the 
activities of membrane-associated enzymes and receptors [5] and increase cell-
sensitivity to insulin [65]. 
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There are also mechanisms through which omega-3 PUFA may adversely affect 
glucose homeostasis.  A previous study showed that diabetics who took a fish-derived 
omega-3 PUFA supplement had lower glucose utilization (insulin sensitivity) and 
increased glucagon-stimulated C-peptide [67]. In another trial, diabetic subjects taking 
fish oil supplements showed reduced hepatic gluconeogenesis [68].  Obese subjects 
with T2D who took fish oil supplements had increased uptake and oxidation of non-
esterified fatty acids in the liver [69]. In another study of obese subjects with T2D, fish 
oil supplementation increased glycerol gluconeogenesis, and the authors hypothesized 
it could cause the deterioration of glycemic control during long-term treatment with 
high doses of fish-oil supplements [69]. Finally, the consumption of seafood may affect 
glucose homeostasis via contaminants in seafood.  Mouse models have shown that 
elevated blood mercury levels may interrupt insulin signaling pathways, and decrease 
plasma insulin and elevate blood glucose levels [70].  
1.5.6.2 Prior Clinical and Epidemiologic 
Research 
Contradictory epidemiologic and clinical data exist on the association of omega-3 
PUFAs and the risk of diabetes and markers of glucose homeostasis. A Cochrane review 
considering fish oil supplement trials in diabetics showed that, overall, the omega-3 
fatty acids did not affect FBG levels, HbA1c, or fasting insulin [14]. Fish oil trials in 
nondiabetic patients have been similarly null [71, 72].  In diabetics, a meta-analyses of 
fish oil supplementation studies found that supplementation was associated with more 
favorable – but non-significant – associations with HbA1c and insulin [73], although the 
AHA no longer recommends fish oil supplementation for diabetics to prevent 
cardiovascular disease [74]. 
Observational studies have provided inconsistent results. Fish and EPA/DHA 
intake have been positively associated with risk of T2D [75-78]; associated with a 
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reduction in risk of T2D [79, 80] and lower FBG [81]; or have had null associations [78, 
82-84].  
Recent reviews and meta-analyses have reported that dietary intake of fatty fish 
and the fish-derived omega-3 PUFAs DHA and EPA are associated with higher risk of T2D 
in American and European populations [85-88] but not Asians [86], but not lean fish or 
shellfish [86], or plasma measures of DHA and EPA [85].   
Studies investigating intake of the vegetable-derived ALA have been similarly 
mixed.  A meta-analysis showed lower risk of incident T2D with higher levels of intake 
[85] but a subsequent analysis two years later showed favorable associations in Asians 
only, although Americans and Europeans had a nonsignificant favorable trend [86]. 
Data from randomized and observational studies may conflict for several 
reasons: (1) study duration: trials were short term compared to observational trials and 
there may not been enough time for the effect of fish oil supplements to be fully 
realized; (2) dose: trials used DHA and EPA doses that far exceed typical dietary intake; 
(3) study populations: different study populations with different food preparation 
methods and cultural differences may not be comparable; and (4) different exposure 
levels: some studies had high levels of ALA, DHA, EPA intake (i.e., fish oil or flaxseed 
supplementation) while others only investigated typical dietary consumption. 
1.6 CLINICAL AND EPIDEMIOLOGICAL ASPECTS OF SUDDEN 
CARDIAC DEATH 
1.6.1 DEFINITION OF SUDDEN CARDIAC 
DEATH 
Definitions of SCD are varied and no agreement has been reached on an official 
definition [89].  
Definitions differ on their inclusions of temporality, geography, disease 
attribution, whether the event was witnessed, age range, and whether sudden cardiac 
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arrest is included [89]. The most widely cited definition was published in 2001 and used 
U.S. vital statistics and death certificate data from 1989 to 1998 [89, 90]. SCD was 
defined as a witnessed or un-witnessed, cardiac disease-related death within one hour 
of symptom onset, taking place out of hospital or in the ER in individuals aged 35 years 
of age or more [89, 90]. The most recent definition in the published literature was 
published in 2008 and used data collected between May 1, 2006, and April 30, 2007 [89, 
91]. That definition was very broad – it included sudden cardiac arrest, required the 
death be from a cardiac cause and occur out of hospital, but had no other restraints [89, 
91].  The most common cause of SCD is a sustained ventricular tachyarrhythmia [92]. 
1.6.2 DESCRIPTIVE EPIDEMIOLOGY 
A systematic review in 2011 [89] found only six peer-reviewed articles regarding 
SCD incidence. The estimated U.S. annual incidence of SCD varied widely from 180,000 
to >450,000 among those 6 studies. Differences were due to differences in data sources, 
year of data collection differences in SCD case definition and case ascertainment, and 
methods of extrapolating to the US population [89]. The most commonly cited source 
[90] standardized rates to the 2000 US population and found an estimated annual 
incidence of 456,076 cases of SCD – 63% of all cardiac deaths.  The most recent source 
(2008) [91] in the review was also the most conservative, with an estimated annual 
incidence of 294,851 cases of SCD.  A 2014 study cited in the AHA Heart Disease and 
Stroke Statistics Report [1] used data from the Oregon Sudden Unexpected Death Study 
and extrapolated a risk-adjusted incidence rate of 69 per 100,000 per year, or 
approximately 210,000 annual cases of SCD in the United States each year [93]. 
1.6.3 MODIFIABLE RISK FACTORS 
Studies have shown a strong concordance between risk factors for CHD and SCD, 
but no clear modifiable risk factors that are specific for SCD have been identified once 
CHD is established [92, 94, 95]. This is most likely due to risks for SCD are linked to risks 
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for CVD that create the structural damage linked to sustained arrhythmia [92]. In fact, 
the strongest predictor of SCD once CHD is established is the degree of cardiac damage 
sustained [92]. 
1.6.4 ELECTROCARDIOGRAPHIC PREDICTORS 
OF SUDDEN CARDIAC DEATH 
The ECG is a graphic recording of the electrical activity of the heart, and it is a 
noninvasive and inexpensive test in the study of cardiac function. The ECG is useful to 
detect arrhythmias, conduction disturbances, and myocardial ischemia. Also, the ECG 
can provide information on susceptibility to SCD. The two ECG variables consistently 
associated with a higher risk of SCD are long QT interval [96, 97] and J-point elevation 
[98, 99] – both are important markers of abnormal ventricular repolarization.  In an ECG, 
the QT interval represents electrical depolarization and repolarization of the left and 
right ventricles and the J-point – the junction of the QRS complex and the ST segment – 
marks the end of depolarization and the beginning of repolarization [100, 101]. 
1.6.4.1 Biological Plausibility 
Studies suggest that fish-derived PUFAs could have anti-arrhythmic effects, thus 
reducing SCD risk. Specifically, fish-derived omega-3 PUFAs may inhibit the fast, voltage-
dependent sodium current and the L-type calcium currents [102, 103] that allow pre-
SCD arrhythmias to be sustained [46].  ALA may favorably influence arrhythmias through 
modification of the eicosanoid system or modulation of L-type calcium channels in the 
sarcolemma of cardiac myocytes [104].   
1.6.4.2 Prior Clinical and Epidemiologic 
Research 
There have been a limited number of studies evaluating whether omega-3 PUFAs 
are associated with repolarization abnormalities detected in the surface ECG – 
prolonged repolarization (prolonged QT interval) [104-107] and early repolarization (J-
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point elevation, JPE) [104]. With respect to prolonged QT interval, intake of the fish-
derived omega-3 PUFAs DHA and EPA have been shown to be associated with shorter 
QT intervals in Greek adults [107] and predominately white Americans aged >65 years 
[106]. A study of white, middle-aged American adults found higher intakes of the 
vegetable-derived omega-3 PUFA ALA were associated with lower risk of prolonged QT 
[104]. With respect to JPE, a study of Japanese men found that higher intake of the fish-
derived omega-3 PUFA DHA and EPA attenuated the association between JPE and 
cardiac death [105].  To our knowledge, no studies have investigated the association of 
ALA with JPE. 
Although omega-3 PUFAs are inversely associated with SCD, and prolonged QT 
interval and JPE are positively associated with SCD, further details regarding the 
association between omega-3 PUFAs, QT interval, and JPE in a biracial cohort of middle-
aged American populations may help elucidate the mechanisms relating omega-3 fatty 
acid consumptions and SCD. 
1.7 MEASUREMENT ERROR 
One difficulty in investigating exposure-disease associations is measurement 
error.  While epidemiologists’ goal is to find the true association (causal effect) between 
exposure and outcome in a population of interest, they are limited to determining the 
association between measured exposure and outcome in a sample of the population of 
interest.  Mis-measured – or unmeasured – covariates and confounders can distort the 
desired association further.  This section will focus on measurement error issues unique 
to dietary exposures and covariates.  It will start a brief description of measurement 
error of the exposure variable, consequences of measurement error with potential 
solutions, and recommendations.  
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1.7.1 TYPES OF MEASUREMENT ERROR 
There are several ways in which dietary measurement error can occur including: 
(1) subject forgets actual consumption; (2) subject purposely misreports due to social 
desirability or other psychological factors; (3) subject accidentally misreports due to 
differences in serving size; and (4) a correctly reported food can be incorrectly 
translated into its nutrient components due to differences in food preparation [108, 
109].  The type of measurement instrument (e.g., 24-hour dietary recall versus food 
frequency questionnaire (FFQ)) can also affect the frequency and magnitude of 
measurement error.  Food records and 24-hour diet recalls are generally considered the 
gold standard for self-reported diet intake [109]. 
Measurement error can be classified as differential or non-differential.  
Differential measurement error of the exposure is one where the error in measuring the 
exposure is dependent on other variables in the analysis.  A classic example is recall bias 
in case-control studies.  Those with the disease are more likely to remember exposures 
of interest than those who do not have the disease.  Non-differential classification bias 
of the exposure is measurement error that is not dependent on other study variables.  
An example is where a technician always rounds a patient’s systolic blood pressure to 
the nearest 5 (e.g, 138 mg Hg becomes 140, 112 mm Hg becomes 100). If exposures are 
dichotomous and misclassification is perfectly non-differential and errors are 
independent then associations will be biased towards the null [110]. In cohort studies 
measurement error of the exposure is generally considered to be non-differential as 
exposure is measured before onset of disease [108] but errors are not independent as 
dietary measurement error generally has bias related to true intake with subjects with 
high intake under-reporting and subjects with low intake over-reporting [108]. This 
“flattened slope phenomenon” can bias results away from the null [111] but random 
variation usually overwhelms the flattened slope phenomenon resulting in an overall 
relative risk estimate biased towards the null [112]. 
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1.7.2 CONSEQUENCES OF MEASUREMENT 
ERROR 
There are three main consequences of exposure measurement error: biased 
measures of association, loss of power, and invalidation of statistical tests. 
1.7.2.1 Biased Measures of Association 
Section 1.7.1 mentioned non-differential measurement error with a 
dichotomous exposure and independent errors will bias towards the null and that over- 
and under-reporting of intake based on actual intake is generally not sufficient to alter 
that trend.   
Two analytic approaches to decrease or eliminate the bias are (1) adjust for 
energy intake and (2) correct the measured exposure values.  Adjusting for energy 
intake [109, 113] allows for exposures to be assessed as part of overall diet composition 
– that is, it addresses the problem that an individual may have consumed more fish than 
another individual simply because he is taller and has more muscle mass.  This type of 
energy adjustment can improve attenuation [108] but there can still be significant bias 
towards the null.  Another potential solution is use of regression calibration [108] or 
multiple imputation [114] to correct the mis-measured exposures using an appropriate 
reference instrument. Reference instruments need to have measurement errors that 
are not correlated with the original exposure measurements [112, 115], so 24-hour 
recalls and food diaries are imperfect solutions [108].  Other reference instrument 
options, however, are recovery biomarkers and concentration biomarkers [116]. These 
are objective measures of intake that indicate how much of the nutrient was absorbed 
(bioavailability), is may be a good measure of usual intake provided between-season 
variability in an individual’s intake is not large [109].  Unfortunately biomarkers can be 
affected by potential confounders – and if these confounders are dietary in nature they 
may be subject to the measurement error inherent in self-report measures resulting in 
additional bias [109]. 
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1.7.2.2 Loss of Power 
All exposure measures are subject to random variation, and the greater the 
deviation from the true value the greater the loss of power [117]. There are two sample-
size related techniques researchers use to increase power: (1) increase sample size of 
individual studies; and (2) increase sample size by performing meta-analyses. 
The first technique researchers use to increase power is to increase sample size, 
oftentimes by establishing large cohort studies such as the Atherosclerosis Risk in 
Communities (ARIC) Study [118]. Unfortunately, increasing sample size may not be 
sufficient to completely address power lost through FFQ measurement error [108]. One 
study found that to maintain desired power calculated assuming no exposure 
measurement error, the measurement error inherent in a FFQ resulted in a needed 
sample size 25-100 times larger for a total energy exposure [108]. 
 Another technique to increase power is to perform meta-analyses of several 
studies – generally observational – thus harnessing the power of each component study 
[108]. Unmeasured confounders, however, can distort results from observational 
studies and meta-analyses can generate very precise but equally distorted measures of 
association [119].  Additionally, heterogeneity of study methods can be an obstacle to 
meta-analyses [120]. 
1.7.2.3 Invalidation of Statistical Tests 
If there is only one mis-measured dietary exposure in the disease model then, 
theoretically, the standard exposure-disease regression (null-hypothesis: no association) 
is statistically appropriate although measures of association may be attenuated [108]. In 
multivariable models with multiple (mis-measured) dietary exposures, the standard 
exposure-disease regression may no longer be statistically valid and the direction of the 
bias is unpredictable [108].  This phenomenon is due to residual confounding resulting 
from the correlated nature of the dietary variables [108]. 
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1.7.2.4 Recommendations 
At a minimum, most dietary exposure models should include total energy as a 
covariate [108, 113].  Another recommendation for addressing dietary measurement 
error is combining dietary data with biomarker data [108]. This technique not only 
reduces exposure measurement error [108, 121], but also allows for an increase in the 
power to detect measures of association [108, 114, 121]. This approach will be 
described further in Section 5 (Manuscript 3). 
Another method for addressing dietary measurement error is regression 
calibration [122, 123] using data from a validation study [108].  Unfortunately the most 
common validated study instrument is a more detailed self-report (e.g., food diary, 24-
hour recall) [108] – these instruments are limited as their measurement errors are 
correlated with true intake and the FFQ [112, 115].  An alternative is to use biomarker 
validation data as a reference instrument to compute attenuation and contamination 
factors [108, 123].  While some studies have shown that regression calibration with self-
report validation data and regression calibration using biomarker data can yield similar 
results [108], this cannot be guaranteed.  Finally, multiple imputation is an approach for 
calibrating mis-measured exposure data [114] and will be discussed in greater detail in 
Section 5 (Manuscript 3). 
1.8 SUMMARY OF THE INTRODUCTION 
In this section, we have described the public health importance of T2D and SCD 
in the United States.  We reviewed biological and epidemiological evidence for long-
chain omega-3 PUFAs, focusing on the potential association of long-chain omega-3 PUFA 
intake with glucose homeostasis and the risk of diabetes, with the risk of CVD and, 
particularly, SCD.  Additionally, we provided an overview of the issues created by 
measurement error in nutritional epidemiology, which could influence the associations 
found when dietary omega-3 PUFAs are the exposure of interest. Overall, we highlight 
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the need for studies that clarify the impact of omega-3 PUFA intake on diabetes risk, 
that assess electrophysiological mechanisms responsible for the association between 
omega-3 PUFA intake and SCD, and that evaluate methods for correction of 
measurement error using biomarker data. In the next section, we provide a description 
of the Atherosclerosis Risk in Communities (ARIC) cohort, which we used to address the 
aims of this dissertation. 
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2 THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) 
STUDY – DATA AND DATA COLLECTION 
2.1 STUDY OVERVIEW 
This dissertation utilized data from the Atherosclerosis Risk in Communities 
(ARIC) Study.  The three aims were to investigate (1) association of seafood and omega-
3 PUFA intake with measures of glucose metabolism; (2) association of seafood and 
omega-3 PUFA intake with ECG predictors of SCD; and (3) if addressing potential 
measurement error in our dietary exposures modifies select outcomes from aims 1 and 
2.  In this section, we describe the ARIC study and how data were obtained for the 
exposures, outcomes, potential confounders, and other covariates of interest. 
2.2 THE ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY 
The ARIC study is a multi-center prospective study designed to investigate the 
etiology and natural history of cardiovascular disease. The health of each participant – 
including a comprehensive physical exam, medical history, interview, and measurement 
of traditional and novel risk factors for CVD, diabetes, and other important health 
outcomes – was assessed at baseline and during follow-up exams using standardized 
protocols.  The study design and methods have been described previously [118].  This 
section summarizes the study population and timeline.  
ARIC is a cohort of 15,792 subjects from four communities.  ARIC participants 
were chosen via probability sampling from four economically and socially diverse US 
communities: Forsyth county, North Carolina; Jackson, Mississippi; suburban 
Minneapolis, Minnesota; and Washington County, Maryland. The Jackson sample 
includes African Americans only.  The other field center samples are representative of 
the populations in their respective communities: mostly white in suburban Minneapolis 
and Washington County, white and African American in Forsyth county.  There were 
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15,792 subjects (8,710 women, 7,082 men; 11,478 whites and 4,314 nonwhites) aged 
45-64 at baseline (visit 1). 
There have been five visits, although this dissertation only utilizes data from 
visits 1 through 4.  The first four visits were approximately 3 years apart: visit 1 (1987-
89), visit 2 (1990-92), visit 3 (1993-95), and visit 4 (1996-98); visit 5 was fifteen years 
later: 2011-13.  Baseline response rates were 46% of the target population in Jackson 
and 65% of the target population in the other communities.  Additionally, survivor 
retention proportions were 93% for visit 2, 86% for visit 3, 80% for visit 4, and 65% for 
visit 5.  Participants were contacted yearly by phone – twice a year starting in 2012 – to 
obtain information about hospital admissions and ascertain vital status. 
   The same data were not collected at every visit. The details of the data 
collection procedures are covered in the next section, focusing on exposures, outcomes, 
potential confounders, and other covariates of interest. 
2.3 EXPOSURE VARIABLE MEASUREMENT 
For our exposures, we focused on dietary consumption of fish and shellfish, the 
fish-derived omega-3 fatty acids DHA and EPA, and the vegetable-derived omega-3 
PUFA ALA.  Biomarker values for circulating concentrations of DHA, EPA, and ALA were 
available for a subset of participants.  Detailed descriptions appear below.   
2.3.1 THE FOOD FREQUENCY 
QUESTIONNAIRE 
Participants’ usual dietary intake was assessed by using an interviewer-
administered, 66-item FFQ administered to all subjects at visit 1 (1987-1989) and visit 3 
(1993-1991). The FFQ was based on the 61-item instrument developed by Willett et al. 
[124].  Three modifications were made for the ARIC version: (1) separation of some 
items into detailed subcategories (notably, the one question on fish intake was broken 
down into three fish categories of dark meat fish, other fish, and shellfish); (2) addition 
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of several food items such as biscuits and donuts; (3) detailed questions were added to 
assess the consumption of beer, wine, and hard liquor. 
The ARIC questionnaire was also validated in a sample (n=419) of black and 
white ARIC participants who repeated the FFQ after three years [125]. The study found 
that, after adjusting for total caloric intake, the median reliability coefficient for blacks 
was 0.42 and the reliability for white ARIC participants was 0.49 – a value similar to that 
of other studies of white subjects.  The study found no difference in the median 
reliability coefficients of men and women after adjusting for total calorie intake. 
Another study investigated the validity of the ARIC FFQ by comparing Minnesota 
field center participants’ dietary fat FFQ data against their plasma fatty acid 
concentrations [126].  Plasma measures reflect the types of fats proportionally 
consumed over the past several weeks to months [127] and the proportionate 
composition in plasma was moderately correlated with dietary intake, with highest 
correlations in the fish-derived omega-3 fatty acids DHA and EPA (r=0.42 and r=0.20 for 
plasma phospholipid measures of DHA and EPA, respectively) [126]. 
2.3.1.1 Fish/Shellfish Servings 
Fish and other seafood intake was assessed through four FFQ questions with 
nine response categories. The questions asked how often they consumed: 3–4 ounces of 
canned tuna fish; 3–5 ounces of dark meat fish such as salmon, mackerel, swordfish, 
sardines, and bluefish; 3–5 ounces of other fish such as cod, perch, catfish, etc.; and 
shrimp, lobster, scallops as a main dish. Interviewers used food models to help 
participants with portion size estimation.  Subjects could provide answers to each 
question ranging from ‘‘never or less than once per month’’ to ‘‘6 times per day.’’  
Applying the same methodology used in another study of seafood intake in the 
ARIC cohort [128], each of the participants’ seafood-related FFQ responses were 
grouped into three exposure categories – (1) omega-3 rich fish (tuna + dark); (2) total 
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fish (tuna + dark+ other); and (3) total seafood (tuna + dark + other + shellfish) – and 
further translated into four weekly serving categories: none, less than one, one to two, 
and more than two.   
2.3.1.2 Intake of ALA, DHA, and EPA 
Data from the FFQ were coded for nutrients and food groups by Harvard 
University.  Nutrient values for each food were obtained from the Harvard database 
[124], which was predominately based on the US Department of Agriculture 
publications [129]. Daily intake of nutrients was calculated by multiplying the nutrient 
content of each food in the portion specified by the frequency of daily consumption and 
then summing the results.  This calculation yielded consumption of ALA, EPA, and DHA 
in grams/day.  Three different classifications of omega-3 fatty acids were investigated: 
(1) vegetable-derived ALA, (2) fish-derived DHA+EPA; and (3) ALA+DHA+EPA. 
2.3.2 BIOMARKER MEASURES OF ALA, 
DHA, AND EPA 
Blood samples were obtained from Minnesota field participants at visit 1 (n= 
3,757) and plasma fatty acids were measured in cholesterol esters and phospholipids 
using gas chromatography [126].  Wang et al. contains a very detailed description of the 
chemical processes used to extract and measure the plasma fatty acids [83].  Since 
cholesterol esters reflect medium-term dietary intake of fatty acids (weeks)  and 
phospholipids reflect intake over a slightly longer duration (weeks to months) [127], we 
used phospholipid measurements in our analyses.  Circulating concentrations of 
individual fatty acids were expressed as a percentage of total fatty acids – we 
investigated concentrations of ALA, DHA+EPA, and ALA+DHA+EPA grouped into 
quartiles. 
It should be noted that there are certain instances where plasma measures may 
not perfectly reflect dietary intake. Things to consider are: (1) sensitivity to intake (do 
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plasma measures change with changes in diet); (2) if the body attempts to maintain 
plasma fatty acid homeostasis; (3) if the measure is sensitive to consumption; and (4) 
usual intake over a year versus the seasonality of plasma levels [109].  Thus, when using 
plasma measures of omega-3 PUFAs as an exposure, the association may not describe 
usual dietary intake but bioavailability. 
Keeping this in mind, previous analyses have shown that plasma measurements 
of omega-3 PUFAs correlate with dietary intake (as measured via a FFQ) in ARIC [126] 
and similar heterogeneous European populations [130].  However, as previously 
mentioned, plasma measurements of fatty acids are not a perfect measurement of 
dietary intake as many factors (e.g., alcohol intake, obesity, chronic diseases) affect fatty 
acid metabolism [126]. 
2.4 OUTCOME MEASURES 
We had two main classifications of outcome variables: glycemia and ECG 
markers of ventricular repolarization associated with SCD.  In these next sections, we 
describe how outcome data were obtained. 
2.4.1 MEASURES OF GLYCEMIA 
Three measures of glycemia were used in this study: FBG, HbA1c, and incident 
T2D.  Detailed descriptions of blood draw [131] and chemistry analyses [132] can be 
found in the ARIC Manual of Operations.   
2.4.1.1 Fasting Blood Glucose 
Data on FBG were obtained during visits 1-4.  Fasting blood samples were drawn 
from an antecubital vein with minimal trauma.  FBG was then measured by a hexokinase 
method on a Coulter DACOS (Coulter Instruments).  In a small validation study blood 
samples from volunteers (n=40) were taken two weeks apart.  For serum glucose the 
intraclass correlation was 0.84, the within-person coefficient of variation (CV) was 4% , 
and the laboratory CV was 2% [133]. 
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2.4.1.2 Hemoglobin A1C 
HbA1c was measured from whole blood samples using high-performance liquid 
chromatography.  HbA1c values capture the average blood glucose concentration over 
approximately the past three months.  The blood was collected during visit 2 (1990-92) 
and stored at -70 Cº for 14-18 years until HbA1c measurements could be obtained.  
Selvin et al. give a detailed description of the measurement process [134].  
Briefly, measurements were obtained in the same laboratory during two 
separate time periods using two different instruments: n=4,918 subjects in 2003-04 
using Tosoh 2.2 Plus HPLC (Tosoh Bioscience, South San Francisco, CA) and n=9,151 
subjects in 2007-08 using Tosoh G7 HPLC.  Both instruments were certified by the 
National Glycohemoglobin Standardization Program (NGSP).  This calibration provides 
stable results despite changes in HbA1c methodologies over time. 
A convenience sample (n=383) was analyzed using both instruments.  Pearson's 
correlation coefficient between the two samples was high (r=0.99) but there was a slight 
bias with 2007-08 values showing a 0.29 higher %HbA1c (p<0.0001).  The intraclass 
correlation coefficient was 0.99 (95% CI: 0.97-0.99) and within-sample CV of 3.9% (95% 
CI: 3.6% to 4.2%).  CVs of 5% or less generally reflect good method performance. 
2.4.1.3 Incident T2D 
Diabetes status was defined based on information collected at visits 1-4.  
Specifically, diabetes was defined as (1) self-report of physician-diagnosed diabetes; (2) 
self-reported use of diabetes medication in the past two weeks; (3) fasting glucose level 
≥ 7.0 mmol/liter (126 mg/dl); or (4) non-fasting glucose level > 11.1 mmol/liter (200 
mg/dl).  For incident T2D, prevalent cases will be excluded at visit 1 and cases newly 
identified at subsequent visits will be considered incident. 
Although this methodology does not distinguish between type 1 diabetes (T1D) 
and T2D, T2D is the most commonly occurring variant of diabetes and rarely occurred 
before age 30 in individuals who were middle-aged in the 1980’s [135].  Other 
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researchers have defined T1D in ARIC as diabetic subjects with age of onset before age 
30 [136].  
2.4.2 ECG PREDICTORS OF SUDDEN CARDIAC 
DEATH 
For each visit in ARIC, a standard, resting, supine 12-lead ECG was obtained for 
each subject a minimum of 1 h after any smoking or caffeine ingestion using MAC PC 
personal cardiography equipment (Marquette Electronics, Inc., Milwaukee, WI).  An 
electrode locator was used to determine and standardize the positioning of chest 
electrodes.  Tracings were sent to be computer coded at the ARIC ECG Reading Center.  
All records with significant Minnesota Code [137] findings as determined by the 
computer, as well as a random sample of tracings, were sent to the ECG coding center 
to be visually coded.  Discrepancies between the computer code and visual code were 
adjudicated by a senior coder. Subsequent processing of the ECGs took place at EPICARE 
(Epidemiological Cardiology Research Center at Wake Forest University, Winston-Salem, 
NC, USA).  We considered four ECG-derived outcomes: QT interval, prolonged QT, J-
point height, and JPE. 
2.4.2.1 QT Interval and Prolonged QT 
The QT interval represents electrical depolarization and repolarization of the 
ventricles.  A participant’s visit 1 QT interval was derived by the Dalhousie ECG analysis 
program using the digital 12-lead ECG.  Subsequent visits used the GE Marquette 12-SL 
analysis program, which generated an average waveform derived from all 12 
simultaneously measured leads. 
We used a heart rate-corrected QT interval (QTc) – as recommended by the AHA, 
the American College of Cardiology, and the Heart Rhythm Society for the 
Standardization and Interpretation of the Electrocardiogram [138].  The most 
appropriate formula for correction is the one resulting in the least amount of correlation 
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between heart rate and the calculated rate-corrected QT [139].  We tested Framingham 
[140] and Hodges [141] and found that the Framingham formula had the least 
correlation with heart rate in our study population (r= -0.23 and r=-0.38, respectively). 
Thus 𝑄𝑇𝑐 = 𝑄𝑇 + 154(1 −
60
𝐻𝑒𝑎𝑟𝑡 𝑅𝑎𝑡𝑒
); where heart rate is in beats per minute. 
In addition to the continuous measure of QT interval, we defined prolonged QTc 
as QTc values of 460 ms or longer in women and 450 ms or longer in men [138]. 
2.4.2.2 J-Point Height and J-Point 
Elevation 
The ST amplitude at the J-point was determined the 2001 version of the GE 
Marquette 12-SL program.  We calculated a continuous measure of the J-point (J-point 
height) as the maximum amplitude of the 12 STJ leads. As has been done in other ARIC 
studies, JPE was defined as a ST amplitude greater than 100 microvolts in at least two 
contiguous leads [142]. 
2.5 POTENTIAL CONFOUNDERS 
We selected potential confounders a priori based on their hypothesized 
relationship with exposure and outcome.  While most variables were measured at 
multiple visits, potential confounders were measured contemporaneously with 
exposure values (visits 1 and 3) to avoid adjusting for confounders measured after our 
exposure of interest [143]. Potential confounders were grouped into four main 
categories: sociodemographic, lifestyle, dietary, and clinical variables. 
2.5.1 SOCIODEMOGRAPHIC VARIABLES  
Sociodemographic variables included age, sex, race, field center, and education 
level.  Age, sex, self-reported race, and field center were obtained at visit 1 and 
confirmed at subsequent visits. For race, participants were handed a card and asked to 
tell the interviewer which best described his or her race. Choices offered were: white, 
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black, American Indian/ Alaskan native, Asian/Pacific Islander, other: specify.  Over 99% 
identified as either white or black race. Education level was measured at visit 1 via self-
report and categorized based on years of education: basic (no high school degree), 
intermediate (completed high school), and advanced (at least some college). 
2.5.2 LIFESTYLE VARIABLES  
Lifestyle variables included body mass index (BMI), physical activity, smoking 
status, and drinking status and amount. Technicians measured height and weight, and 
BMI was calculated as weight (kilograms) divided by height squared (meters2). Physical 
activity was measured at visits 1 and 3 using the Baecke questionnaire [144]. The 
questionnaire included 16 items about usual exertion, and three indexes ranging from 1 
(low) to 5 (high) were derived for physical activity at work, during leisure time, and in 
sports. The reliability and validity of the Baecke questionnaire are good for both male 
and female subjects, and equal to many other physical activity instruments [145]. The 
three physical activity scores were summed and then translated into tertiles of physical 
activity (low, medium, and high). Smoking status was assessed via self-report and 
participants classified as current smokers, former smokers (more than 100 cigarettes in 
the past), and never smokers. Alcohol intake status (current, former, never) and amount 
(grams/day) were measured at visits 1 and 3. 
2.5.3 DIETARY VARIABLES  
Dietary variables included trans fatty acids, saturated fatty acids, and dietary 
fiber. Intake of trans fatty acids, saturated fatty acids, and dietary fiber were measured 
at visits 1 and 3 via FFQ and translated into nutrient values as described in Section 
2.3.1.2. 
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2.5.4 CLINICAL VARIABLES  
Clinical variables included hypertension, LDL, HDL, and triglycerides. During each 
visit, three blood pressure measurements were taken with a random-zero 
sphygmomanometer after 5 minutes of the participant in the sitting position; the mean 
of the last two measurements was used.  Hypertension was defined as a systolic blood 
pressure above 140 mmHg, a diastolic above 90 mmHg, or self-reported use of 
antihypertensive medication.  For metrics requiring phlebotomy, blood was drawn after 
a minimum 8-hour fasting period with minimal trauma from an antecubital vein [146]. 
Plasma total cholesterol and triglycerides were measured by enzymatic methods [132], 
and LDL cholesterol was calculated using the Friedewald formula [147]. HDL cholesterol 
was measured after dextran-magnesium precipitation of non-HDL lipoproteins [132]. 
2.6 OTHER COVARIATES OF INTEREST 
Other variables of interest include self-reported medication use, variables used 
for inclusion/exclusion criteria that had not yet been defined, and variables used to 
stratify participants into sub-populations of interest. 
2.6.1 PRESCRIPTION AND NON-PRESCRIPTION 
MEDICATION 
Prior to each visit, participants were asked to bring all prescription and non-
prescription medications used in the two weeks leading up to the visit.  Trained 
interviewers collected information on the medications that participants reported taking, 
and these were coded according to drug category. 
2.6.2 INCLUSION AND EXCLUSION CRITERIA  
For all analyses, participants with prevalent or incident CVD – defined as 
coronary heart disease (CHD), heart failure (HF) or stroke – were excluded from analysis.  
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Prevalent disease was established at visit 1.  Incident disease was identified at 
subsequent visits, or through three surveillance methods: (1) ARIC Study participants 
were contacted annually by phone (twice a year after 2012) and all hospitalizations and 
deaths during the previous year were identified; (2) local hospitals provided lists of 
cardiovascular disease discharges, which were examined for participant hospitalizations 
and qualifying CVD outcomes; and (3) death certificates.  
Prevalent CHD was defined by a positive history of angina or intermittent 
claudication by the Rose questionnaire [148, 149], a self-reported physician-diagnosed 
history of a heart attack, evidence of old myocardial infarction by electrocardiogram, or 
a self-reported history of cardiovascular surgery or angioplasty [150].  Incident CHD was 
defined as fatal CHD, definite or probable MI, and/or coronary revascularization.   
HF prevalence criteria (at visit 1) included current medication use for HF and/or 
having manifest HF as defined by Gothenburg criteria stage 3, which requires the 
presence of specific cardiac and pulmonary symptoms as well as medical treatment for 
HF [151].  Incident HF was defined as either (1) a hospitalization which included an 
International Classification of Diseases, 9th revision (ICD-9), discharge code of 428 in any 
position; or (2) a death certificate with a ICD-9 code of 428 or an ICD-10 code of I50 in 
any position.  Non-hospitalized, non-fatal HF was not captured. 
Prevalent stroke (visit 1) was defined as a self-reported history of physician-
diagnosed stroke [152].  Incident stroke (definite or probable) was defined as evidence 
of sudden or rapid onset of neurological symptoms lasting for >24 hours or leading to 
death.  Furthermore, these neurological symptoms could not have been attributable to 
non-stroke causes including major brain trauma, neoplasm, coma due to metabolic 
disorders or disorders of fluid or electrolyte balance, vasculitis involving the brain, 
peripheral neuropathy, hematologic abnormalities, or central nervous system infections.  
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2.6.3 GLYCEMIA STATUS  
Manuscript 1 (omega-3 PUFAs and glycemia) will involve analyzing different 
populations of subjects, specifically non-diabetic participants, diabetic participants, and 
those with pre-diabetic conditions.  As such, the ARIC population will need to be divided 
into subgroups defined below.  Variables involved in classifying participants were 
collected at each visit. 
2.6.3.1 Type 2 Diabetes (T2D) 
As previously mentioned, diabetes status was updated at each visit and defined 
as (1) self-report of physician-diagnosed diabetes; (2) self-reported use of diabetes 
medication in the past two weeks; (3) fasting glucose level ≥ 7.0 mmol/liter (126 mg/dl); 
or (4) non-fasting glucose level ≥ 11.1 mmol/liter (200 mg/dl). 
2.6.3.2 Pre-Diabetics (Pre-T2D) 
FBG was tested at each visit.  Those with FBG between 100-125 mg/dL were 
classified as having pre-diabetes (Pre-T2D). 
2.6.3.3 Normoglycemics (NGT) 
The normoglycemic (NGT) population was defined as participants without T2D or 
Pre-T2D. 
2.7 SUMMARY 
This dissertation used data from the ARIC study collected over four visits from 
1987 through 1998.  Use of these data offer many strengths.  It is a population-based, 
biracial cohort who were followed over several years with repeated measures of 
exposures, outcomes, and covariates.  
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3 MANUSCRIPT 1: INTAKE OF LONG-CHAIN OMEGA-3 
POLYUNSATURATED FATTY ACIDS, INCIDENCE OF DIABETES, 
AND MARKERS OF GLUCOSE HOMEOSTASIS IN THE 
ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY 
3.1 SYNOPSIS 
Background: The incidence and prevalence rates of type 2 diabetes are high in the 
United States, with blacks disproportionately affected. The evidence regarding the 
association of dietary intake of fish, fish-derived omega-3 fatty acids, and vegetable-
derived omega-3 fatty acids has been mixed.  
Methods: We studied the association of consumption of seafood, the fish-derived 
omega-3 polyunsaturated fatty acids (PUFAs) eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA), and the vegetable-derived omega-3 PUFA alpha-linoleic 
acid (ALA) with fasting blood glucose (FBG) (n=13,173), HbA1c (n=11,575), and incident 
type 2 diabetes (T2D) (n=11,874) in a bi-racial cohort of individuals aged 45–64 
participating in the Atherosclerosis Risk in Communities (ARIC) study.  Intake of seafood, 
DHA, EPA, and ALA were measured via food frequency questionnaire. FBG and HbA1c 
were obtained using blood samples collected during study visits and diabetes status was 
identified through self-report and lab values.  To estimate differences across exposure 
categories, linear regression was used for continuous outcomes (FBG, HbA1c) adjusting 
for repeated measures as appropriate.  Cox proportional hazards regression with time 
varying covariates was used for the incident T2D outcome. 
Results: In multivariable analyses, intake of seafood and DHA+EPA was favorably 
associated with FBG and HbA1c in non-diabetic participants, although the magnitude of 
the associations were very small ranging between a decrease of 0.35 to 1.35 mg/dL for 
FBG and a decrease of 0.01 to 0.10 percentage points for HbA1c when comparing 
extreme categories.  ALA was not associated with FBG or HbA1c in non-diabetic 
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participants.  Among diabetic participants, intake of seafood, fish-derived DHA+EPA, and 
the vegetable derived ALA was adversely associated with FBG and HbA1c, with 
differential effects for seafood in men (favorable) versus women (adverse) and whites 
(favorable) versus blacks (adverse).  Finally, higher intake of the vegetable derived ALA 
was associated with higher risk of incident T2D in normoglycemics (HR=4.0, 95% CI: 1.7, 
9.6, comparing extreme quartiles), while seafood and the fish-derived DHA+EPA were 
not. 
Conclusions: In this population based cohort, dietary intake of seafood and all omega-3 
nutrients – including ALA – were adversely associated with FBG and HbA1c in diabetic 
participants, although there were differential effects by sex and race for seafood.  In 
contrast, neither seafood nor DHA+EPA was associated with time to incident T2D, but 
higher intake of ALA was associated with higher risk. 
3.2 INTRODUCTION 
Approximately 9% of the adult population in the United States aged 20+ years 
has been diagnosed with type 2 diabetes (T2D), with the highest age-adjusted 
prevalence among non-Hispanic black adults with less than a high school education 
(16.0%) and the lowest among non-Hispanic white adults with more than a high school 
education (6.6%) [1].  Having diabetes is associated with a greater clustering of 
cardiovascular disease (CVD) risk factors compared to those without diabetes [1, 153].  
Lifestyle factors are an important component of preventive strategies to improve 
cardiovascular health, and key among those factors is diet [2].    
Fish consumption has been frequently included in dietary guidelines for the 
prevention of CVD and its risk factors. Both the American Heart Association and the 
American Diabetes Association recommend at least two servings of oily fish a week to 
promote cardiovascular health [3, 154].  Oily fish is rich in the long-chain omega-3 
polyunsaturated fatty acids (PUFAs) docosahexaenoic acid (DHA) and eicosapentaenoic 
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acid (EPA).  These, along with the vegetable-derived omega-3 PUFA alpha-linolenic acid 
(ALA) play major roles in physiological processes [5]. 
Studies investigating seafood intake and intake of fish-derived and vegetable-
derived omega-3 PUFAs with markers of glucose homeostasis have been mixed.  Recent 
reviews and meta-analyses have reported that dietary intake of fatty fish and the fish-
derived omega-3 PUFAs DHA and EPA are associated with higher risk of T2D in American 
and European populations [85-88] but not Asians [86].  There was no association found 
between dietary intake of lean fish or shellfish with T2D [86]; and plasma measures of 
DHA and EPA were also not associated with a higher risk of T2D [85].  In diabetics, a 
meta-analyses of fish oil supplementation studies found that supplementation had 
favorable – but non-significant – associations with HbA1c and insulin [73], although the 
AHA no longer recommends fish oil supplementation for diabetics for the prevention of 
cardiovascular disease [74]. 
Studies investigating intake of the vegetable-derived ALA have been similarly 
mixed.  A meta-analysis found higher intake of ALA was associated with lower risk of 
incident T2D [85] but a subsequent analysis two years later showed favorable 
associations in Asians only, although Americans and Europeans had a nonsignificant 
favorable trend [86]. 
Given the inconsistent nature of the previous literature, we tested the 
associations among dietary intakes of seafood, the fish-derived omega-3 PUFAs DHA 
and EPA, and the vegetable derived omega-3 PUFA ALA with glycemia outcomes in the 
Atherosclerosis Risk in Communities (ARIC) study – a population-based, biracial cohort, 
with twelve years of follow-up data and repeated measures for the exposures and 
outcomes of interest. 
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3.3 METHODS 
3.3.1 STUDY POPULATION 
The ARIC study has been described previously [155]. Briefly, ARIC is a prospective 
study of cardiovascular disease including 15,792 men and women 45–64 years of age at 
baseline (visit 1). Participants were recruited from four US communities using 
probability sampling techniques. The communities and racial composition were: 
predominately white subjects from suburbs of Minneapolis, Minnesota, and Washington 
County, Maryland; black subjects from Jackson, Mississippi; and white and black 
subjects from Forsyth County, North Carolina. 
Visit 1 data were collected in 1987–89 and three additional exams were 
performed at approximately 3-year intervals (1990–92, 1993–95, 1996–98). A fifth exam 
was conducted in 2011-13 (visit 5), but those data were not utilized in this study as 
outcomes would have occurred more than 20 years after our exposure assessment. 
Our exclusion criteria were as follows (see Figure 3-1).  We excluded participants 
with missing values for exposures, outcomes, or covariates.  Those whose race was 
neither black nor white (n = 48) were excluded, and we further excluded black 
participants at the Minneapolis and Washington County sites (n = 55) due to small n.  
We excluded those participants who had prevalent or incident coronary heart disease, 
heart failure, or stroke as (1) prevalent conditions influence how patients have their 
comorbidities managed, diagnosed and treated; and (2) diagnoses may result in changes 
to previously reported dietary and lifestyle behaviors.  Finally, participants who reported 
implausible caloric intakes were excluded for potentially unreliable exposure data. 
Implausible was defined as less than 500 kcal/day for women and 700 kcal/day for men 
or more than 3500 kcal/day for women and 4500 kcal/day for men.  These ranges 
represent the sex-specific first and 99th percentiles for ARIC energy intake distributions – 
see Tell et al. for the initial description of the exclusion methodology and justification 
[156] and Steffen et al. for first use of current ranges [157]. 
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3.3.2 FASTING STATUS 
All participants self-reported 8-hour and 12-hour fasting status.  Compliance was 
high in non-diabetics, with approximately 98% reporting having fasted for at least 8 
hours and 96% reporting fasting for at least 12 hours.  Compliance was lower in those 
with diabetes, with approximately 88% reporting 8 or more hours and 84% reporting 12 
or more hours fasting. 
3.3.3 GLYCEMIA STATUS POPULATION 
ASSIGNMENT 
At each visit, participants who met the inclusion/exclusion criteria were 
categorized by glycemia status: diabetic participants, those with pre-diabetic conditions, 
and normoglycemic participants. 
Diabetic participants were identified at each visit based on the following criteria 
(1) self-report of physician-diagnosed diabetes; (2) self-reported use of diabetes 
medication in the past two weeks; (3) fasting glucose level ≥ 7.0 mmol/liter (126 mg/dl); 
or (4) non-fasting glucose level > 11.1 mmol/liter (200 mg/dl).  If a participant was not 
diabetic, then the participant was defined as having pre-diabetes (Pre-T2D) if his/her 
fasting blood glucose value was between 100 mg/dl and 125 mg/dl.  The normoglycemic 
(NGT) population was defined as those who had neither Pre-T2D nor diabetes. 
3.3.4 OUTCOME ASSESSMENT 
Three measures of glucose metabolism are used in this study: Fasting Blood 
Glucose (FBG), HbA1c, and incident T2D.  Detailed descriptions of blood draw [146] and 
chemistry analyses [132] can be found in the ARIC Manual of Operations. For outcomes 
that could be influenced by use of anti-hyperglycemic medications (i.e., FBG, HbA1c), a 
correction factor was applied (see the Correction Factor section 3.3.4.4). 
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3.3.4.1 Fasting Blood Glucose   
FBG was measured at visits 1-4.  Fasting blood samples were drawn from an 
antecubital vein with minimal trauma.  FBG was then measured by a hexokinase method 
on a Coulter DACOS (Coulter Instruments).  In a small validation study blood samples 
from volunteers (n=40) were taken two weeks apart.  For serum glucose the intraclass 
correlation was 0.84, the within-person coefficient of variation (CV) was 4%, and the 
laboratory CV was 2% [133]. 
3.3.4.2 Hemoglobin A1c 
HbA1c was measured from whole blood samples using high-performance liquid 
chromatography.  The blood was collected during visit 2 (1990-92) and stored at -70 Cº 
for 14-18 years until HbA1c measurements could be obtained.   
Selvin et al. give a detailed description of the HbA1c measurement process [158], 
but briefly, measurements were obtained in the same laboratory during two separate 
time periods using two different instruments: n=4,918 subjects in 2003-04 using Tosoh 
2.2 Plus HPLC (Tosoh Bioscience, South San Francisco, CA) and n=9,151 subjects in 2007-
08 using Tosoh G7 HPLC.  Both instruments were certified by the National 
Glycohemoglobin Standardization Program (NGSP) and standardized to the Diabetes 
Control and Complications Trial assay. This calibration provides stable results despite 
changes in HbA1c methodologies over time.  A convenience sample (n=383) was 
analyzed using both instruments.  Pearson's correlation coefficient between the two 
samples was high (r=0.99) but there was a slight bias with 2007-08 values showing a 
0.29 higher %HbA1c (p<0.0001).  The intraclass correlation coefficient was 0.99 (95% CI: 
0.97-0.99) and within-sample coefficient of variation (CV) of 3.9% (95% CI: 3.6% to 
4.2%). 
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3.3.4.3 Incident Type 2 Diabetes 
As previously mentioned, diabetes was defined as (1) self-report of physician-
diagnosed diabetes; (2) self-reported use of diabetes medication in the past two weeks; 
(3) fasting glucose level ≥ 7.0 mmol/liter (126 mg/dl); or (4) non-fasting glucose level > 
11.1 mmol/liter (200 mg/dl).   
Although investigators did not distinguish type 1 diabetes mellitus from T2D, T2D 
is the most commonly occurring variant of diabetes and rarely occurs before age 30 in 
individuals who were middle-aged in the 1980’s [135].  Defining participants who met 
these criteria as having T2D is consistent with other ARIC studies where type 1 diabetes 
was defined as subjects with age of onset before age 30 [136]. 
Analyses with incident T2D as the outcome of interest excluded participants who 
had prevalent diabetes at visit 1.  Participants who met the diabetes criteria at 
subsequent visits were considered to have incident T2D and date of onset was defined 
as the visit date. 
3.3.4.4 Correction Factor 
For those participants who reported taking anti-hyperglycemic medications – 
insulin (mixed, beef, pork, human, or unspecified), sulfonylureas or sulfonylurea 
combinations, biguanides, meglitinides, aldose reductase inhibitors, alpha-glucosidase 
inhibitors, thiazolidinediones, or other – we applied a correction factor using the 
approach described in Tobin et al. [159] and other studies with glycemia outcomes [160, 
161].  Specifically, for medicated participants, we added a constant of 1 mmol/dl (18 
mg/dl) to fasting blood glucose measures and 1 percentage point to HbA1c values.  
These constants were based on pharmaceutical studies, systematic reviews, and meta-
analyses of the effect of medication on glycemia biomarkers [162-166]. 
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3.3.5 EXPOSURE ASSESSMENT 
In this study, we focused on dietary consumption of fish and shellfish, the fish-
derived omega-3 fatty acids DHA and EPA, and the vegetable-derived ALA. 
Participants’ usual dietary intake was assessed by an interviewer-administered, 
66-item food frequency questionnaire (FFQ). The FFQ was based on the instrument 
developed by Willett et al. [167], with three principal modifications: (1) Data regarding 
alcohol consumption were obtained using a separate, more detailed instrument; (2) 
Several food items were added (e.g., donuts, biscuits, and cornbread); and (3) Some 
items were split into detailed subcategories – notably a single item on fish consumption 
was separated into three specific fish items. 
The 61-item Willett version has been validated against 28-day food record, but 
the validation took place in a population of educated, predominately white women 
[124, 167]. The ARIC questionnaire was also validated in a sample (n=419) of black and 
white ARIC participants who repeated the FFQ after three years [125]. The study found 
that, after adjusting for total caloric intake, the median reliability coefficient for blacks 
was 0.42 and the reliability for white ARIC participants was 0.49 – a value similar to that 
of other studies of white subjects.  The study found no difference in the median 
reliability coefficients of men and women after adjusting for total calorie intake. 
Another study investigated the validity of the ARIC FFQ by comparing Minnesota 
field center participants’ intake of dietary fat as measured via FFQ against their plasma 
fatty acid concentrations [126].  Plasma measures reflect the types of fats proportionally 
consumed over the past several weeks to months [127] and the proportionate 
composition in plasma was moderately correlated with dietary intake, with highest 
correlations in the fish-derived omega-3 fatty acids DHA and EPA (r=0.42 and r=0.20 for 
plasma phospholipid measures of DHA and EPA, respectively) [126]. 
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3.3.5.1 Fish/Shellfish Servings 
Fish and other seafood intake was assessed through four FFQ questions with 
nine response categories. Participants were asked how often they consumed: 3–4 
ounces of canned tuna fish; 3–5 ounces of dark meat fish such as salmon, mackerel, 
swordfish, sardines, and bluefish; 3–5 ounces of other fish such as cod, perch, catfish, 
etc.; and shrimp, lobster, scallops as a main dish. Interviewers used food models to help 
participants with portion size estimation. Subjects could provide answers to each 
question ranging from ‘‘never or less than once per month’’ to ‘‘6 times per day.’’  
Applying the same methodology used in another study of seafood intake in the 
ARIC cohort [128], each of the participants’ seafood-related FFQ responses were 
grouped into three exposure categories: (1) omega-3 rich fish (tuna + dark); (2) total fish 
(tuna + dark+ other); and (3) total seafood (tuna + dark + other + shellfish). Exposure 
categories were categorized into four weekly serving categories: none, less than one, 
one to two, and more than two. 
3.3.5.2 Quartiles of Omega-3 PUFA 
Daily intake of macro- and micronutrients was calculated via the FFQ by 
multiplying the nutrient content of each food by the frequency of daily consumption 
and then summing the results [124]. This process yielded daily intake of nutrients 
expressed as grams per day. Three different classifications of omega-3 fatty acids were 
investigated: (1) vegetable-derived ALA, (2) fish-derived DHA+EPA; and (3) 
ALA+DHA+EPA. 
Intake of nutrients was adjusted using the residual method [168, 169]. In this 
method, nutrient residuals (observed intake – predicted intake) are obtained from the 
regression of total nutrient intake on total energy intake.  The nutrient residuals are 
then rescaled by adding the overall mean nutrient intake to each participant’s residual.  
For this manuscript, we created rescaled residuals for the three nutrient classifications – 
ALA, DHA+EPA, and ALA+DHA+EPA – and categorized these into quartiles.   
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We selected the residual method rather than the standard multivariable method 
(quartiles of raw nutrient values as the exposure with total energy intake as a covariate) 
because (1) with the residual method, differences in exposure values amongst 
participants are due to differences in nutrient intake from the nutrient composition of 
the diet (versus overall variation in nutrient intake, which is due to diet composition and 
calorie amount) [169]; (2) when dietary exposure variables are categorized, the residual 
and the standard multivariable models are no longer mathematically equivalent [168-
170]; and (3) the residual model allows for greater precision [168].  All regression 
models where residual-adjusted nutrients were the exposure of interest included total 
energy intake (kcal/day) as a covariate. 
3.3.6 POTENTIAL CONFOUNDERS 
We selected potential confounders a priori based on their hypothesized 
relationship with exposure and outcome.  While most variables were measured at 
multiple visits, potential confounders were measured contemporaneously with 
exposure values (visits 1 and 3) to avoid adjusting for confounders measured after our 
exposure of interest [143]. Potential confounders were grouped into four main 
categories: sociodemographic, lifestyle, dietary, and clinical variables. 
3.3.6.1 Sociodemographic Variables 
Sociodemographic variables included age, sex, race, field center, and education 
level.  Age, sex, and self-reported race were obtained at visit 1 and confirmed at 
subsequent visits. Education level was measured at visit 1 via self-report and 
categorized based on years of education. We grouped education level as basic (no high 
school degree), intermediate (completed high school), and advanced (at least some 
college). 
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3.3.6.2 Lifestyle Variables 
Lifestyle variables include body mass index (BMI), physical activity, smoking 
status, and drinking status and amount.  Technicians measured height and weight, and 
BMI was calculated as weight (kilograms) divided by height squared (meters2). Physical 
activity was measured at visits 1 and 3 using the Baecke questionnaire [144]. The 
questionnaire included 16 items about usual exertion, and three indexes ranging from 1 
(low) to 5 (high) were derived for physical activity at work, during leisure time, and in 
sports. The reliability and validity of the Baecke questionnaire are good for both male 
and female subjects, and equal to many other physical activity instruments [145]. The 
three physical activity scores were summed and then translated into tertiles of physical 
activity (low, medium, and high). Smoking status was assessed via self-report and 
participants were classified as current smokers, former smokers (more than 100 
cigarettes in the past), and never smokers. Alcohol intake status (current, former, never) 
and amount (grams/day) were measured at visits 1 and 3.  
3.3.6.3 Dietary Variables 
Dietary variables included trans fatty acids, saturated fatty acids, and dietary 
fiber.  Intake of trans fatty acids, saturated fatty acids, and total dietary fiber from all 
plant sources (fruits, legumes, cereals, and vegetables) were measured at visits 1 and 3 
via FFQ and translated into nutrient values as described in the exposure section (Section 
3.3.5). 
3.3.6.4 Clinical Variables 
Clinical variables included hypertension, LDL, HDL, and triglycerides.  During each 
visit, three blood pressure measurements were taken with a random-zero 
sphygmomanometer and the mean of the last two measurements was used.  
Hypertension was defined as a systolic blood pressure above 140 mmHg, a diastolic 
above 90 mmHg, or self-reported use of antihypertensive medication.  Participants with 
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missing hypertension values (n=62 visit 1; n=56 visit 3) were imputed as not having 
hypertension (no disease). For metrics requiring phlebotomy, blood was drawn after a 
minimum 8-hour fasting period with minimal trauma from an antecubital vein [146]. 
Plasma total cholesterol and triglycerides were measured by enzymatic methods [132], 
and LDL cholesterol was calculated using the Friedewald formula [147]. HDL cholesterol 
was measured after dextran-magnesium precipitation of non-HDL lipoproteins [132]. 
3.3.7 STATISTICAL ANALYSES 
The statistical methods used varied by the study design used to investigate the 
relationship between the exposure and outcome of interest.  Outcome-specific study 
populations, study designs, and statistical methods are described in this section. 
For clarity, Figure 3-2 depicts the study design for all three outcomes of interest 
including the temporality of the exposure, outcomes, covariates, and subpopulations 
based on glycemia status.   
The green ovals represent exposures and covariates obtained at visit 1 and visit 
3.  Visit 1 values were used in regressions involving outcomes obtained at visit 1 and 
visit 2, whereas visit 3 values were used for outcomes obtained at visits 3 and 4.  The 
blue arrow gives the timeline for each of the ARIC visits.  The grey boxes represent that 
participants’ glycemia status (T2D, Pre-T2D, NGT) and was updated at each of the four 
ARIC visits (where applicable).  Similarly, the pink box demonstrates that 
inclusion/exclusion criteria were updated and applied at each visit (where applicable). 
All statistical analyses were performed with SAS (version 9.4, Enterprise guide 
7.1, SAS Institute Inc., Cary, NC, USA). 
3.3.7.1 Fasting Blood Glucose 
For this outcome, we used a quasi-repeated cross-sectional design where each 
participant who met the inclusion/exclusion criteria at visit 1 could be included in the 
analysis up to four times (visit 1, plus once for each subsequent visit where he/she met 
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the inclusion/exclusion criteria).  For each visit meeting the inclusion/exclusion criteria, 
we noted the participant’s glycemia status and outcome (FBG).  As previously 
mentioned, exposure and confounder values from visit 1 were used in observations for 
visits 1 and 2, and observations for visits 3 and 4 used exposure and covariate values 
from visit 3.  Associations between fish/shellfish servings, quartiles of omega-3 PUFA 
intake, and FBG were estimated using generalized estimating equations to account for 
repeated measures, using a normal distribution and an identify link, and assuming an 
independent working correlation structure.  A sensitivity analysis was conducted 
evaluating the impact of assuming an unstructured working correlation structure and 
this modification did not appreciably alter our results.  Because our sample size was 
large, we did not test for violations of the normality assumptions [171]. 
3.3.7.2 Hemoglobin A1c 
For this outcome, we used a modified cross-sectional study design.  Exposures 
and covariates were measured at visit 1, glycemia status and HbA1c were measured at 
visit 2, and inclusion/exclusion criteria were applied at both visits 1 and 2.  Associations 
between fish/shellfish servings, quartiles of omega-3 PUFA intake, and HbA1c were 
estimated using linear regression.  Because our sample size was large, we did not test 
for violations of the normality assumptions [171]. 
3.3.7.3 Incident Type 2 Diabetes 
For this outcome, we used a prospective study design.  Those free of diabetes at 
visit 1 were followed through each of the subsequent visits until either diagnosis or 
censoring.  We used Cox proportional hazards regression models to estimate hazard 
ratios (HRs) for incident T2D by level of fish/shellfish consumption and quartiles of 
omega-3 PUFA intake. Exposure status and potential confounders were modeled as 
time-dependent covariates with visit 1 data used for the period between visit 1 and visit 
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3, and visit 3 data afterwards.  Because we used time-varying covariates, we did not test 
for violations of the proportional hazards assumption. 
3.3.8 COVARIATE ADJUSTMENT MODELS 
Three models were used to adjust for potential confounders measured 
contemporaneously with exposure values: Model 1 adjusted for sociodemographic 
variables (age, sex, race, center, education); Model 2 further adjusted for lifestyle 
variables (BMI, physical activity, smoking status, drinking status and amount) and 
dietary variables (trans fatty acids, saturated fatty acids, and dietary fiber); Model 3 
further adjusted for clinical variables (hypertension, HDL, LDL, triglycerides).  All models 
included total energy intake (kcal/day) as a covariate.  
3.3.9 GLYCEMIA STATUS AS AN EFFECT 
MEASURE MODIFIER 
For all outcomes, we evaluated whether glycemia status (NGT, Pre-T2D, and, if 
applicable, T2D) was an effect measure modifier on the multiplicative scale by including 
the interaction term (glycemia status*exposure) in the regression models and 
considering the term’s p-value.  If the interaction term was significant (p<0.1), the term 
was kept in the model and results were presented for each sub-population (i.e., one set 
of results for those with NGT, another for those with Pre-T2D, and if applicable, another 
for those with T2D).  If the interaction term was not significant, then we presented one 
set of results for the full cohort.  In either instance, we tested for a linear trend in the 
association between our exposure and outcome by modeling the exposure category 
medians as a continuous variable. 
3.3.10 RACE AND SEX AS EFFECT MEASURE 
MODIFIERS 
Where appropriate, we tested for effect modification by race and sex by 
considering race*exposure and sex*exposure interaction terms.  For HbA1c and FBG 
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outcomes, if we had previously found that glycemia status was an effect modifier, race 
and sex interaction terms were tested in glycemia status-stratified subsets of data to 
avoid testing a three-way interaction (race*exposure*glycemia status; or 
sex*exposure*glycemia status).   
For Incident T2D, if we had previously found that glycemia status (NGT vs. Pre-
T2D) was an effect modifier, we could not subset the data as we did for continuous 
outcomes without introducing an overly complicated person time model.  Consider a 
participant who was NGT at visit 1 and transitioned to Pre-T2D at visit 2 and then was 
diagnosed with T2D at visit 3.  If we were to subset the data based on diabetes status, 
that participant would contribute three years of person time to the NGT time-to-event 
dataset and three years of person time to the Pre-T2D dataset.  For simplicity, we used a 
single dataset and tested the interaction term –exposure*race (or sex)*glycemia status 
(NGT or Pre-T2D).   
Finally, to avoid being overly reliant on p-values across multiple 
exposure/outcome/glycemia status models, we qualitatively compared the measures of 
association by race and by sex.  That is, we reviewed exposure/outcome results for 
white participants and compared them to results for black participants.  We performed 
the same qualitative analysis for male- and female-specific results. 
3.3.11 SENSITIVITY ANALYSES 
We performed several sets of sensitivity analyses.  In Section 3.3.7 we described 
the working correlation structure sensitivity analyses (independent vs. unstructured).  
We also examined if including protein (grams/day) as a covariate altered our 
associations, as seafood is high in protein and protein has been shown to be associated 
with incident T2D [172, 173].  For FBG outcomes, we investigated if limiting our analysis 
to those who self-reported compliance with the 12-hour fasting request appreciably 
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altered our results.  Finally, among those with T2D, we considered results stratified 
based on antihyperglycemic medication use.  
3.4 RESULTS 
The characteristics of the 13,173 participants who met the least restrictive 
inclusion/exclusion criteria (FBG analyses) by categories of total seafood intake (total 
fish + shellfish) are shown in Table 3-1. 
The greatest proportion of participants consumed one to two servings of 
seafood per week (45%).  The fewest number of participants fell into the lowest 
exposure category with zero servings of seafood per week (8%).  Those who consumed 
more seafood tended to be younger, female, and more educated.  Additionally, there 
was a greater proportion of black participants at higher levels of total seafood compared 
consumption compared to lower levels of consumption.  Clinically, cardiovascular risk 
profiles varied across seafood consumption categories.  Prevalence of hypertension and 
BMI were higher with greater amounts of seafood consumption; smoking rates were 
lower with greater seafood consumption.   
3.4.1 ASSOCIATIONS WITH FASTING BLOOD 
GLUCOSE 
For each of the three food exposures (total seafood, total fish, total omega-3 rich 
fish) and the three omega-3 PUFA exposures (quartiles of ALA, DHA+EPA, and ALA+ 
DHA+EPA) the exposure*glycemia status interaction term was significant.  P-values for 
the interactions along with glycemia status-specific results are reported in tables 3-2 
through 3-7.  Including protein as a covariate in the regression models did not 
substantively change our results (data not shown). 
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3.4.1.1 Normoglycemic and Pre-Diabetic 
Populations 
3.4.1.1.1 Fish/Shellfish Servings and Quartiles of Fish-Derived Omega-3 PUFAs 
(DHA+EPA) 
In most models, intake of seafood and DHA+EPA was associated with lower FBG 
in both NGT and pre-T2D populations, though these associations were of small 
magnitude and possibly not clinically relevant (tables 3-2 through 3-5). With zero 
servings/week as the reference category for the food exposures, differences in FBG for 
those consuming less than one, one to two, or more than 2 servings were all less than 
1.26 mg/dl.  With the first quartile as the reference category for DHA+EPA, all 
differences in FBG were less than 1.35 mg/dl. 
3.4.1.1.2 Quartiles of Vegetable-Derived Omega-3 PUFAs (ALA) 
In both NGT and pre-T2D populations, intake of ALA was not associated with FBG 
(tables 3-3 and 3-5). 
3.4.1.2 Diabetic Populations 
3.4.1.2.1 Fish/Shellfish Servings 
In those with T2D, intake of fish/shellfish was associated with higher FBG (Table 
3-6).  Total fish had the largest association with FBG, with those consuming two or more 
servings per week having 16.1 mg/dl higher FBG compared to those consuming no fish 
(Model 3, 95% CI: 6.5, 25.6, p=0.003).  Results for total seafood were similar to those for 
total fish (Figure 3-3).  Differences in FBG among categories of omega-3 rich fish were 
smaller than the differences in FBG for total fish or total seafood, but also statistically 
significant.  Participants who consumed two or more servings of omega-3 rich fish per 
week had 7.8 mg/dl higher FBG values on average compared to those who consumed 
none (Model 3, 95% CI: -0.9, 16.5, p=0.003).  Figure 3-3 shows all three exposures and 
their association with FBG.  Limiting the populations to those who self-reported fasting 
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for 12 or more hours did not substantively change our results; and stratifying by 
antihyperglycemic medication use also yielded similar results (data not shown). 
3.4.1.2.2 Omega-3 PUFA Intake 
Among participants with T2D, intake of vegetable-derived ALA, fish-derived 
DHA+EPA, and total omega-3 PUFA (ALA+DHA+EPA) was associated with higher FBG 
values (Table 3-7).  The largest difference in FBG for the highest quartile of intake 
(compared to quartile 1) was in DHA+EPA+ALA (Model 3, Q4 vs. Q1 = 23.4 mg/dl, 95% 
CI: 16.3, 30.5).  When considered separately, ALA and DHA+EPA were also statistically 
significantly associated with FBG, with differences across quartiles of ALA (compared to 
the first quartile) slightly larger than those for DHA+EPA (Model 3, Q4 vs. Q1 (95% CI): 
ALA = 18.1 mg/dL, 95% CI: 11.2, 25.0; DHA+EPA = 16.6 mg/dL 95% CI: 9.4, 23.7).  Figure 
3-4 shows all three omega-3 PUFA exposures and their associations with FBG.  Limiting 
the populations to those who self-reported fasting for 12 or more hours did not 
substantively change our results; and stratifying by antihyperglycemic medication use 
also yielded similar results (data not shown). 
3.4.1.3 FBG Race and Sex Effect 
Modifier Analyses 
Among those with NGT and Pre-T2D, and where the race*exposure or 
sex*exposure interaction terms were statistically significant, the differences in 
associations amongst race- and sex-stratified groups were so small as to be clinically 
irrelevant. 
For those with T2D, there was no evidence of effect modification by race or sex 
for the three omega-3 PUFA quartile exposures (ALA, DHA+EPA, ALA+DHA+EPA).  
However, there was evidence of effect modification by race and sex for total seafood 
intake and total fish intake.  The association between total seafood and FBG in diabetic 
women suggested an adverse effect whereas there was no association in diabetic males.  
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Intake of total fish had similar point estimates, but overall the interaction term was non-
significant (figures 3-5 and 3-6).  The association between total seafood and FBG and 
total fish and FBG in blacks and whites suggested there may be effect modification by 
race, although the interaction term was not statistically significant (figures 3-7 and 3-8).  
3.4.2 ASSOCIATIONS WITH HBA1C 
As seen in Figure 3-1, there were n=11,575 participants who met the 
inclusion/exclusion criteria for the HbA1c analysis.  For each of the three food exposures 
(total seafood, total fish, total omega-3 rich fish) and the three omega-3 PUFA 
exposures (quartiles of ALA, DHA+EPA, and ALA+ DHA+EPA) the exposure*glycemia 
status interaction term was significant.  Glycemia status-specific results are reported in 
tables 3-8 through 3-13.  Including protein as a covariate in the regression models did 
not substantively change our results (data not shown). 
3.4.2.1 Normoglycemic Populations 
3.4.2.1.1 Fish/Shellfish Servings 
As seen in Table 3-8, intake of total seafood (Model 3, p=0.07) and total fish 
(Model 3, p=0.06) had borderline significant p-values, with higher intake of fish/seafood 
associated with lower HbA1c values, but the associations were of small magnitude; the 
largest point estimate was 0.11 percentage points (Model 3, 2+ servings total seafood 
versus none, 95% CI: -0.19, -0.02). Omega-3 rich fish was not associated with HbA1c 
(Model 3, p=0.33). 
3.4.2.1.2 Omega-3 PUFA Intake 
Intake of DHA+EPA was significantly associated with lower HbA1c values in NGT 
populations (Table 3-9).  Compared to those in the lowest quartile of DHA+EPA intake, 
those in the fourth quartile of intake had 0.09 percentage points lower HbA1c (Model 3, 
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95% CI: -0.16, -0.03).  Neither ALA nor ALA+DHA+EPA intake was significantly associated 
with HbA1c (Table 3-9). 
3.4.2.2 Pre-Diabetic Populations 
Neither fish/shellfish servings nor quartiles of fish-derived omega-3 PUFAs 
DHA+EPA were associated with HbA1c among participants with Pre-T2D (tables 3-10 
and 3-11).  Associations resulting from Model 1 showed a significant positive association 
between intake of ALA and HbA1c (Q4 - Q1 = 0.09 percentage points, 95% CI: 0.01, 
0.16), the association disappeared after additional adjustment (p=0.32 Model 2; p=0.29 
Model 3). 
3.4.2.3 Diabetic Populations 
3.4.2.3.1 Fish/Shellfish Servings 
In those with T2D, higher intakes of total seafood and of total fish (compared to 
lower) were associated with higher HbA1c.  There was no association between omega-3 
rich fish intake and HbA1c. (Table 3-12; Figure 3-9) 
Of the three seafood exposures, total fish had the largest point estimate among 
the fully adjusted model results, with those consuming two or more servings per week 
having 0.28 percentage points higher HbA1c compared to those consuming no fish 
(Model 3, p=<0.0001, 95% CI: 0.05, 0.51).  Results for total seafood followed a similar 
pattern.  Stratifying by antihyperglycemic medication use also yielded similar results 
(data not shown). 
3.4.2.3.2 Omega-3 PUFA Intake 
In those with T2D, intake of DHA+EPA and ALA was associated with higher HbA1c 
values (Table 3-13).  The largest difference in HbA1c, when comparing quartile 4 to 
quartile 1, was in DHA+EPA+ALA (Model 3, Q4 vs. Q1 = 1.06 percentage points, 95% CI: 
0.89, 1.22).  The fish-derived omega-3 PUFAs DHA+EPA and the vegetable-derived 
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omega-3 PUFA ALA were also statistically significant, with differences in HbA1c across 
quartiles of ALA slightly larger than those for DHA+EPA (Model 3, Q4 vs. Q1 (95% CI): 
ALA = 0.88 percentage points (0.71, 1.04), DHA+EPA = 0.50 percentage points (0.34, 
0.66). (Figure 3-10.)  Stratifying by antihyperglycemic medication use also yielded similar 
results (data not shown). 
3.4.2.4 HbA1c Race and Sex Effect 
Modifier Analyses 
Among those with NGT and Pre-T2D, in instances where the race*exposure or 
sex*exposure interaction terms were significant, the differences in the 
exposure/outcome relationship by race and sex categories were so small as to be 
clinically irrelevant (data not shown).   
For those with T2D, there was no evidence of effect modification by race or sex 
for the three PUFA exposures (DHA+EPA+ALA, DHA+EPA, ALA) but there was evidence of 
effect modification by race and sex for total seafood intake and total fish intake.   
The association between total seafood and HbA1c in diabetic women suggested 
an adverse effect whereas results for diabetic males showed a non-significant beneficial 
association. Intake of total fish had similar point estimates, but the interaction term was 
not significant (figures 3-11 and 3-12).   
The association between total seafood and HbA1c and total fish and HbA1c in 
blacks and whites suggested there may be effect modification by race, although the 
interaction term was not statistically significant (figures 3-13 and 3-14).  
3.4.3 ASSOCIATIONS WITH INCIDENT T2D 
As seen in Figure 3-1, there were n=11,874 participants who met the 
inclusion/exclusion criteria for the incident T2D analysis.  Results are reported in tables 
3-14 through 3-16.  Including protein as a covariate in the regression models did not 
substantively change our results (data not shown). 
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3.4.3.1 Normoglycemic and Pre-Diabetic 
3.4.3.1.1 Fish/Shellfish Servings and Fish-Derived Omega-3 
As shown in tables 3-14 and 3-15, neither the whole food exposures (total 
seafood, total fish, omega-3 rich fish) nor the fish-derived omega-3 fatty acids DHA+EPA 
were significantly associated with incident T2D.  There was no evidence of effect 
modification by diabetes status (NGT and Pre-T2D). 
3.4.3.1.2 Vegetable-Derived Omega-3 PUFA (ALA) Intake 
As seen in Table 3-16, ALA intake was adversely associated with incident T2D.  
The population*exposure interaction was significant, likely because associations in NGT 
were strong (Model 3, Q4 vs. Q1, HR=4.0, 95% CI: 1.65, 9.64) and those in Pre-T2D were 
mostly null (Model 3, Q4 vs. Q1, HR=1.1, 95% CI: 0.75, 1.6). 
3.4.3.2 Incident T2D Race and Sex Effect 
Modifier Analyses 
There was no evidence of effect modification by race or sex in the incident T2D 
analyses. 
3.5 DISCUSSION 
In this population-based study of middle aged adults, our investigation of the 
relationship among seafood, omega-3 PUFA, and markers of glycemia is summarized in 
Table 3-18. 
Among those participants who were diabetic, we found consistent evidence that 
higher intake of fish and shellfish, the fish-derived omega-3 PUFAs DHA+EPA, and the 
vegetable derived omega-3 PUFA ALA was adversely associated with both FBG and 
HbA1c.  Moreover, there was evidence of effect modification, with adverse associations 
in blacks and females and non-significant favorable associations in whites and males – 
although the interaction terms often failed to reach statistical significance. 
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Among those participants who were not diabetic (NGT and Pre-T2D), we found 
that while intake of fish and shellfish and of the fish-derived omega-3 PUFA DHA+EPA 
was associated with lower values of FBG and HbA1c in those with NGT and Pre-T2D, 
these differences were quite small and of uncertain clinical relevance.  Furthermore, 
while intake of the vegetable-derived omega-3 PUFA ALA was not associated with FBG 
or HbA1c in those with NGT or Pre-T2D, intake of ALA was associated with higher risk of 
incident T2D. 
3.5.1 DIABETIC POPULATIONS 
3.5.1.1 Fish/Shellfish Servings and Fish-
Derived Omega-3 PUFA 
(DHA+EPA) Intake 
Our results for seafood intake and intake of fish-derived omega-3 PUFA in 
diabetics are consistent with other studies.  A recent systematic review and meta-
analysis evaluated the associations of DHA, EPA, and seafood with incident type 2 
diabetes (T2D) and found that consumption of fish-derived omega-3 PUFAs higher risk 
of T2D in Americans; although risk was reduced in Asians and Australians [86]. Another 
meta-analysis of cohort studies found that intake of fish and fish-derived omega-3 
PUFAs might be weakly positively associated with T2D, especially in American (versus 
Asian) populations [174]. 
There are data to support the biological plausibility of fish-derived omega-3 
PUFAs DHA and EPA adversely affecting glucose homeostasis in those with T2D. A 
previous study showed that diabetics who took a FDn3FA supplement had lower glucose 
utilization (insulin sensitivity) and increased glucagon-stimulated C-peptide [67]. In 
another trial, diabetic subjects taking fish oil supplements showed reduced hepatic 
gluconeogenesis [68].  Obese subjects with T2D who took fish oil supplements had 
increased uptake and oxidation of non-esterified fatty acids in the liver [69]. In another 
study of obese subjects with T2D, fish oil supplementation increased glycerol 
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gluconeogenesis, and the authors hypothesized it could cause the deterioration of 
glycemic control during long-term treatment with high doses of fish-oil supplements 
[69]. Finally, the associations may be due to contaminants in seafood.  Mouse models 
have shown that elevated blood mercury levels may interrupt insulin signaling 
pathways, and decrease plasma insulin and elevate blood glucose levels [70]. 
The relationship between fish and omega-3 PUFAs with FBG and HbA1c in those 
with T2D was similar but not exact.  While higher intakes of omega-3 PUFA (in quartiles) 
was associated with higher values of both FBG and HbA1c, the relationship across 
servings of seafood was less consistent (figures 3-15 and 3-16).  These differences may 
be an artifact of residual confounding by total energy intake as, consistent with other 
researchers, we did not apply the residual method to whole foods [175, 176], although 
we did adjust for total energy intake.  It may also be a result of protein in seafood, as 
protein has been found to be associated with T2D [172].  However, when we did a 
sensitivity analysis including total protein (grams/day) as a covariate, the measures of 
association did not appreciably change.  It could be that these differences offer insight 
into omega-3 PUFAs influence on biological pathways.  FBG is a marker for impaired 
fasting glucose (IFG) while HbA1c can be used to diagnose impaired glucose tolerance 
(IGT). The progression from NGT to IFG results from a decrease in insulin secretion 
followed by changes in hepatic insulin sensitivity. In contrast, progression from NGT to 
IGT is a consequence of low whole-body insulin sensitivity followed by beta cell 
compensation and exhaustion [177, 178].  The mechanism through which omega-3 
PUFA acts on FBG may be similar to the mechanism through which NGT transitions to 
IFG (decreases in insulin secretion and sensitivity) whereas the mechanism through 
which omega-3 PUFA acts on HbA1c may be similar to that of NGT to IGT (beta cell 
exhaustion).  Further studies may help determine if differences in association are due to 
bias, biological mechanism, or due to chance.  
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3.5.1.2 Effect Modification by Race and 
Sex in Type 2 Diabetics 
(Fish/Shellfish Servings) 
There was a significant interaction by sex for the associations of servings per 
week of total seafood (shellfish + total fish) with FBG, with females showing adverse 
associations and males non-significant favorable associations.  This finding was mirrored 
in the association of total fish intake with FBG and in the associations of HbA1c with 
total seafood and total fish, although none of these last three findings reached statistical 
significance. 
A recent meta-analysis found evidence of sex-specific differences of omega-3 
PUFAs effect insulin resistance, but the relationship was reversed with favorable results 
in women but not men [179]. Lack of consistency of our results with previous studies 
should make us cautious in the interpretation of the sex interaction found in the ARIC 
study. 
Results also suggested that there may be effect modification by race for servings 
per week of total fish and total seafood with FBG and HbA1c – while associations were 
null for whites and adverse for blacks, all interaction terms were non-significant.  
Regardless, this finding suggests that the relationship between dietary intake of 
fish/shellfish and glycemic control may differ by race or region.  Because data were not 
collected on food preparation methods, differences could be due to regional/cultural 
differences in food preparation. 
3.5.1.3 Vegetable-Derived Omega-3 
PUFA (ALA) Intake 
Previous studies have found null [180-182] or favorable associations with ALA 
intake and glycemic control in diabetics [183] or those glucose intolerance [184, 185].  
Our finding that ALA intake is associated with reductions in glycemic control in diabetics 
is novel.  A potential mechanism to explain our findings is that while ALA is not 
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efficiently converted to DHA and EPA – only 0.2-0.8% of ALA is converted to EPA and 0-
4% of ALA is converted to DHA [186] – this conversion could explain the adverse 
associations of ALA with glycemic control in diabetics.  There is also the potential for a 
Type 1 error given the number of analyses we performed. 
3.5.1.4 Limitations in Diabetic 
Population Sub-Studies  
The results in the diabetic populations should be interpreted with caution.  
Individuals with diabetes lack the feedback mechanisms that regulate insulin and 
glucose levels, and daily variance in glucose measures can be influenced by medication 
type and adherence, lifestyle habits like diet, exercise, sleep hygiene, and stress 
management, and clinician protocols.  We attempted to adjust for confounding by 
including physical activity and education level (proxy for socioeconomic status) in our 
regression models, but there may still be residual confounding.  Additionally, there is 
likely unmeasured confounding by sleep quality, stress level, provider-specific treatment 
plans, non-diabetic mediation use, diet quality, and other variables.   
FBG is also influenced by fasting status.  Among diabetics that met the FBG 
inclusion/exclusion criteria, self-reported 8-hour fasting compliance ranged from 86.2% 
(visit 3) to 91.2% (visit 2), with an overall average of 88.3%.  Self-reported 12-hour 
fasting compliance was similar, with a minimum of 81.2% compliance (visit 4) and a 
maximum of 85.6 (visit 2), with an overall average of 83.7%.  When we limited our 
analyses to those who reported fasting for at least 12 hours, results were not 
substantively different. 
We also could not account for intra-individual variability in glucose 
measurements, and studies have shown daily variation in FBG levels can be 15% or more 
[187].  Even if we were to assume that any single FBG measure falls within an 
individual’s range, and that the distribution of measurements in the lower, medium, and 
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upper parts of individuals’ ranges were nondifferential across exposure categories, that 
quasi-misclassification could bias our estimates away from the null [188, 189]. 
Despite these limitations, our results for FBG and HbA1c were relatively 
consistent across exposures, with diabetics consuming greater amounts of omega-3 
PUFAs having higher FBG and HbA1c values than diabetics who consumed less.  We also 
performed sensitivity analyses where diabetic participants were stratified based on 
antihyperglycemic medication use.  Results in the subpopulations were not different 
than those found in the full diabetic population.  Further studies designed to address 
the limitations described could provide additional insight into the relationship between 
seafood and omega-3 PUFA intake and glycemic control in those with diabetes. 
3.5.2 NORMOGLYCEMIC AND PRE-DIABETIC 
POPULATIONS 
3.5.2.1 Fish/Shellfish Servings and Fish-
Derived Omega-3 PUFA 
(DHA+EPA) Intake 
While the effect of fish, shellfish, and DHA+EPA was favorable but modest in 
non-diabetics, this is consistent with other studies that have shown fish oil improves 
insulin secretion, resistance, and sensitivity in non-diabetics [190-192]. 
3.5.2.2 Vegetable-Derived Omega-3 
PUFA (ALA) Intake 
Our findings regarding ALA and incident T2D are novel.  With respect to its 
association with incident diabetes, previous meta-analysis studies have found that 
higher intake of ALA was not associated with incident T2D [85, 174] or that it was 
associated with reduced risk of T2D in Asian populations but not in Americans [86]. 
There is also the potential for a Type 1 error given the number of analyses we 
performed. 
   61 
 
3.6 STRENGTHS AND LIMITATIONS 
This study has many strengths.  It is a population-based, biracial cohort of 
participants who were followed over several years with multiple measures of exposures, 
outcomes, and covariates.  Furthermore, we could study the same individuals over time 
as some moved among NGT, Pre-T2D, and T2D, provided they met our 
inclusion/exclusion criteria. Finally, we had multiple markers of glucose homeostasis.  
However, our study is not without limitations.  There are the limitations we 
listed in section 3.5.1.4 that are specific to our diabetes sub-population analyses.  
Furthermore, with dietary data, there is always the potential for misclassification bias.  
FFQs have been shown to underestimate total caloric intake when compared to doubly 
labeled water, and our dietary data were based on FFQ [193]. Additionally, data were 
not available on fish preparation technique. Analysis in the Cardiovascular Health Study 
have shown that fish preparation method differentially effects the association between 
fish-derived omega-3 PUFAs and CHD, with only intake of tuna and other baked or 
broiled fish associated with cardiovascular benefits, with no or deleterious associations 
for fried fish or fish sandwiches [8].  Fish preparation technique may also effect the 
relationship among seafood, fish-derived and vegetable-derived omega-3 PUFAs, and 
markers of glucose homeostasis.  A similar hypothesis was suggested by Muley et al. 
[86] – that different preparation methods may results in differential effects; and while 
that study was focused on country-specific differences, there are differences in 
preparation techniques among different regions of the United States as well.  Our FFQ 
rolled up fish into very broad categories – different types of fatty fish may have different 
composition of fish-derived omega-3 FA which may significantly alter the overall effect 
of fish. As previously mentioned, the range of seafood intake in the ARIC population was 
limited.  Finally, there is potential for unmeasured confounding. 
   62 
 
3.7 CONCLUSION 
In summary, our results suggest that higher dietary intake of omega-3 fatty acids 
is associated with higher values of FBG and HbA1c amongst diabetics, and with greater 
risk of incident T2D amongst non-diabetics. 
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3.8 FIGURES 
 
Figure 3-1. Inclusion Exclusion Criteria, ARIC, 1987-1998. 
 
Figure 3-2.  Outcome-specific study design depiction with variable temporality, ARIC, 1987-1998. 
  
Exclusion Criteria Visit 1 Visit 2 Visit 3 Visit 4
Cohort 15,792           15,792           15,792           15,792           
Not at Visit -                 1,444             2,905             4,136             
Race Criteria 103                91                   80                   69                   
Covariate Exclusions 1,042             888                2,238             2,248             
Prevalent CVD 1,443             962                845                1,963             
Outcome Exclusions 31                   67 14                   68
Final Visit N (FBG) 13,173           12,340           9,710             7,308             
HbA1c Outcome N Incident T2D Outcome N
Met FBG criteria @ Visit 1 13,173           Met FBG criteria @ Visit 1 13,173           
Not at Visit 2 833 Prevalent T2D 1,299             
No HbA1c value 765 Final Incident T2D Dataset 11,874          
Final HbA1c dataset 11,575          
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Figure 3-3. Associations among seafood types (servings/week) and FBG (mg/dL) in those with diabetes 
(Model 3), ARIC, 1987-1998. 
 
Figure 3-4. Associations among omega-3 PUFA (quartiles) and FBG (mg/dL) in those with diabetes 
(Model 3), ARIC, 1987-1998. 
   65 
 
 
Figure 3-5. Sex modifies the associations between total seafood (servings/week) and FBG (mg/dL) in 
those with diabetes (Model 3), p for interaction = 0.01, ARIC, 1987-1998. 
 
Figure 3-6. Sex modifies the associations between total fish (servings/week) and FBG (mg/dL) in those 
with diabetes (Model 3), p for interaction = 0.26, ARIC, 1987-1998. 
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Figure 3-7. Race modifies the associations between total seafood (servings/week) and FBG (mg/dL) in 
those with diabetes (Model 3), p for interaction = 0.20, ARIC, 1987-1998. 
 
Figure 3-8. Race modifies the associations between total fish (servings/week) and FBG (mg/dL) in those 
with diabetes (Model 3), p for interaction = 0.32, ARIC, 1987-1998. 
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Figure 3-9. Associations among seafood types (servings/week) and HbA1c in those with diabetes (Model 
3), ARIC, 1987-1993. 
 
Figure 3-10. Associations among omega-3 PUFA (quartiles) and HbA1c in those with diabetes (Model 3), 
ARIC, 1987-1993. 
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Figure 3-11. Sex modifies the associations between total seafood (servings/week) and HbA1c in those 
with diabetes (Model 3), p for interaction = 0.14, ARIC, 1987-1993. 
 
Figure 3-12. Sex modifies the associations between total fish (servings/week) and HbA1c in those with 
diabetes (Model 3), p for interaction = 0.40, ARIC, 1987-1993. 
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Figure 3-13. Race modifies the associations between total seafood (servings/week) and HbA1c in those 
with diabetes (Model 3), p for interaction = 0.75, ARIC, 1987-1993. 
 
Figure 3-14. Race modifies the associations between total fish (servings/week) and HbA1c in those with 
diabetes (Model 3), p for interaction = 0.60, ARIC, 1987-1993. 
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Figure 3-15. Deltas for FBG (mg/dL) and HbA1c (percentage points) across servings of total seafood, 
total fish, and total omega-3 rich fish in those with diabetes; fully adjusted model; ARIC, 1987-93 
(HbA1c), 1987-1998 (FBG). 
 
Figure 3-16. Deltas for FBG (mg/dL) and HbA1c (percentage points) across quartiles of ALA+DHA+EPA, 
DHA+EPA, and ALA in those with diabetes; fully adjusted model; ARIC, 1987-93 (HbA1c), 1987-1998 
(FBG). 
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3.9 TABLES 
Table 3-1. Baseline characteristics of ARIC participants (n=13,173) by weekly servings of seafood (total 
fish + shellfish), 1987–1989. Values correspond to mean (SD) or N (%) 
   
Zero 
Svgs/Week 
Less Than 1 
Svgs/Week 
One to Two 
Svgs/Week 
Two or More 
Svgs/Week 
N   989 (7.5%) 1,624 (12.3%) 6,046 (45.9%) 4,514 (34.3%) 
Sociodemographic Covariates      
  Age (years) 54.7 (5.8) 54.0 (5.8) 53.9 (5.7) 53.8 (5.7) 
  Male 535 (54.1%) 762 (46.9%) 2,678 (44.3%) 1,785 (39.5%) 
  White 903 (91.3%) 1,419 (87.4%) 4,597 (76.0%) 2,951 (65.4%) 
  Education     
  Basic 272 (27.5%) 313 (19.3%) 1,338 (22.1%) 956 (21.2%) 
  Intermediate 440 (44.5%) 779 (48.0%) 2,529 (41.8%) 1,706 (37.8%) 
  Advanced 277 (28.0%) 532 (32.8%) 2,179 (36.0%) 1,852 (41.0%) 
Lifestyle Covariates      
  BMI (kg/m2) 26.7 (4.9) 26.8 (4.7) 27.3 (5.2) 28.0 (5.4) 
  Physical Activity^     
  Low 359 (36.3%) 578 (35.6%) 2,112 (34.9%) 1,418 (31.4%) 
  Medium 317 (32.1%) 551 (33.9%) 2,035 (33.7%) 1,514 (33.5%) 
  High 313 (31.6%) 495 (30.5%) 1,899 (31.4%) 1,582 (35.0%) 
  Current Smokers 273 (27.6%) 439 (27.0%) 1,562 (25.8%) 1,096 (24.3%) 
  Current Alcohol Drinkers 517 (52.3%) 991 (61.0%) 3,551 (58.7%) 2,523 (55.9%) 
Dietary Covariates      
  Total Energy Intake (kcal/day) 1,519 (610) 1,522 (582) 1,583 (579) 1,752 (621) 
  Cereal Fiber (grams/day) 3.4 (2.5) 3.3 (2.2) 3.4 (2.2) 3.8 (2.5) 
  Dietary Fiber (grams/day) 15.0 (8.2) 14.8 (6.8) 16.2 (7.3) 19.7 (8.8) 
  Saturated Fats (grams/day) 21.5 (10.6) 22.0 (10.8) 21.9 (10.5) 22.6 (10.6) 
  Trans Fats (grams/day) 3.0 (1.9) 3.0 (1.8) 3.0 (1.8) 2.9 (1.8) 
Clinical Covariates      
  Hypertension 989 (25.9%) 1,624 (27.1%) 6,046 (30.5%) 4,514 (34.0%) 
  
Systolic Blood Pressure, 
mmHg 120.0 (17.2) 119.6 (17.2) 120.6 (18.4) 121.3 (19.0) 
  
Diastolic Blood Pressure, 
mmHg 72.4 (10.4) 72.7 (10.8) 73.5 (11.0) 74.0 (11.4) 
  
High Density Lipoprotein 
Cholesterol, mg/dL 50.2 (15.7) 51.8 (16.7) 52.5 (16.9) 53.5 (17.3) 
  
Low Density Lipoprotein 
Cholesterol, mg/dL 137.5 (15.7) 135.5 (38.1) 136.9 (38.7) 138.0 (40.4) 
  Triglycerides, mg/dL 126.8 (63.8) 124.2 (64.7) 122.2 (62.7) 122.4 (64.1) 
*Svgs=Servings 
^Work+Leisure+Sport Averaged and Divided into Low/Medium/High 
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Table 3-2. Associations of seafood consumption (servings/week) with fasting blood glucose in participants who are normoglycemic, ARIC, 1987-1998. Mg/dL 
deltas and 95% confidence intervals from generalized estimating equations. 
  
Zero 
Servings/Week 
Less Than 1 
Servings/Week 
One to Two 
Servings/Week 
Two or More 
Servings/Week P Model  P Trend P Interaction 
Total Seafood Total N (all Visits) 1,809 3,015 9,400 6,349    
 FBG Mean (Std) 92.5 (5.3) 92.3 (5.5) 92.5 (5.2) 92.6 (5.3)    
 Model 1 0 (ref) -0.3 (-0.7, 0.1) -0.6 (-1.0, -0.2) -0.9 (-1.4, -0.5) 0.001 0.0004 0.003 
 Model 2 0 (ref) -0.3 (-0.7, 0.1) -0.6 (-1.0, -0.2) -1.1 (-1.7, -0.6) 0.0003 0.0001 0.003 
 Model 3 0 (ref) -0.3 (-0.7, 0.1) -0.6 (-1.0, -0.2) -1.1 (-1.6, -0.5) 0.001 0.0003 0.003 
Total Fish Total N (all Visits) 2,275 3,637 9,549 5,112    
 FBG Mean (Std) 92.5 (5.3) 92.4 (5.4) 92.4 (5.2) 92.6 (5.3)    
 Model 1 0 (ref) -0.3 (-0.6, 0.1) -0.7 (-1.1, -0.4) -1.0 (-1.5, -0.5) <.0001 <.0001 0.001 
 Model 2 0 (ref) -0.3 (-0.6, 0.1) -0.8 (-1.2, -0.4) -1.3 (-1.8, -0.7) <.0001 <.0001 0.001 
 Model 3 0 (ref) -0.2 (-0.6, 0.1) -0.7 (-1.1, -0.4) -1.2 (-1.7, -0.7) <.0001 <.0001 0.001 
Omega-3 Rich Fish Total N (all Visits) 4,562 5,525 7,506 2,980    
 FBG Mean (Std) 92.6 (5.3) 92.4 (5.3) 92.4 (5.3) 92.6 (5.3)    
 Model 1 0 (ref) -0.1 (-0.4, 0.2) -0.3 (-0.6, 0.0) -0.3 (-0.8, 0.1) 0.19 0.08 0.02 
 Model 2 0 (ref) -0.1 (-0.4, 0.2) -0.4 (-0.7, -0.1) -0.7 (-1.2, -0.2) 0.03 0.01 0.02 
 Model 3 0 (ref) 0.0 (-0.3, 0.3) -0.4 (-0.7, 0.0) -0.5 (-1.0, 0.0) 0.05 0.02 0.01 
FBG: fasting blood glucose 
Std: standard deviation 
P Model: p value for the exposure term 
P Trend: p value for exposure modeled linearly using the median values in each category 
P Interaction: Significance of the exposure*glycemia population term 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables (hypertension, HDL, LDL, triglycerides)  
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Table 3-3. Associations of fatty acid intake (in quartiles) with fasting blood glucose in participants who are normoglycemic, ARIC, 1987-1998. Mg/dL deltas 
and 95% confidence intervals from generalized estimating equations. 
  Q1 Q2 Q3 Q4 P Model  P Trend P Interaction 
ALA + DHA + EPA Total N (all Visits) 5,265 5,296 5,152 4,860    
 FBG Mean (Std) 92.5 (5.3) 92.5 (5.2) 92.5 (5.3) 92.4 (5.3)    
 Model 1 0 (ref) 0.0 (-0.3, 0.3) -0.3 (-0.6, 0.0) -0.6 (-0.9, -0.3) 0.0003 <.0001 <.0001 
 Model 2 0 (ref) -0.1 (-0.4, 0.2) -0.5 (-0.9, -0.2) -1.0 (-1.4, -0.5) <.0001 <.0001 <.0001 
 Model 3 0 (ref) 0.0 (-0.4, 0.3) -0.4 (-0.8, -0.1) -1.0 (-1.4, -0.5) <.0001 <.0001 <.0001 
DHA + EPA Total N (all Visits) 5,220 5,303 5,072 4,978    
 FBG Mean (Std) 92.7 (5.3) 92.4 (5.3) 92.4 (5.3) 92.5 (5.3)    
 Model 1 0 (ref) -0.5 (-0.9, -0.2) -0.9 (-1.2, -0.5) -1.1 (-1.5, -0.7) <.0001 <.0001 0.0002 
 Model 2 0 (ref) -0.6 (-0.9, -0.3) -1.0 (-1.3, -0.6) -1.4 (-1.8, -0.9) <.0001 <.0001 0.0002 
 Model 3 0 (ref) -0.6 (-0.9, -0.2) -1.0 (-1.3, -0.6) -1.3 (-1.7, -0.8) <.0001 <.0001 0.0001 
ALA Total N (all Visits) 5,311 5,330 5,032 4,900    
 FBG Mean (Std) 92.5 (5.4) 92.4 (5.3) 92.5 (5.2) 92.5 (5.3)    
 Model 1 0 (ref) -0.1 (-0.3, 0.2) 0.0 (-0.3, 0.3) 0.1 (-0.2, 0.3) 0.84 0.28 <.0001 
 Model 2 0 (ref) 0.0 (-0.4, 0.3) 0.0 (-0.4, 0.5) 0.1 (-0.5, 0.7) 0.87 0.56 <.0001 
 Model 3 0 (ref) -0.1 (-0.4, 0.3) 0.1 (-0.3, 0.5) 0.2 (-0.4, 0.8) 0.59 0.41 <.0001 
FBG: fasting blood glucose 
Std: standard deviation 
P Model: p value for the exposure term 
P Trend: p value for exposure modeled linearly using the median values in each category 
P Interaction: Significance of the exposure*glycemia population term 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables (hypertension, HDL, LDL, triglycerides) 
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Table 3-4. Associations of seafood consumption (servings/week) with fasting blood glucose in participants with pre-diabetes, ARIC, 1987-1998. Mg/dL 
deltas and 95% confidence intervals from generalized estimating equations. 
  
Zero 
Servings/Week 
Less Than 1 
Servings/Week 
One to Two 
Servings/Week 
Two or More 
Servings/Week P Model  P Trend P Interaction 
Total Seafood Total N (all Visits) 1,309 2,142 7,334 5,008    
 FBG Mean (Std) 107.6 (6.2) 107.9 (6.2) 108.0 (6.3) 107.9 (6.3)    
 Model 1 0 (ref) 0.2 (-0.2, 0.7) -0.2 (-0.7, 0.2) -0.8 (-1.3, -0.3) 0.0003 <.0001 0.003 
 Model 2 0 (ref) 0.3 (-0.2, 0.7) -0.3 (-0.7, 0.2) -1.0 (-1.6, -0.4) <.0001 <.0001 0.003 
 Model 3 0 (ref) 0.3 (-0.2, 0.7) -0.2 (-0.7, 0.3) -1.0 (-1.6, -0.4) 0.0001 <.0001 0.003 
Total Fish Total N (all Visits) 1,680 2,610 7,447 4,056    
 FBG Mean (Std) 107.8 (6.2) 107.9 (6.2) 108.0 (6.3) 107.9 (6.3)    
 Model 1 0 (ref) -0.1 (-0.5, 0.4) -0.5 (-1.0, -0.1) -1.1 (-1.6, -0.5) <.0001 <.0001 0.001 
 Model 2 0 (ref) -0.1 (-0.5, 0.4) -0.6 (-1.0, -0.2) -1.3 (-1.9, -0.7) <.0001 <.0001 0.001 
 Model 3 0 (ref) -0.1 (-0.5, 0.4) -0.6 (-1.0, -0.1) -1.3 (-1.9, -0.7) <.0001 <.0001 0.001 
Omega-3 Rich Fish Total N (all Visits) 3,585 4,116 5,849 2,243    
 FBG Mean (Std) 108.0 (6.3) 107.9 (6.2) 108.0 (6.3) 107.7 (6.2)    
 Model 1 0 (ref) 0.1 (-0.3, 0.4) -0.1 (-0.5, 0.2) -0.5 (-0.9, 0.0) 0.20 0.04 0.02 
 Model 2 0 (ref) 0.0 (-0.3, 0.4) -0.3 (-0.6, 0.1) -0.8 (-1.3, -0.3) 0.03 0.002 0.02 
 Model 3 0 (ref) 0.1 (-0.3, 0.4) -0.2 (-0.6, 0.1) -0.8 (-1.3, -0.3) 0.02 0.003 0.01 
FBG: fasting blood glucose 
Std: standard deviation 
P Model: p value for the exposure term 
P Trend: p value for exposure modeled linearly using the median values in each category 
P Interaction: Significance of the exposure*glycemia population term 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables (hypertension, HDL, LDL, triglycerides)  
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Table 3-5. Associations of fatty acid intake (in quartiles) with fasting blood glucose in those with pre-diabetes, ARIC, 1987-1998. Mg/dL deltas and 95% 
confidence intervals from generalized estimating equations. 
  Q1 Q2 Q3 Q4 P Model  P Trend P Interaction 
ALA + DHA + EPA Total N (all Visits) 4,198 3,926 3,830 3,839    
 FBG Mean (Std) 107.9 (6.3) 107.8 (6.1) 108.0 (6.3) 108.0 (6.3)    
 Model 1 0 (ref) -0.3 (-0.6, 0.1) -0.2 (-0.6, 0.1) -0.6 (-1.0, -0.2) 0.0004 <.0001 <.0001 
 Model 2 0 (ref) -0.5 (-0.8, -0.1) -0.5 (-1.0, -0.1) -1.1 (-1.6, -0.6) <.0001 <.0001 <.0001 
 Model 3 0 (ref) -0.4 (-0.8, 0.0) -0.4 (-0.9, 0.0) -1.0 (-1.5, -0.5) <.0001 <.0001 <.0001 
DHA + EPA Total N (all Visits) 4,071 3,985 3,886 3,851    
 FBG Mean (Std) 107.9 (6.2) 107.9 (6.3) 107.9 (6.2) 107.9 (6.3)    
 Model 1 0 (ref) -0.3 (-0.7, 0.1) -0.8 (-1.2, -0.3) -1.0 (-1.5, -0.6) <.0001 <.0001 0.0002 
 Model 2 0 (ref) -0.4 (-0.7, 0.0) -0.9 (-1.4, -0.5) -1.3 (-1.8, -0.8) <.0001 <.0001 0.0002 
 Model 3 0 (ref) -0.3 (-0.7, 0.1) -0.9 (-1.3, -0.4) -1.3 (-1.8, -0.8) <.0001 <.0001 0.0001 
ALA Total N (all Visits) 4,128 3,993 3,855 3,817    
 FBG Mean (Std) 108.0 (6.3) 107.7 (6.2) 108.0 (6.3) 107.9 (6.2)    
 Model 1 0 (ref) -0.4 (-0.7, 0.0) -0.1 (-0.5, 0.2) -0.1 (-0.5, 0.2) 0.45 0.56 <.0001 
 Model 2 0 (ref) -0.4 (-0.8, 0.0) -0.2 (-0.7, 0.3) -0.1 (-0.8, 0.5) 0.34 0.51 <.0001 
 Model 3 0 (ref) -0.4 (-0.8, 0.0) -0.1 (-0.6, 0.4) 0.0 (-0.6, 0.6) 0.31 0.63 <.0001 
FBG: fasting blood glucose 
Std: standard deviation 
P Model: p value for the exposure term 
P Trend: p value for exposure modeled linearly using the median values in each category 
P Interaction: Significance of the exposure*glycemia population term 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables (hypertension, HDL, LDL, triglycerides) 
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Table 3-6. Associations of seafood consumption (servings/week) with fasting blood glucose in those with diabetes, ARIC, 1987-1998. Mg/dL deltas and 95% 
confidence intervals from generalized estimating equations. 
  
Zero 
Servings/Week 
Less Than 1 
Servings/Week 
One to Two 
Servings/Week 
Two or More 
Servings/Week P Model  P Trend P Interaction 
Total Seafood Total N (all Visits) 334 535 2,158 1,756    
 FBG Mean (Std) 174.8 (71.7) 176.5 (72.5) 185.0 (76.0) 190.7 (79.4)    
 Model 1 0 (ref) 1.4 (-10.1, 12.8) 9.4 (-0.5, 19.3) 14.6 (4.3, 24.8) <.0001 <.0001 0.003 
 Model 2 0 (ref) 1.3 (-10.1, 12.7) 9.3 (-0.6, 19.2) 14.3 (4.0, 24.5) <.0001 <.0001 0.003 
 Model 3 0 (ref) 1.5 (-9.9, 12.9) 9.2 (-0.7, 19.1) 14.2 (4.0, 24.5) <.0001 <.0001 0.003 
Total Fish Total N (all Visits) 406 644 2,250 1,483    
 FBG Mean (Std) 173.9 (71.1) 176.9 (72.0) 185.8 (76.8) 191.8 (79.5)    
 Model 1 0 (ref) 2.5 (-7.5, 12.6) 10.8 (1.8, 19.8) 16.5 (6.9, 26.0) <.0001 <.0001 0.001 
 Model 2 0 (ref) 2.5 (-7.5, 12.5) 10.7 (1.7, 19.7) 16.1 (6.6, 25.6) <.0001 <.0001 0.001 
 Model 3 0 (ref) 2.5 (-7.4, 12.5) 10.6 (1.6, 19.6) 16.1 (6.5, 25.6) <.0001 <.0001 0.001 
Omega-3 Rich Fish Total N (all Visits) 992 1,130 1,878 783    
 FBG Mean (Std) 180.7 (77.5) 179.9 (73.1) 189.8 (77.8) 189.1 (77.9)    
 Model 1 0 (ref) -0.5 (-7.8, 6.8) 9.3 (2.2, 16.5) 8.6 (-0.1, 17.3) 0.01 0.03 0.02 
 Model 2 0 (ref) -0.7 (-7.9, 6.6) 9.0 (1.9, 16.2) 8.0 (-0.7, 16.7) 0.002 0.003 0.02 
 Model 3 0 (ref) -0.8 (-8.1, 6.4) 8.8 (1.7, 16.0) 7.8 (-0.9, 16.5) 0.003 0.01 0.01 
FBG: fasting blood glucose 
Std: standard deviation 
P Model: p value for the exposure term 
P Trend: p value for exposure modeled linearly using the median values in each category 
P Interaction: Significance of the exposure*glycemia population term 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables (hypertension, HDL, LDL, triglycerides)  
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Table 3-7. Associations of fatty acid intake (in quartiles) with fasting blood glucose in those with diabetes, ARIC, 1987-1998. Mg/dL deltas and 95% 
confidence intervals from generalized estimating equations. 
  Q1 Q2 Q3 Q4 P Model  P Trend P Interaction 
ALA + DHA + EPA Total N (all Visits) 856 1,086 1,351 1,490    
 FBG Mean (Std) 169.2 (68.4) 182.9 (77.8) 188.3 (76.3) 194.1 (79.4)    
 Model 1 0 (ref) 13.1 (5.7, 20.5) 18.3 (11.2, 25.4) 23.9 (16.9, 31.0) <.0001 <.0001 <.0001 
 Model 2 0 (ref) 12.9 (5.5, 20.3) 18.0 (10.9, 25.1) 23.4 (16.4, 30.5) <.0001 <.0001 <.0001 
 Model 3 0 (ref) 12.7 (5.4, 20.1) 17.9 (10.8, 25.0) 23.4 (16.3, 30.4) <.0001 <.0001 <.0001 
DHA + EPA Total N (all Visits) 971 1,056 1,320 1,436    
 FBG Mean (Std) 173.8 (69.7) 186.3 (77.8) 186.1 (78.3) 192.1 (78.4)    
 Model 1 0 (ref) 11.7 (4.4, 19.1) 11.1 (4.0, 18.3) 16.9 (9.7, 24.1) <.0001 <.0001 0.0002 
 Model 2 0 (ref) 11.7 (4.4, 19.0) 11.1 (3.9, 18.3) 16.5 (9.4, 23.7) <.0001 <.0001 0.0002 
 Model 3 0 (ref) 11.7 (4.3, 19.0) 11.0 (3.8, 18.1) 16.5 (9.4, 23.7) <.0001 <.0001 0.0001 
ALA Total N (all Visits) 909 1,031 1,368 1,475    
 FBG Mean (Std) 171.5 (69.6) 184.0 (76.9) 191.2 (79.2) 189.8 (77.7)    
 Model 1 0 (ref) 12.3 (4.9, 19.7) 19.2 (12.2, 26.2) 17.9 (11.0, 24.8) <.0001 <.0001 <.0001 
 Model 2 0 (ref) 12.4 (5.0, 19.8) 19.3 (12.3, 26.3) 18.0 (11.0, 24.9) <.0001 <.0001 <.0001 
 Model 3 0 (ref) 12.4 (5.0, 19.8) 19.2 (12.2, 26.2) 18.1 (11.2, 25.0) <.0001 <.0001 <.0001 
FBG: fasting blood glucose 
Std: standard deviation 
P Model: p value for the exposure term 
P Trend: p value for exposure modeled linearly using the median values in each category 
P Interaction: Significance of the exposure*glycemia population term 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables (hypertension, HDL, LDL, triglycerides) 
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Table 3-8. Associations of seafood consumption (servings/week) with HbA1c in participants who are normoglycemic, ARIC, 1987-1993. Percentage point 
deltas and 95% confidence intervals. 
  
Zero 
Servings/Week 
Less Than 1 
Servings/Week 
One to Two 
Servings/Week 
Two or More 
Servings/Week P Model  P Trend P Interaction 
Total Seafood Total N 495 792 2,862 2,116    
 HbA1c Mean (Std) 5.4 (0.5) 5.3 (0.5) 5.4 (0.4) 5.4 (0.5) 
   
 Model 1 0 (ref) 0.0 (-0.1, 0.1) -0.1 (-0.2, 0.0) -0.1 (-0.2, 0.0) 0.07 0.0244 0.002 
 Model 2 0 (ref) 0.0 (-0.1, 0.1) -0.1 (-0.2, 0.0) -0.1 (-0.2, 0.0) 0.07 0.02 0.005 
 Model 3 0 (ref) 0.0 (-0.1, 0.1) -0.1 (-0.2, 0.0) -0.1 (-0.2, 0.0) 0.07 0.0155 0.005 
Total Fish Total N 614 999 2,927 1,725    
 HbA1c Mean (Std) 5.4 (0.5) 5.3 (0.5) 5.4 (0.5) 5.4 (0.5) 
   
 Model 1 0 (ref) 0.0 (-0.1, 0.1) -0.1 (-0.1, 0.0) -0.1 (-0.2, 0.0) 0.08 0.02 <.0001 
 Model 2 0 (ref) 0.0 (-0.1, 0.1) -0.1 (-0.1, 0.0) -0.1 (-0.2, 0.0) 0.06 0.01 <.0001 
 Model 3 0 (ref) 0.0 (-0.1, 0.1) -0.1 (-0.1, 0.0) -0.1 (-0.2, 0.0) 0.06 0.01 <.0001 
Omega-3 Rich Fish Total N 1,309 1,601 2,347 1,008    
 HbA1c Mean (Std) 5.4 (0.5) 5.4 (0.4) 5.4 (0.5) 5.4 (0.4) 
   
 Model 1 0 (ref) 0.0 (-0.1, 0.0) 0.0 (-0.1, 0.0) -0.1 (-0.1, 0.0) 0.36 0.10 <.0001 
 Model 2 0 (ref) 0.0 (-0.1, 0.0) 0.0 (-0.1, 0.0) -0.1 (-0.1, 0.0) 0.31 0.07 <.0001 
 Model 3 0 (ref) 0.0 (-0.1, 0.0) 0.0 (-0.1, 0.0) -0.1 (-0.1, 0.0) 0.33 0.08 <.0001 
Std: standard deviation 
P Model: p value for the exposure term 
P Trend: p value for exposure modeled linearly using the median values in each category 
P Interaction: Significance of the exposure*glycemia population term 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables (hypertension, HDL, LDL, triglycerides) 
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Table 3-9. Associations of fatty acid intake (in quartiles) with HbA1c in participants who are normoglycemic, ARIC, 1987-1993. Percentage point deltas and 
95% confidence intervals. 
  Q1 Q2 Q3 Q4 P Model  P Trend P Interaction 
ALA + DHA + EPA Total N 1,570 1,614 1,564 1,517    
 HbA1c Mean (Std) 5.3 (0.4) 5.4 (0.4) 5.4 (0.4) 5.4 (0.5) 
   
 Model 1 0 (ref) 0.0 (0.0, 0.1) 0.0 (-0.1, 0.1) 0.0 (-0.1, 0.1) 0.84 0.60 <.0001 
 Model 2 0 (ref) 0.0 (-0.1, 0.1) 0.0 (-0.1, 0.0) -0.1 (-0.1, 0.0) 0.31 0.06 <.0001 
 Model 3 0 (ref) 0.0 (-0.1, 0.1) 0.0 (-0.1, 0.0) -0.1 (-0.1, 0.0) 0.31 0.06 <.0001 
DHA + EPA Total N 1,600 1,584 1,547 1,534    
 HbA1c Mean (Std) 5.4 (0.5) 5.4 (0.4) 5.4 (0.5) 5.4 (0.4) 
   
 Model 1 0 (ref) -0.1 (-0.1, 0.0) -0.1 (-0.1, 0.0) -0.1 (-0.2, 0.0) 0.04 0.02 <.0001 
 Model 2 0 (ref) -0.1 (-0.1, 0.0) -0.1 (-0.1, 0.0) -0.1 (-0.2, 0.0) 0.03 0.01 <.0001 
 Model 3 0 (ref) -0.1 (-0.1, 0.0) -0.1 (-0.1, 0.0) -0.1 (-0.2, 0.0) 0.03 0.01 <.0001 
ALA Total N 1,562 1,633 1,547 1,523    
 HbA1c Mean (Std) 5.3 (0.4) 5.4 (0.4) 5.4 (0.4) 5.4 (0.6) 
   
 Model 1 0 (ref) 0.0 (-0.1, 0.1) 0.0 (-0.1, 0.1) 0.1 (0.0, 0.1) 0.28 0.09 <.0001 
 Model 2 0 (ref) 0.0 (-0.1, 0.0) 0.0 (-0.1, 0.0) 0.0 (-0.1, 0.1) 0.62 0.66 <.0001 
 Model 3 0 (ref) 0.0 (-0.1, 0.0) 0.0 (-0.1, 0.0) 0.0 (-0.1, 0.1) 0.60 0.67 <.0001 
Std: standard deviation 
P Model: p value for the exposure term 
P Trend: p value for exposure modeled linearly using the median values in each category 
P Interaction: Significance of the exposure*glycemia population term 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables (hypertension, HDL, LDL, triglycerides)  
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Table 3-10. Associations of seafood consumption (servings/week) with HbA1c in participants with pre-diabetes, ARIC, 1987-1993. Percentage point deltas 
and 95% confidence intervals. 
  
Zero 
Servings/Week 
Less Than 1 
Servings/Week 
One to Two 
Servings/Week 
Two or More 
Servings/Week P Model  P Trend P Interaction 
Total Seafood Total N 313 531 2,039 1,426    
 HbA1c Mean (Std) 5.6 (0.6) 5.5 (0.5) 5.7 (0.7) 5.7 (0.8) 
   
 Model 1 0 (ref) -0.1 (-0.2, 0.0) 0.0 (-0.1, 0.1) 0.0 (-0.1, 0.1) 0.13 0.07 0.002 
 Model 2 0 (ref) -0.1 (-0.2, 0.0) 0.0 (-0.1, 0.1) 0.0 (-0.1, 0.1) 0.16 0.06 0.005 
 Model 3 0 (ref) -0.1 (-0.2, 0.0) 0.0 (-0.1, 0.1) 0.0 (-0.1, 0.1) 0.15 0.05 0.005 
Total Fish Total N 409 663 2,051 1,186    
 HbA1c Mean (Std) 5.6 (0.6) 5.6 (0.6) 5.7 (0.7) 5.7 (0.8) 
   
 Model 1 0 (ref) -0.1 (-0.2, 0.0) 0.0 (-0.1, 0.1) 0.0 (-0.1, 0.1) 0.21 0.07 <.0001 
 Model 2 0 (ref) -0.1 (-0.2, 0.0) 0.0 (-0.1, 0.1) 0.0 (-0.1, 0.1) 0.17 0.05 <.0001 
 Model 3 0 (ref) -0.1 (-0.2, 0.0) 0.0 (-0.1, 0.1) 0.0 (-0.1, 0.1) 0.17 0.05 <.0001 
Omega-3 Rich Fish Total N 945 1,104 1,582 678    
 HbA1c Mean (Std) 5.6 (0.6) 5.6 (0.5) 5.7 (0.8) 5.7 (0.9) 
   
 Model 1 0 (ref) -0.1 (-0.1, 0.0) 0.0 (0.0, 0.1) 0.0 (-0.1, 0.1) 0.10 0.09 <.0001 
 Model 2 0 (ref) -0.1 (-0.1, 0.0) 0.0 (-0.1, 0.1) 0.0 (-0.1, 0.1) 0.14 0.10 <.0001 
 Model 3 0 (ref) -0.1 (-0.1, 0.0) 0.0 (-0.1, 0.1) 0.0 (-0.1, 0.1) 0.15 0.10 <.0001 
Std: standard deviation 
P Model: p value for the exposure term 
P Trend: p value for exposure modeled linearly using the median values in each category 
P Interaction: Significance of the exposure*glycemia population term 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables (hypertension, HDL, LDL, triglycerides) 
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Table 3-11. Associations of fatty acid intake (in quartiles) with HbA1c in those with pre-diabetes, ARIC, 1987-1993. Percentage point deltas and 95% 
confidence intervals. 
  Q1 Q2 Q3 Q4 P Model  P Trend P Interaction 
ALA + DHA + EPA Total N 1,180 1,052 1,051 1,026    
 HbA1c Mean (Std) 5.6 (0.6) 5.6 (0.6) 5.7 (0.8) 5.7 (0.8) 
   
 Model 1 0 (ref) 0.0 (-0.1, 0.1) 0.1 (0.0, 0.1) 0.1 (0.0, 0.1) 0.42 0.15 <.0001 
 Model 2 0 (ref) 0.0 (-0.1, 0.0) 0.0 (-0.1, 0.1) 0.0 (-0.1, 0.1) 0.48 0.15 <.0001 
 Model 3 0 (ref) 0.0 (-0.1, 0.0) 0.0 (-0.1, 0.1) 0.0 (-0.1, 0.1) 0.51 0.14 <.0001 
DHA + EPA Total N 1,109 1,108 1,054 1,038    
 HbA1c Mean (Std) 5.6 (0.6) 5.6 (0.5) 5.7 (0.9) 5.7 (0.8) 
   
 Model 1 0 (ref) -0.1 (-0.1, 0.0) 0.0 (-0.1, 0.1) 0.0 (-0.1, 0.1) 0.12 0.06 <.0001 
 Model 2 0 (ref) 0.0 (-0.1, 0.0) 0.0 (-0.1, 0.1) 0.0 (-0.1, 0.1) 0.10 0.04 <.0001 
 Model 3 0 (ref) 0.0 (-0.1, 0.0) 0.0 (-0.1, 0.1) 0.0 (-0.1, 0.1) 0.11 0.04 <.0001 
ALA Total N 1,168 1,087 1,032 1,022    
 HbA1c Mean (Std) 5.6 (0.7) 5.6 (0.6) 5.7 (0.8) 5.7 (0.8) 
   
 Model 1 0 (ref) 0.0 (-0.1, 0.1) 0.1 (0.0, 0.1) 0.1 (0.0, 0.2) 0.02 0.004 <.0001 
 Model 2 0 (ref) 0.0 (-0.1, 0.0) 0.0 (0.0, 0.1) 0.0 (0.0, 0.1) 0.32 0.42 <.0001 
 Model 3 0 (ref) 0.0 (-0.1, 0.0) 0.0 (0.0, 0.1) 0.0 (0.0, 0.1) 0.29 0.38 <.0001 
Std: standard deviation 
P Model: p value for the exposure term 
P Trend: p value for exposure modeled linearly using the median values in each category 
P Interaction: Significance of the exposure*glycemia population term 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables (hypertension, HDL, LDL, triglycerides) 
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Table 3-12. Associations of seafood consumption (servings/week) with HbA1c in those with diabetes, ARIC, 1987-1993. Percentage point deltas and 95% 
confidence intervals. 
  
Zero 
Servings/Week 
Less Than 1 
Servings/Week 
One to Two 
Servings/Week 
Two or More 
Servings/Week P Model  P Trend P Interaction 
Total Seafood Total N 57 101 449 394    
 HbA1c Mean (Std) 8.4 (2.5) 8.2 (2.6) 8.5 (2.4) 8.7 (2.5) 
   
 Model 1 0 (ref) -0.2 (-0.5, 0.1) 0.1 (-0.2, 0.3) 0.1 (-0.1, 0.4) 0.001 0.001 0.002 
 Model 2 0 (ref) -0.2 (-0.5, 0.0) 0.0 (-0.2, 0.3) 0.1 (-0.1, 0.4) 0.002 0.002 0.005 
 Model 3 0 (ref) -0.2 (-0.5, 0.0) 0.0 (-0.2, 0.3) 0.1 (-0.1, 0.4) 0.002 0.001 0.005 
Total Fish Total N 69 118 473 341    
 HbA1c Mean (Std) 8.3 (2.4) 8.1 (2.5) 8.5 (2.5) 8.7 (2.5) 
   
 Model 1 0 (ref) -0.2 (-0.4, 0.1) 0.1 (-0.1, 0.3) 0.3 (0.1, 0.5) <.0001 <.0001 <.0001 
 Model 2 0 (ref) -0.1 (-0.4, 0.1) 0.1 (-0.1, 0.3) 0.3 (0.1, 0.5) <.0001 <.0001 <.0001 
 Model 3 0 (ref) -0.1 (-0.4, 0.1) 0.1 (-0.1, 0.3) 0.3 (0.1, 0.5) <.0001 <.0001 <.0001 
Omega-3 Rich Fish Total N 186 230 414 171    
 HbA1c Mean (Std) 8.6 (2.5) 8.3 (2.4) 8.7 (2.5) 8.5 (2.4) 
   
 Model 1 0 (ref) -0.3 (-0.4, -0.1) 0.1 (0.0, 0.3) 0.0 (-0.2, 0.2) <.0001 0.20 <.0001 
 Model 2 0 (ref) -0.3 (-0.5, -0.1) 0.1 (-0.1, 0.2) -0.1 (-0.3, 0.1) <.0001 0.20 <.0001 
 Model 3 0 (ref) -0.3 (-0.5, -0.1) 0.1 (-0.1, 0.2) -0.1 (-0.3, 0.1) <.0001 0.21 <.0001 
Std: standard deviation 
P Model: p value for the exposure term 
P Trend: p value for exposure modeled linearly using the median values in each category 
P Interaction: Significance of the exposure*glycemia population term 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables (hypertension, HDL, LDL, triglycerides) 
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Table 3-13. Associations of fatty acid intake (in quartiles) with HbA1c in those with diabetes, ARIC, 1987-1993. Percentage Point deltas and 95% confidence 
intervals. 
  Q1 Q2 Q3 Q4 P Model  P Trend P Interaction 
ALA + DHA + EPA Total N 155 222 295 329    
 HbA1c Mean (Std) 7.6 (2.3) 8.4 (2.5) 8.8 (2.5) 8.8 (2.4) 
   
 Model 1 0 (ref) 0.8 (0.6, 1.0) 1.1 (0.9, 1.3) 1.1 (0.9, 1.3) <.0001 <.0001 <.0001 
 Model 2 0 (ref) 0.7 (0.6, 0.9) 1.1 (0.9, 1.3) 1.1 (0.9, 1.2) <.0001 <.0001 <.0001 
 Model 3 0 (ref) 0.7 (0.6, 0.9) 1.1 (0.9, 1.2) 1.1 (0.9, 1.2) <.0001 <.0001 <.0001 
DHA + EPA Total N 176 232 284 309    
 HbA1c Mean (Std) 8.1 (2.4) 8.4 (2.5) 8.6 (2.5) 8.8 (2.4) 
   
 Model 1 0 (ref) 0.2 (0.0, 0.4) 0.3 (0.2, 0.5) 0.5 (0.4, 0.7) <.0001 <.0001 <.0001 
 Model 2 0 (ref) 0.2 (0.0, 0.4) 0.3 (0.2, 0.5) 0.5 (0.3, 0.7) <.0001 <.0001 <.0001 
 Model 3 0 (ref) 0.2 (0.0, 0.4) 0.3 (0.2, 0.5) 0.5 (0.3, 0.7) <.0001 <.0001 <.0001 
ALA Total N 168 212 302 319    
 HbA1c Mean (Std) 7.7 (2.3) 8.4 (2.6) 8.9 (2.5) 8.7 (2.4) 
   
 Model 1 0 (ref) 0.6 (0.4, 0.8) 1.0 (0.9, 1.2) 0.9 (0.7, 1.1) <.0001 <.0001 <.0001 
 Model 2 0 (ref) 0.6 (0.4, 0.8) 1.0 (0.9, 1.2) 0.9 (0.7, 1.0) <.0001 <.0001 <.0001 
 Model 3 0 (ref) 0.6 (0.4, 0.8) 1.0 (0.9, 1.2) 0.9 (0.7, 1.0) <.0001 <.0001 <.0001 
Std: standard deviation 
P Model: p value for the exposure term 
P Trend: p value for exposure modeled linearly using the median values in each category 
P Interaction: Significance of the exposure*glycemia population term 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables (hypertension, HDL, LDL, triglycerides) 
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Table 3-14. Associations of seafood consumption (servings/week) with incident T2D in non-diabetics, ARIC, 1987-1998. Hazard Ratios and 95% confidence 
intervals. 
  
Zero 
Servings/Week 
Less Than 1 
Servings/Week 
One to Two 
Servings/Week 
Two or More 
Servings/Week P Model  P Trend P Interaction 
Total Seafood Total N 907 1,486 5,478 4,003    
 Incident T2D N (%) 69 (7.6%) 113 (7.6%) 468 (8.5%) 372 (9.3%) 
   
 Model 1 1 (ref) 0.9 (0.6, 1.5) 1.0 (0.7, 1.5) 0.9 (0.6, 1.4) 0.89 0.96 0.30 
 Model 2 1 (ref) 0.9 (0.5, 1.3) 1.0 (0.6, 1.4) 0.9 (0.6, 1.4) 0.88 0.70 0.30 
 Model 3 1 (ref) 0.9 (0.5, 1.3) 1.0 (0.7, 1.4) 0.9 (0.6, 1.4) 0.86 0.69 0.33 
Total Fish Total N 980 1,562 3,892 1,940    
 Incident T2D N (%) 90 126 400 244 
   
 Model 1 1 (ref) 1.0 (0.6, 1.4) 1.0 (0.7, 1.5) 1.0 (0.7, 1.6) 0.94 0.70 0.18 
 Model 2 1 (ref) 0.9 (0.6, 1.3) 1.0 (0.7, 1.5) 1.1 (0.7, 1.6) 0.80 0.47 0.16 
 Model 3 1 (ref) 0.9 (0.6, 1.3) 1.0 (0.7, 1.5) 1.0 (0.7, 1.5) 0.79 0.60 0.17 
Omega-3 Rich Fish Total N 1,933 2,304 3,047 1,090    
 Incident T2D N (%) 184 216 331 129 
   
 Model 1 1 (ref) 1.1 (0.8, 1.5) 1.0 (0.8, 1.3) 1.0 (0.7, 1.5) 0.85 1.00 0.63 
 Model 2 1 (ref) 1.2 (0.9, 1.6) 1.0 (0.8, 1.4) 1.1 (0.7, 1.6) 0.74 0.88 0.54 
 Model 3 1 (ref) 1.2 (0.9, 1.6) 1.0 (0.8, 1.4) 1.0 (0.7, 1.5) 0.79 0.97 0.57 
T2D: type 2 diabetes 
P Model: p value for the exposure term 
P Trend: p value for exposure modeled linearly using the median values in each category 
P Interaction: Significance of the exposure*glycemia population term 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables (hypertension, HDL, LDL, triglycerides) 
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Table 3-15. Associations of fatty acid intake (in quartiles) with incident T2D in non-diabetics, ARIC, 1987-1998. Hazard Ratios and 95% confidence intervals. 
  Q1 Q2 Q3 Q4 P Model  P Trend P Interaction 
DHA + EPA Total N 2,125 2,098 2,102 2,049    
 Incident T2D N (%) 214 (10.1%) 179 (8.5%) 229 (10.9%) 238 (11.6%) 
   
 Model 1 1 (ref) 0.9 (0.7, 1.2) 1.0 (0.7, 1.3) 0.9 (0.6, 1.2) 0.80 0.51 0.60 
 Model 2 1 (ref) 0.9 (0.7, 1.2) 1.0 (0.7, 1.3) 0.9 (0.7, 1.2) 0.89 0.71 0.54 
 Model 3 1 (ref) 0.9 (0.7, 1.3) 1.0 (0.7, 1.3) 0.9 (0.7, 1.3) 0.94 0.67 0.55 
T2D: type 2 diabetes 
P Model: p value for the exposure term 
P Trend: p value for exposure modeled linearly using the median values in each category 
P Interaction: Significance of the exposure*glycemia population term 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables (hypertension, HDL, LDL, triglycerides) 
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Table 3-16. Associations of fatty acid intake (in quartiles) with incident T2D among normoglycemic participants, ARIC, 1987-1998. Hazard Ratios and 95% 
confidence intervals. 
  
Q1 Q2 Q3 Q4 P Model  P Trend P Interaction 
ALA + DHA + EPA Total N 1,291 1,293 1,269 1,190    
 Incident T2D N (%) 37 (2.9%) 30 (2.3%) 46 (3.6%) 58 (4.9%)    
 Model 1 1 (ref) 1.0 (0.4, 2.6) 1.5 (0.7, 3.6) 2.1 (1.0, 4.8) 0.17 0.03 0.10 
 Model 2 1 (ref) 1.0 (0.4, 2.6) 1.6 (0.7, 3.7) 2.3 (1.0, 5.2) 0.12 0.02 0.06 
 Model 3 1 (ref) 1.1 (0.4, 2.8) 1.7 (0.7, 4.0) 2.4 (1.1, 5.4) 0.10 0.02 0.05 
ALA Total N 1,297 1,335 1,247 1,164    
 Incident T2D N (%) 35 (2.7%) 35 (2.6%) 50 (4.0%) 51 (4.4%)    
 Model 1 1 (ref) 1.8 (0.7, 4.7) 1.6 (0.6, 4.2) 3.4 (1.4, 7.9) 0.02 0.004 0.01 
 Model 2 1 (ref) 2.0 (0.8, 5.1) 1.7 (0.6, 4.5) 3.8 (1.6, 9.1) 0.01 0.002 0.01 
 Model 3 1 (ref) 2.0 (0.8, 5.2) 1.8 (0.6, 4.8) 4.0 (1.6, 9.6) 0.01 0.001 0.01 
T2D: type 2 diabetes 
P Model: p value for the exposure term 
P Trend: p value for exposure modeled linearly using the median values in each category 
P Interaction: Significance of the exposure*glycemia population term 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables (hypertension, HDL, LDL, triglycerides) 
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Table 3-17. Associations of fatty acid intake (in quartiles) with incident T2D among participants with pre-diabetes, ARIC, 1987-1998. Hazard Ratios and 95% 
confidence intervals. 
  Q1 Q2 Q3 Q4 P Model  P Trend P Interaction 
ALA + DHA + EPA Total N 868 807 847 809    
 Incident T2D N (%) 156 (18.0%) 152 (18.8%) 199 (23.5%) 182 (22.5%)    
 Model 1 1 (ref) 1.0 (0.7, 1.4) 1.2 (0.9, 1.7) 0.9 (0.6, 1.2) 0.17 0.08 0.10 
 Model 2 1 (ref) 1.0 (0.7, 1.3) 1.3 (0.9, 1.8) 0.9 (0.6, 1.2) 0.12 0.05 0.06 
 Model 3 1 (ref) 1.0 (0.7, 1.4) 1.3 (0.9, 1.8) 0.9 (0.6, 1.2) 0.10 0.04 0.05 
ALA Total N 844 831 817 839    
 Incident T2D N (%) 162 (19.2%) 152 (18.3%) 193 (23.6%) 182 (21.7%)    
 Model 1 1 (ref) 0.9 (0.6, 1.2) 1.4 (1.1, 1.9) 1.0 (0.7, 1.4) 0.02 0.01 0.01 
 Model 2 1 (ref) 0.8 (0.6, 1.2) 1.4 (1.0, 2.0) 1.1 (0.7, 1.6) 0.01 0.01 0.01 
 Model 3 1 (ref) 0.9 (0.6, 1.2) 1.5 (1.0, 2.0) 1.1 (0.7, 1.6) 0.01 0.004 0.01 
T2D: type 2 diabetes 
P Model: p value for the exposure term 
P Trend: p value for exposure modeled linearly using the median values in each category 
P Interaction: Significance of the exposure*glycemia population term 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables (hypertension, HDL, LDL, triglycerides) 
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Table 3-18. Summary of results for fish/shellfish consumption (servings/week), DHA+EPA, and ALA with glycemia outcomes in normoglycemic, pre-diabetic, 
and diabetic populations, ARIC, 1987-1998. 
 
Normoglycemic and Pre-
Diabetic 
Diabetic 
Effect Modification in 
Diabetic Population 
FBG HbA1c 
Incident 
T2D 
FBG HbA1c 
Black vs. 
White 
Females 
vs. Males 
Fish/Shellfish Favorable Null Null Adverse Adverse 
n.s. 
Adverse 
(blacks) 
n.s. 
Favorable 
(whites) 
Adverse 
(females) 
n.s. 
Favorable 
(males) 
DHA+EPA Favorable 
Favorable 
(NGT) 
n.s. 
Favorable 
(Pre-T2D) 
Null Adverse Adverse None None 
ALA Null Null 
Adverse 
(moreso 
in NGT) 
Adverse Adverse None None 
NGT: normoglycemic 
FBG: fasting blood glucose 
T2D: type 2 diabetes 
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4 MANUSCRIPT 2: INTAKE OF OMEGA-3 POLYUNSATURATED 
FATTY ACIDS AND ELECTROCARDIOGRAPHIC PREDICTORS 
OF SUDDEN CARDIAC DEATH IN THE ATHEROSCLEROSIS 
RISK IN COMMUNITIES (ARIC) STUDY 
4.1 SYNOPSIS 
Background: Intake of omega-3 polyunsaturated fatty acids (PUFAs) has been associated 
with lower incidence of sudden cardiac death (SCD).  ECG predictors of SCD include 
prolonged QT interval and elevation of the QRS-ST junction or J-point elevation, and 
these may be markers of the mechanism underlying the association observed by intake 
of omega-3 PUFAs.  
Methods: We studied the association of consumption of seafood, fish-derived omega-3 
PUFAs (eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)), and vegetable-
derived omega-3 PUFAs (alpha-linoleic acid (ALA)) with J-point height and heart rate-
corrected QT (QTc) interval in individuals initially aged 45–64 from the Atherosclerosis 
Risk in Communities (ARIC) cohort (n = 12,611). Intake of seafood, DHA, EPA, and ALA 
were measured via food frequency questionnaire. QTc interval, and J-point height were 
measured using ECGs obtained during study visits.  Generalized estimating equations 
were used to estimate odds ratios of prolonged QTc and J-point elevation and 
differences in continuous measures of QTc interval duration and J-point height by 
servings/week of seafood and quartiles of omega-3 PUFAs or by fish intake. 
Results: The 12,611 participants contributed exposure/outcome data for a mean of 3.0 
visits between 1987 and 1998.  In multivariable analyses, higher intakes of 
ALA+DHA+EPA and ALA were associated with a shorter QTc interval (-0.8 ms, 95% CI -
1.5, -0.2 and -1.0 ms, 95% CI -1.7, -0.3 comparing the top to the bottom quartile of 
ALA+DHA+EPA and ALA alone intake, respectively). The other exposures (DHA+EPA, 
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total fish + shellfish, total fish, and omega-3 rich fish) were not associated with QTc 
internal.  None of the exposures were associated with the other outcomes examined 
(prolonged QTc, J-point elevation, J-point height). 
Conclusions: Results from this population-based cohort provided limited evidence that 
omega-3 fatty acids are associated with prolonged QT interval, J-point height, or J-point 
elevation after controlling for potential confounders. 
4.2 INTRODUCTION 
Findings from observational and experimental trials indicate that individuals who 
regularly consume fish high in omega-3 polyunsaturated fatty acids (PUFAs) have lower 
incidence of sudden cardiac death (SCD) compared to those who consume no or little 
fish [46, 51, 194, 195], but the exact mechanisms underlying this association are 
unconfirmed. Alpha linoleic acid (ALA), a vegetable-derived omega-3 PUFA, has also 
been shown to be inversely associated with SCD [196]. 
Two ECG-measured variables associated with a higher risk of SCD are presence of 
prolonged QT interval and J-point elevation (JPE) [96-99, 142]. In an ECG, the QT interval 
represents electrical depolarization and repolarization of the left and right ventricles 
and the J-point – the junction of the QRS complex and the ST segment – marks the end 
of depolarization and the beginning of repolarization [100, 101]. A prolonged QT interval 
is indicative of abnormally prolonged repolarization and is associated with SCD [96, 97]. 
Additionally, early repolarization characterized by an elevation of the J-point has been 
associated with idiopathic ventricular fibrillation and SCD [98, 99]. 
There have been a limited number of studies evaluating whether omega-3 PUFAs 
are associated with repolarization abnormalities – prolonged repolarization (prolonged 
QT interval) [104-107] and early repolarization (JPE) [104]. With respect to prolonged QT 
interval, intake of the fish-derived omega-3 PUFAs docosahexaenoic acid (DHA) and 
eicosapentanoic acid (EPA) have been shown to be associated with shorter QT intervals 
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in Greek adults [107] and predominately white Americans aged >65 years [106]. A study 
of white, middle-aged American adults found higher intakes of the vegetable-derived 
omega-3 PUFA ALA were associated with lower risk of prolonged QT [104]. With respect 
to JPE, a study of Japanese men found that higher intake of the fish-derived omega-3 
PUFA DHA and EPA attenuated the association between JPE and cardiac death [105].  To 
our knowledge, no studies have investigated the association of ALA with JPE. 
Although omega-3 PUFAs are inversely associated with SCD, and prolonged QT 
interval and JPE are positively associated with SCD, further details regarding the 
association between omega-3 PUFAs, QT interval, and JPE in a biracial cohort of middle-
aged American populations may help elucidate the mechanisms relating omega-3 fatty 
acid consumptions and SCD. Thus, this study investigates whether consumption of 
seafood, the fish-derived omega-3 PUFAs DHA and EPA, and the vegetable-derived 
omega-3 PUFA ALA are associated with heart rate-corrected QT interval (QTc) or the 
height of the QRS-ST junction (J-point) in the Atherosclerosis Risk in Communities (ARIC) 
study. We hypothesize that higher dietary intake of fish, DHA, EPA, and ALA will be 
associated with shorter QTc intervals and lower J-points. 
4.3 METHODS 
4.3.1 STUDY POPULATION 
The ARIC study has been described previously [155]. Briefly, ARIC is a prospective 
study of cardiovascular disease including 15,792 men and women 45–64 years of age at 
baseline (visit 1). Participants were recruited from four US communities using 
probability sampling techniques. The communities and racial composition were: 
predominately white subjects from suburbs of Minneapolis, Minnesota, and Washington 
County, Maryland; black subjects from Jackson, Mississippi; and white and black 
subjects from Forsyth County, North Carolina. 
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Visit 1 data were collected in 1987–89 and three additional exams were 
performed at approximately 3-year intervals (1990–92, 1993–95, 1996–98). A fifth exam 
was conducted in 2011-13 (visit 5), but those data were not utilized in this study as 
outcomes would have occurred more than 20 years after our exposure assessment. 
Our exclusion criteria were as follows (Figure 4-1).  We excluded participants 
with missing values for exposures, outcomes (missing ECG data), or covariates.  Those 
whose race was neither black nor white (n = 48) were excluded, and we further 
excluded black participants at the Minneapolis and Washington County sites (n = 55) 
due to small n.  We excluded those participants who had prevalent or incident coronary 
heart disease, heart failure, or stroke as (1) prevalent conditions influence how patients 
have their comorbidities managed, diagnosed and treated; and (2) diagnoses may result 
in changes to previously reported dietary behaviors.  We excluded participants who self-
reported use of antiarrhythmic medications and those whose duration of the QRS 
complex was ≥120 ms, as those individuals have major conduction defects that make 
the interpretation of primary repolarization abnormalities inappropriate [197].  Finally, 
participants who reported implausible caloric intakes were excluded for potentially 
unreliable exposure data. Implausible was defined as less than 500 kcal/day for women 
and 700 kcal/day for men or more than 3500 kcal/day for women and 4500 kcal/day for 
men.  These ranges represent the sex-specific first and 99th percentiles for ARIC energy 
intake distributions – see Tell et al. for the initial description of the exclusion 
methodology and justification [156] and Steffen et al. for first use of current ranges 
[157]. 
4.3.2 OUTCOME ASSESSMENT 
At each visit, a standard, resting, supine 12-lead ECG was obtained for each 
subject a minimum of 1 hour after any smoking or caffeine ingestion using MAC PC 
personal cardiography equipment (Marquette Electronics, Inc., Milwaukee, WI). 
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Subsequent processing of the ECGs took place at EPICARE (Epidemiological Cardiology 
Research Center at Wake Forest University, Winston-Salem, NC, USA).  Outcomes of 
interest were assigned using these ECG data where the participant met the 
inclusion/exclusion criteria. 
4.3.2.1 QTc Interval 
We used a heart rate-corrected QT interval (QTc) – as recommended by the AHA, 
the American College of Cardiology, and the Heart Rhythm Society for the 
Standardization and Interpretation of the Electrocardiogram [138].  The most 
appropriate formula for correction is the one resulting in the least amount of correlation 
between heart rate and the calculated rate-corrected QT [139].  We tested Framingham 
[140] and Hodges [141] and found that the Framingham formula had the least 
correlation with heart rate in our study population (r= -0.23 and r=-0.38, respectively). 
In addition to the continuous measure of QT interval, we defined prolonged QT as QTc 
values of 460 ms or longer in women and 450 ms or longer in men [138]. 
4.3.2.2  J-Point Elevation 
We calculated a continuous measure of the J-point as the maximum amplitude 
of the 12 STJ leads. As has been done in other ARIC studies, JPE was defined as a ST 
amplitude greater than 100 microvolts in at least two contiguous leads [142]. 
4.3.3 EXPOSURE ASSESSMENT 
In this study, we focused on dietary consumption of fish and shellfish, the fish-
derived omega-3 fatty acids DHA and EPA, and the vegetable-derived ALA. 
Participants’ usual dietary intake was assessed by an interviewer-administered, 
66-item food frequency questionnaire (FFQ). The FFQ was based on the instrument 
developed by Willett et al. [167], with three principal modifications: (1) Data regarding 
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alcohol consumption were obtained using a separate, more detailed instrument; (2) 
Several food items were added (e.g., donuts, biscuits, and cornbread); and (3) Some 
items were split into detailed subcategories – notably a single item on fish consumption 
was separated into three specific fish items. 
The 61-item Willett version has been validated against 28-day food record, but 
the validation took place in a population of educated, predominately white women 
[124, 167]. The ARIC questionnaire was also validated in a sample (n=419) of black and 
white ARIC participants who repeated the FFQ after three years [125]. The study found 
that, after adjusting for total caloric intake, the median reliability coefficient for blacks 
was 0.42 and the reliability for white ARIC participants was 0.49 – a value similar to that 
of other studies of white subjects.  The study found no difference in the median 
reliability coefficients of men and women after adjusting for total calorie intake. 
Another study investigated the validity of the ARIC FFQ by comparing Minnesota 
field center participants’ dietary fat FFQ data against their plasma fatty acid 
concentrations [126].  Plasma measures reflect the types of fats proportionally 
consumed over the past several weeks to months [127] and the proportionate 
composition in plasma was moderately correlated with dietary intake, with highest 
correlations in the fish-derived omega-3 fatty acids DHA and EPA (r=0.42 and r=0.20 for 
plasma phospholipid measures of DHA and EPA, respectively) [126]. 
4.3.3.1 Fish/Shellfish Servings 
Fish and other seafood intake was assessed through four FFQ questions with 
nine response categories. Participants were asked how often they consumed: 3–4 
ounces of canned tuna fish; 3–5 ounces of dark meat fish such as salmon, mackerel, 
swordfish, sardines, and bluefish; 3–5 ounces of other fish such as cod, perch, catfish, 
etc.; and shrimp, lobster, scallops as a main dish. Interviewers used food models to help 
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participants with portion size estimation. Subjects could provide answers to each 
question ranging from ‘‘never or less than once per month’’ to ‘‘6 times per day.’’  
Each of the participants’ seafood-related FFQ responses were grouped into three 
exposure categories: (1) omega-3 rich fish (tuna + dark); (2) total fish (tuna + dark + 
other); and (3) total seafood (tuna + dark + other + shellfish). Exposure categories were 
categorized into four weekly serving categories: none, less than one, one to two, and 
more than two. 
4.3.3.2 Quartiles of Omega-3 PUFA 
Daily intake of macro- and micronutrients was calculated via the FFQ by 
multiplying the nutrient content of each food by the frequency of daily consumption 
and then summing the results [124]. This process yielded daily intake of nutrients 
expressed as grams per day. Three different classifications of omega-3 fatty acids were 
investigated: (1) vegetable-derived ALA, (2) fish-derived DHA+EPA; and (3) total omega-
3 PUFA ALA+DHA+EPA. 
Intake of nutrients was adjusted using the residual method [168, 169]. In this 
method, nutrient residuals (observed intake – predicted intake) are obtained from the 
regression of total nutrient intake on total energy intake.  The nutrient residuals are 
then rescaled by adding the overall mean nutrient intake to each participant’s residual.  
For this manuscript, we created rescaled residuals for the three nutrient classifications – 
ALA, DHA+EPA, and ALA+DHA+EPA – and categorized each into quartiles.   
We selected the residual method rather than the standard multivariable method 
(quartiles of raw nutrient values as the exposure with total energy intake as a covariate) 
because (1) with the residual method, differences in exposure values amongst 
participants are due to differences in nutrient intake from the nutrient composition of 
the diet (versus overall variation in nutrient intake, which is due to diet composition and 
calorie amount) [169]; (2) when dietary exposure variables are categorized, the residual 
   96 
 
and the standard multivariable models are no longer mathematically equivalent [168-
170]; and (3) the residual model allows for greater precision [168].  All regression 
models where residual-adjusted nutrients were the exposure of interest included total 
energy intake (kcal/day) as a covariate. 
4.3.4 POTENTIAL CONFOUNDERS  
We selected potential confounders a priori based on their hypothesized 
relationship with exposure and outcome.  While most variables were measured at 
multiple visits, potential confounders were measured contemporaneously with 
exposure values (visits 1 and 3) to avoid adjusting for confounders measured after our 
exposure of interest [143]. Potential confounders were grouped into four main 
categories: sociodemographic, lifestyle, dietary, and clinical variables. 
4.3.4.1 Sociodemographic Variables  
Sociodemographic variables included age, sex, race, field center, and education 
level.  Age, sex, self-reported race, and center were obtained at visit 1 and confirmed at 
subsequent visits. Education level was measured at visit 1 via self-report and 
categorized based on years of education. We grouped education level as basic (no high 
school degree), intermediate (completed high school), and advanced (at least some 
college). 
4.3.4.2 Lifestyle Variables  
Lifestyle variables included body mass index (BMI), physical activity, smoking 
status, and drinking status and amount. Technicians measured height and weight, and 
BMI was calculated as weight (kilograms) divided by height squared (meters2). Physical 
activity was measured at visits 1 and 3 using the Baecke questionnaire [144]. The 
questionnaire included 16 items about usual exertion, and three indexes ranging from 1 
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(low) to 5 (high) were derived for physical activity at work, during leisure time, and in 
sports. The reliability and validity of the Baecke questionnaire are good for both male 
and female subjects, and equal to many other physical activity instruments [145]. The 
three physical activity scores were summed and then translated into tertiles of physical 
activity (low, medium, and high). Smoking status was assessed via self-report and 
participants classified as current smokers, former smokers, and never smokers. Alcohol 
intake status (current, former, never) and amount (grams/day) were measured at visits 
1 and 3. 
4.3.4.3 Dietary Variables  
Dietary variables included trans fatty acids, saturated fatty acids, and dietary 
fiber. Intake of trans fatty acids, saturated fatty acids, and dietary fiber were measured 
at visits 1 and 3 via FFQ and translated into nutrient values as described in the exposure 
section (Section 4.3.3). 
4.3.4.4 Clinical Variables  
Clinical variables included hypertension, LDL, HDL, and triglycerides. During each 
visit, three blood pressure measurements were taken with a random-zero 
sphygmomanometer and the mean of the last two measurements was used.  
Hypertension was defined as a systolic blood pressure above 140 mmHg, a diastolic 
above 90 mmHg, or self-reported use of antihypertensive medication.  Participants with 
missing hypertension values (n=62 visit 1; n=56 visit 3) were imputed as not having 
hypertension (no disease).  For metrics requiring phlebotomy, blood was drawn after a 
minimum 8-hour fasting period with minimal trauma from an antecubital vein [146]. 
Plasma total cholesterol and triglycerides were measured by enzymatic methods [132], 
and LDL cholesterol was calculated using the Friedewald formula [147]. HDL cholesterol 
was measured after dextran-magnesium precipitation of non-HDL lipoproteins [132]. 
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4.3.5 STUDY DESIGN 
Figure 4-2 depicts the study design for all three outcomes of interest including 
the temporality of the exposure and outcomes.  The blue arrow gives the timeline for 
each of the ARIC visits.  The green ovals represent exposures and covariates obtained at 
visit 1 and visit 3.  As mentioned in the potential confounder section (Section 4.3.4), visit 
1 values were used in regressions involving outcomes obtained at visit 1 and visit 2, 
whereas visit 3 values were used for outcomes obtained at visits 3 and 4.  The green 
oval shapes represent that participants’ outcomes and inclusion/exclusion criteria 
updated at each of the four ARIC visits (where applicable).  The pink box lists the 
inclusion/exclusion criteria, and demonstrates the consistency across all four visits. 
As depicted in the Figure 4-2, we used a quasi-repeated cross-sectional design 
where each participant who met the inclusion/exclusion criteria at visit 1 could be 
included in the analysis up to four times (once at visit 1 and again for each subsequent 
visit where he/she met that visit’s inclusion/exclusion criteria).  Outcome data were 
obtained from each visit meeting the inclusion/exclusion criteria.  As previously 
mentioned, exposure and confounder values from visit 1 were used in observations for 
visits 1 and 2, and observations for visits 3 and 4 used exposure and covariate values 
from visit 3.   
4.3.6 STATISTICAL ANALYSES 
To evaluate the associations of fish/shellfish servings and quartiles of omega-3 
PUFA intake with continuous outcomes (QTc, J-point height), we used generalized 
estimating equations to account for repeated measures, using a normal distribution and 
an identity link.  Associations with dichotomous outcomes (prolonged QTc, JPE) were 
estimated using generalized estimating equations, with a binomial distribution, a logit 
link.  All analyses assumed an independent working correlation structure.  A sensitivity 
analysis was conducted evaluating the impact of assuming an unstructured working 
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correlation structure and this modification did not appreciably alter our results.  Finally, 
we tested for a linear trend across categories of intake by modeling the category 
medians as a continuous variable. 
All statistical analyses were performed with SAS (version 9.4, Enterprise guide 
7.1, SAS Institute Inc., Cary, NC, USA). 
4.3.6.1 Covariate Adjustment Models  
Three models were used to adjust for potential confounders measured 
contemporaneously with exposure values: Model 1 adjusted for sociodemographic 
variables (age, sex, race, center, education); Model 2 further adjusted for lifestyle 
variables (BMI, physical activity, smoking status, drinking status and amount) and 
dietary variables (trans fatty acids, saturated fatty acids, and dietary fiber); Model 3 
further adjusted for clinical variables (hypertension, HDL, LDL, triglycerides).  All models 
included total energy intake (kcal/day) as a covariate. 
4.4 RESULTS 
During the first four ARIC visits (1987-1998), the 12,611 participants contributed 
exposure/outcome data for a mean of 3.0 visits (range 1-4, standard deviation 1.1) 
generating 38,345 observations. J-point elevation was identified in 2,071 ECGs among 
1,205 (9.6%) participants, while prolonged QTc was measured in 558 ECGs among 452 
(3.6%) participants.  Baseline characteristics of the 12,611 eligible participants by 
categories of total seafood intake (total fish + shellfish) are shown in Table 4-1. 
The greatest proportion of participants (46%) consumed one to two servings of 
seafood per week, while only 8% reported no seafood consumption at all. Those who 
consumed more seafood tended to be younger, female, and were more educated. 
Additionally, there was a greater proportion of black participants at higher levels of total 
seafood consumption compared to lower levels. Clinically, cardiovascular risk profiles 
   100 
 
varied across seafood categories. Prevalence of hypertension was higher with greater 
seafood consumption, as was average BMI; smoking rates were lower with greater 
seafood consumption.  
4.4.1 ASSOCIATIONS WITH QTC RELATED 
OUTCOMES 
4.4.1.1 Prolonged QTc 
4.4.1.1.1 Fish/Shellfish Servings 
Overall, fish intake was not associated with prolonged QTc (Table 4-2). The fully 
adjusted multivariable odds ratio of prolonged QTc in those consuming >2 servings 
seafood/week was 1.1 (95% CI: 0.74, 1.60) when compared to those who did not 
consume any seafood (p for trend = 0.71). Results were similar for total fish (OR=1.0, 
95% CI: 0.73, 1.50) and omega-3 rich fish (OR=1.2, 95% CI: 0.86, 1.65), comparing >2 
servings/week to no intake in the fully adjusted model. 
4.4.1.1.2 Omega-3 PUFA Intake 
Intake of ALA+DHA+EPA was not associated with prolonged QTc interval.  The 
fully adjusted multivariable odds ratio of prolonged QTc in those in the highest quartile 
of ALA+DHA+EPA was 0.9 (95% CI: 0.67, 1.17).  Results were similar when considering 
DHA+EPA (Model 3 OR=1.0; 95% CI: 0.74, 1.33) and ALA (Model 3 OR=0.7; 95% CI: 0.54, 
1.02) separately. See Table 4-3 for detailed results. 
4.4.1.2 QTc Interval 
4.4.1.2.1 Fish/Shellfish Servings 
Higher total seafood intake was associated with shorter mean QTc interval, 
though this association was not statistically significant (Model 3 highest vs. lowest 
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intake: -0.7 ms, 95% CI: -1.59, 0.16 comparing highest versus lowest category, p for 
trend = 0.07). Neither total fish nor omega-3 rich fish was associated with QTc interval 
(Table 4-4). 
4.4.1.2.2 Omega-3 PUFAs Intake 
QTc interval was shorter in individuals with higher intake of ALA+DHA+EPA, with 
0.8 ms shorter QTc in the top versus bottom quartiles (Model 3: 95% CI: -1.51, -0.22, p 
for trend = 0.01) (Table 4-5). This association was mostly due to an association between 
ALA intake and QTc duration. Individuals in the highest quartile of ALA intake had a 1 ms 
shorter QTc compared to the lowest in the fully adjusted models (95% CI: -1.73, -0.30, p 
for trend = 0.01). No association was observed between DHA+EPA intake and QTc 
duration. 
4.4.2 ASSOCIATIONS WITH J-POINT RELATED 
OUTCOMES 
4.4.2.1 J-Point Elevation 
4.4.2.1.1 Fish/Shellfish Servings 
Overall, consumption of total seafood, total fish, or omega-3 rich fish was not 
associated with the odds of JPE.  Total seafood and total fish each had their highest 
point estimates in the “less than one serving/week” category (Total Seafood Model 3 
OR= 1.2, 95% CI: 0.89, 1.53; Total Fish Model 3 OR= 1.1, 95% CI: 0.89, 1.44), but overall 
the association was null (Table 4-6). 
4.4.2.1.2 Omega-3 PUFA Intake 
As with fish/shellfish intake, intake of ALA+DHA+EPA was not associated with JPE 
(Model 3, Q4 vs. Q1 OR= 1.0, 95% CI: 0.86, 1.24).  Results were similar when considering 
DHA+EPA (fish-derived) and ALA (vegetable derived) separately (Table 4-7). 
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4.4.2.2 J-Point Height 
Consistent with the analysis for presence of J-point elevation, neither 
fish/shellfish consumption, nor omega-3 fatty acid intake (all, fish-derived, or vegetable-
derived) were associated with J-point height (tables 4-8 and 4-9). 
4.5 DISCUSSION 
In this population-based study of middle-aged adults, our investigation of the 
relationship among seafood, omega-3 PUFA, and ECG predictors of SCD suggested that 
higher total omega-3 fatty acid intake, particularly from the vegetable-derived ALA, was 
associated with shorter QTc interval and lower odds of prolonged QTc in multivariable 
adjusted models.  All other analyses were null. 
4.5.1 QTC INTERVAL 
Our null findings regarding the association of fish and fish-derived PUFA with QTc 
did not replicate the results of previous studies, but there were differences in 
population attributes.  While intake of fish-derived omega-3 PUFAs was shown to be 
associated with shorter QT intervals in Greek adults [107] and predominately white 
Americans aged >65 years [106], the ARIC study included black participants whereas the 
other two did not. Also, while intake of seafood and fish-derived omega-3 PUFAs was 
similar in the two studies, the U.S. study participants were significantly older at baseline 
compared to ARIC participants (65 versus 45 years) [106]. 
Our finding that ALA is favorably associated with QTc is similar to a study of 
white, middle aged adults in the U.S. that found higher intakes of ALA were associated 
with lower risk of prolonged QT [104].  The authors posited many biological mechanisms 
through which ALA could affect arrhythmias including modification of the eicosanoid 
system and modulation of L-type calcium channels in the sarcolemma of cardiac 
myocytes [104].   
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4.5.2 J-POINT ELEVATION AND J-POINT HEIGHT 
We did not find any significant association between seafood intake and 
measures of J-point height or JPE.  Nor did we find any significant associations with 
omega-3 fatty acids as the exposure of interest.  In a single study that investigated 
middle-aged Japanese men, the authors found a relationship between omega-3 PUFAs 
and J-point elevation [105]. It is possible that the Japanese study was better powered to 
detect an association as it had a much higher consumption of seafood compared to the 
ARIC population (half of the Japanese subjects had fish-derived omega-3 fatty acid 
intake ≥0.35% of total energy intake compared to ≥0.12% in ARIC participants). 
In spite of the lack of strong and consistent epidemiological evidence, there is 
biological plausibility for an effect. Studies suggest that fish-derived PUFAs could have 
anti-arrhythmic effects, thus reducing SCD risk. Specifically, fish-derived omega-3 PUFAs 
may inhibit the fast, voltage-dependent sodium current and the L-type calcium currents 
[102, 103] that allow pre-SCD arrhythmias to be sustained [46].  
4.6 STRENGTHS AND LIMITATIONS 
This study has many strengths.  It is a population-based, biracial cohort of 
participants who were followed over several years with multiple measures of exposures, 
outcomes, and covariates.  However, our study is not without limitations. With dietary 
data, there is always the potential for misclassification bias.  FFQs have been shown to 
work reasonably well at ranking subjects’ food intake.  While absolute values may not 
be reflective of actual intake, they are reflective of intake relative to other study 
participants [169, 198].  FFQs have also been shown to underestimate total caloric 
intake when compared to doubly labeled water [193].  Additionally, data were not 
available on fish preparation technique. Analysis in the Cardiovascular Health Study has 
shown that fish preparation method differentially affects the association between fish-
derived omeag-3 PUFAs and CHD, with only intake of tuna and other baked or broiled 
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fish associated with cardiovascular benefits, but no or deleterious associations for fried 
fish or fish sandwiches [8]. Also, as previously mentioned, the range of seafood intake in 
the ARIC population was limited, and this inhibits our ability to find associations that 
exist at higher intake levels.  Finally, as with all observational epidemiology studies, 
there is potential for unmeasured confounding.  While we attempted to adjust for 
confounders in our analysis, there may be common causes of fish intake and ECG results 
that we have missed or mis-measured. 
4.7 CONCLUSION 
In summary, our results suggest that higher dietary intake of omega-3 fatty 
acids, particularly of vegetable-derived ALA, is associated with favorable differences in 
QT measures but not J-point height.  However, given the number of statistical tests 
carried out, our finding regarding QTc may be due to type I error.  Additional studies in 
different populations are needed to substantiate our results. 
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4.8 FIGURES 
 
Figure 4-1. Flowchart of inclusion/exclusion criteria, ARIC, 1987-1998 
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Figure 4-2. Study design depiction with variable temporality, ARIC, 1987-1998 
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4.9 TABLES 
Table 4-1. Baseline characteristics of ARIC participants (n=12,611) by weekly servings of seafood 
consumption (tuna, dark meat fish, other fish, and shellfish), 1987–1989. Values correspond to mean 
(SD) or N (%) 
  
  
Zero 
Svgs/Week 
Less Than 1 
Svgs/Week 
One to Two 
Svgs/Week 
Two or More 
Svgs/Week 
N   945 (7.5%) 1,560 (12.4%) 5,791 (45.9%) 4,315 (34.2%) 
Sociodemographic Covariates 
 
      
  Age (years) 54.6 (5.8) 53.9 (5.8) 53.9 (5.7) 53.8 (5.7) 
  Male 502 (53.1%) 718 (46.0%) 2,531 (43.7%) 1,706 (39.5%) 
  White 864 (91.4%) 1,362 (87.3%) 4,399 (76.0%) 2,825 (65.5%) 
  Education         
  Basic 259 (27.4%) 300 (19.2%) 1,279 (22.1%) 903 (20.9%) 
  Intermediate 423 (44.8%) 749 (48.0%) 2,418 (41.8%) 1,646 (38.1%) 
  Advanced 263 (27.8%) 511 (32.8%) 2,094 (36.2%) 1,766 (40.9%) 
Lifestyle Covariates 
 
      
  BMI (kg/m2) 26.8 (4.9) 26.8 (4.7) 27.3 (5.2) 27.9 (5.4) 
  Physical Activity^         
  Low 342 (36.2%) 558 (35.8%) 2,022 (34.9%) 1,344 (31.1%) 
  Medium 302 (32.0%) 527 (33.8%) 1,963 (33.9%) 1,455 (33.7%) 
  High 301 (31.9%) 475 (30.4%) 1,806 (31.2%) 1,516 (35.1%) 
  Current Smokers 260 (27.5%) 429 (27.5%) 1,499 (25.9%) 1,056 (24.5%) 
  Current Alcohol Drinkers 498 (52.7%) 953 (61.1%) 3,405 (58.8%) 2,420 (56.1%) 
Dietary Covariates 
 
      
  
Total Energy Intake 
(kcal/day) 1,512 (609) 1,521 (579) 1,580 (577) 1,749 (620) 
  Cereal Fiber (grams/day) 3.4 (2.5) 3.3 (2.2) 3.4 (2.2) 3.8 (2.5) 
  
Dietary Fiber 
(grams/day) 15.0 (8.1) 14.7 (6.7) 16.2 (7.3) 19.7 (8.8) 
  
Saturated Fats 
(grams/day) 21.4 (10.6) 21.9 (10.7) 21.8 (10.4) 22.5 (10.6) 
  Trans Fats (grams/day) 3.0 (1.9) 3.0 (1.8) 2.9 (1.8) 2.9 (1.8) 
Clinical Covariates 
 
      
  Hypertension 945 (25.6%) 1,560 (26.8%) 5,791 (30.3%) 4,315 (33.7%) 
  
Systolic Blood Pressure, 
mmHg 120.1 (17.2) 119.4 (17.3) 120.5 (18.5) 121.2 (18.9) 
  
Diastolic Blood Pressure, 
mmHg 72.4 (10.4) 72.7 (10.8) 73.5 (11.1) 73.9 (11.3) 
  
High Density Lipoprotein 
Cholesterol, mg/dL 50.3 (15.8) 51.8 (16.7) 52.6 (17.0) 53.5 (17.3) 
  
Low Density Lipoprotein 
Cholesterol, mg/dL 137.6 (15.8) 135.3 (38.4) 136.6 (38.7) 137.8 (40.3) 
  Triglycerides, mg/dL 126.8 (63.7) 124.0 (64.6) 121.7 (62.4) 122.2 (63.8) 
*Svgs=Servings 
^Work+Leisure+Sport Averaged and Divided into Low/Medium/High  
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Table 4-2. Associations of seafood consumption (in servings/week) with prolonged QTc in ARIC participants (n=12,611), 1987-1998. Odds ratios and 95% 
confidence intervals from generalized estimating equations. 
  
Zero 
Servings/Week 
Less Than 1 
Servings/Week 
One to Two 
Servings/Week 
Two or More 
Servings/Week P Model  P Trend 
Total Seafood N 3,213 5,355 17,574 12,203   
 Prol QTc n (%) 40 (1.2%) 85 (1.6%) 251 (1.4%) 182 (1.5%)   
 Model 1 1.0 (ref) 1.3 (0.9, 2.0) 1.1 (0.8, 1.6) 1.2 (0.8, 1.7) 0.62 0.95 
 Model 2 1.0 (ref) 1.3 (0.9, 1.9) 1.1 (0.8, 1.6) 1.1 (0.7, 1.6) 0.63 0.70 
 Model 3 1.0 (ref) 1.3 (0.9, 1.9) 1.1 (0.8, 1.6) 1.1 (0.7, 1.6) 0.64 0.71 
Total Fish N 4,070 6,436 17,926 9,913   
 Prol QTc n (%) 54 (1.3%) 106 (1.6%) 239 (1.3%) 159 (1.6%)   
 Model 1 1.0 (ref) 1.3 (0.9, 1.8) 1.0 (0.7, 1.3) 1.1 (0.8, 1.6) 0.21 0.80 
 Model 2 1.0 (ref) 1.2 (0.9, 1.8) 0.9 (0.7, 1.3) 1.1 (0.7, 1.5) 0.21 0.98 
 Model 3 1.0 (ref) 1.2 (0.9, 1.8) 0.9 (0.7, 1.3) 1.0 (0.7, 1.5) 0.21 0.96 
Omega-3 Rich Fish N 8,524 10,018 14,208 5,595   
 Prol QTc n (%) 116 (1.4%) 141 (1.4%) 206 (1.4%) 95 (1.7%)   
 Model 1 1.0 (ref) 1.1 (0.8, 1.4) 1.1 (0.8, 1.4) 1.2 (0.9, 1.7) 0.63 0.18 
 Model 2 1.0 (ref) 1.0 (0.8, 1.4) 1.0 (0.8, 1.3) 1.2 (0.9, 1.7) 0.75 0.28 
 Model 3 1.0 (ref) 1.0 (0.8, 1.4) 1.0 (0.8, 1.3) 1.2 (0.9, 1.7) 0.74 0.28 
Prol QTc: Prolonged QTc 
P Model: p value for the exposure term 
P Trend: p value for exposure modeled linearly using the median values in each category 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables (hypertension, HDL, LDL, triglycerides) 
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Table 4-3. Associations of fatty acid intake (in quartiles) with prevalence of prolonged QTc in ARIC participants (n=12,611), 1987-1998. Odds ratios and 95% 
confidence intervals from generalized estimating equations. 
  Q1 Q2 Q3 Q4 P Model  P Trend 
ALA + DHA + EPA N 9,701 9,795 9,459 9,390   
 Prol QTc n (%) 137 (1.4%) 141 (1.4%) 126 (1.3%) 154 (1.6%)   
 Model 1 1.0 (ref) 1.0 (0.7, 1.3) 0.8 (0.6, 1.0) 1.0 (0.7, 1.2) 0.17 0.57 
 Model 2 1.0 (ref) 0.9 (0.7, 1.2) 0.7 (0.5, 1.0) 0.9 (0.7, 1.2) 0.12 0.35 
 Model 3 1.0 (ref) 0.9 (0.7, 1.2) 0.7 (0.5, 1.0) 0.9 (0.7, 1.2) 0.13 0.32 
DHA + EPA N 10,372 9,007 9,514 9,452   
 Prol QTc n (%) 138 (1.3%) 133 (1.5%) 128 (1.3%) 159 (1.7%)   
 Model 1 1.0 (ref) 1.0 (0.8, 1.4) 0.9 (0.7, 1.2) 1.0 (0.8, 1.4) 0.71 0.79 
 Model 2 1.0 (ref) 1.0 (0.8, 1.3) 0.9 (0.7, 1.2) 1.0 (0.7, 1.3) 0.66 0.97 
 Model 3 1.0 (ref) 1.0 (0.8, 1.3) 0.9 (0.7, 1.1) 1.0 (0.7, 1.3) 0.64 0.97 
ALA N 9,872 9,566 9,615 9,292   
 Prol QTc n (%) 144 (1.5%) 136 (1.4%) 146 (1.5%) 132 (1.4%)   
 Model 1 1.0 (ref) 0.8 (0.6, 1.0) 0.8 (0.6, 1.1) 0.8 (0.6, 1.1) 0.23 0.27 
 Model 2 1.0 (ref) 0.7 (0.6, 1.0) 0.8 (0.6, 1.0) 0.8 (0.5, 1.0) 0.14 0.12 
 Model 3 1.0 (ref) 0.7 (0.6, 1.0) 0.8 (0.6, 1.0) 0.7 (0.5, 1.0) 0.12 0.10 
Prol QTc: Prolonged QTc 
P Model: p value for the exposure term 
P Trend: p value for exposure modeled linearly using the median values in each category 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables (hypertension, LDL, HDL, triglycerides) 
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Table 4-4. Associations of seafood consumption (in servings/week) with QTc interval (in milliseconds) in ARIC participants (n=12,611), 1987-1998. 
Millisecond deltas and 95% confidence intervals from generalized estimating equations. 
  
Zero 
Servings/Week 
Less Than 1 
Servings/Week 
One to Two 
Servings/Week 
Two or More 
Servings/Week P Model  P Trend 
Total Seafood Total N (all Visits) 3,213 5,355 17,574 12,203   
 QTc Mean (Std) 412.7 (17.0) 412.6 (16.3) 412.2 (17.1) 412.3 (16.9)   
 Model 1 0.0 (ref) -0.2 (-1.1, 0.7) -0.4 (-1.2, 0.4) -0.3 (-1.1, 0.6) 0.81 0.47 
 Model 2 0.0 (ref) -0.3 (-1.2, 0.6) -0.6 (-1.4, 0.2) -0.7 (-1.6, 0.1) 0.34 0.05 
 Model 3 0.0 (ref) -0.4 (-1.2, 0.5) -0.6 (-1.4, 0.2) -0.7 (-1.6, 0.2) 0.39 0.07 
Total Fish Total N (all Visits) 4,070 6,436 17,926 159 (9,913)   
 QTc Mean (Std) 412.3 (16.8) 412.2 (16.4) 412.3 (17.0) 412.4 (17.1)   
 Model 1 0.0 (ref) -0.3 (-1.1, 0.5) -0.1 (-0.9, 0.6) -0.1 (-0.9, 0.7) 0.86 0.86 
 Model 2 0.0 (ref) -0.4 (-1.2, 0.4) -0.4 (-1.1, 0.4) -0.6 (-1.4, 0.2) 0.56 0.25 
 Model 3 0.0 (ref) -0.5 (-1.3, 0.3) -0.4 (-1.1, 0.3) -0.6 (-1.4, 0.2) 0.53 0.28 
Omega-3 Rich Fish Total N (all Visits) 8,524 10,018 14,208 5,595   
 QTc Mean (Std) 411.8 (16.8) 412.1 (16.8) 412.5 (17.0) 412.9 (17.0)   
 Model 1 0.0 (ref) -0.1 (-0.7, 0.5) 0.2 (-0.4, 0.8) 0.4 (-0.4, 1.1) 0.57 0.26 
 Model 2 0.0 (ref) -0.2 (-0.8, 0.4) -0.1 (-0.6, 0.5) -0.1 (-0.9, 0.6) 0.92 0.85 
 Model 3 0.0 (ref) -0.2 (-0.8, 0.4) 0.0 (-0.6, 0.5) -0.1 (-0.8, 0.7) 0.90 0.99 
Std: standard deviation 
P Model: p value for the exposure term 
P Trend: p value for exposure modeled linearly using the median values in each category 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables (hypertension, HDL, LDL, triglycerides) 
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Table 4-5. Associations of fatty acid intake (in quartiles) with QTc interval (in milliseconds) in ARIC participants (n=12,611), 1987-1998. Millisecond deltas 
and 95% confidence intervals from generalized estimating equations. 
  Q1 Q2 Q3 Q4 P Model  P Trend 
ALA + DHA + EPA Total N (all Visits) 9,701 9,795 9,459 9,390   
 QTc Mean (Std) 412.7 (16.4) 412.4 (17.3) 412.1 (16.8) 412.1 (17.1)   
 Model 1 0.0 (ref) -0.4 (-1.0, 0.2) -0.6 (-1.2, 0.0) -0.4 (-1.0, 0.2) 0.30 0.17 
 Model 2 0.0 (ref) -0.5 (-1.1, 0.1) -0.8 (-1.4, -0.2) -0.9 (-1.5, -0.2) 0.03 0.01 
 Model 3 0.0 (ref) -0.5 (-1.1, 0.1) -0.8 (-1.4, -0.2) -0.8 (-1.5, -0.2) 0.04 0.01 
DHA + EPA Total N (all Visits) 10,372 9,007 9,514 9,452   
 QTc Mean (Std) 412.1 (16.5) 412.1 (16.9) 412.4 (16.9) 412.7 (17.4)   
 Model 1 0.0 (ref) 0.1 (-0.5, 0.6) 0.3 (-0.3, 0.9) 0.1 (-0.5, 0.8) 0.79 0.66 
 Model 2 0.0 (ref) -0.1 (-0.7, 0.5) 0.0 (-0.6, 0.6) -0.3 (-1.0, 0.3) 0.67 0.32 
 Model 3 0.0 (ref) -0.1 (-0.7, 0.5) 0.0 (-0.6, 0.7) -0.3 (-0.9, 0.3) 0.68 0.35 
ALA Total N (all Visits) 9,872 9,566 9,615 9,292   
 QTc Mean (Std) 412.7 (16.5) 412.6 (17.0) 412.5 (17.6) 411.4 (16.5)   
 Model 1 0.0 (ref) -0.4 (-0.9, 0.2) -0.3 (-0.9, 0.3) -0.7 (-1.3, -0.1) 0.20 0.03 
 Model 2 0.0 (ref) -0.5 (-1.1, 0.1) -0.6 (-1.2, 0.1) -1.0 (-1.7, -0.3) 0.05 0.005 
 Model 3 0.0 (ref) -0.5 (-1.1, 0.1) -0.5 (-1.2, 0.1) -1.0 (-1.7, -0.3) 0.05 0.01 
Std: standard deviation 
P Model: p value for the exposure term 
P Trend: p value for exposure modeled linearly using the median values in each category 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables (hypertension, HDL, LDL, triglycerides) 
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Table 4-6. Associations of seafood consumption (in servings/week) with prevalence of J-point elevation in ARIC participants (n=12,611), 1987-1998. Odds 
ratios and 95% confidence intervals from generalized estimating equations. 
  
Zero 
Servings/Week 
Less Than 1 
Servings/Week 
One to Two 
Servings/Week 
Two or More 
Servings/Week P Model  P Trend 
Total Seafood N 3,213 5,355 17,574 12,203   
 JPE n (%) 144 (4.5%) 262 (4.9%) 910 (5.2%) 755 (6.2%)   
 Model 1 1.0 (ref) 1.1 (0.9, 1.5) 1.0 (0.8, 1.2) 0.9 (0.7, 1.2) 0.31 0.40 
 Model 2 1.0 (ref) 1.2 (0.9, 1.5) 1.0 (0.8, 1.3) 1.0 (0.8, 1.3) 0.36 0.77 
 Model 3 1.0 (ref) 1.2 (0.9, 1.5) 1.0 (0.8, 1.3) 1.0 (0.8, 1.3) 0.36 0.76 
Total Fish N 4,070 6,436 17,926 9,913   
 JPE n (%) 188 (4.6%) 328 (5.1%) 932 (5.2%) 623 (6.3%)   
 Model 1 1.0 (ref) 1.1 (0.9, 1.4) 0.9 (0.7, 1.1) 1.0 (0.8, 1.2) 0.07 0.61 
 Model 2 1.0 (ref) 1.1 (0.9, 1.5) 0.9 (0.7, 1.1) 1.0 (0.8, 1.3) 0.07 0.95 
 Model 3 1.0 (ref) 1.1 (0.9, 1.4) 0.9 (0.7, 1.1) 1.0 (0.8, 1.3) 0.07 1.00 
Omega-3 Rich Fish JPE n (Total N) 8,524 10,018 14,208 5,595   
 ST Seg Ht Mean (Std) 490 (5.7%) 518 (5.2%) 775 (5.5%) 288 (5.1%)   
 Model 1 1.0 (ref) 1.0 (0.9, 1.2) 1.0 (0.8, 1.2) 1.0 (0.8, 1.2) 0.99 0.82 
 Model 2 1.0 (ref) 1.0 (0.9, 1.2) 1.0 (0.9, 1.2) 1.0 (0.8, 1.3) 0.97 0.81 
 Model 3 1.0 (ref) 1.0 (0.9, 1.2) 1.0 (0.9, 1.2) 1.0 (0.8, 1.3) 0.98 0.87 
JPE: J-point elevation 
P Model: p value for the exposure term 
P Trend: p value for exposure modeled linearly using the median values in each category 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables (hypertension, HDL, LDL, triglycerides) 
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Table 4-7. Associations of fatty acid intake (in quartiles) with prevalence of J-point elevation in ARIC participants (n=12,611), 1987-1998. Odds ratios and 
95% confidence intervals from generalized estimating equations. 
  Q1 Q2 Q3 Q4 P Model  P Trend 
ALA + DHA + EPA N 9,701 9,795 9,459 9,390   
 JPE n (%) 449 (4.6%) 499 (5.1%) 536 (5.7%) 587 (6.3%)   
 Model 1 1.0 (ref) 0.9 (0.8, 1.1) 0.9 (0.7, 1.0) 0.9 (0.8, 1.1) 0.55 0.50 
 Model 2 1.0 (ref) 1.0 (0.8, 1.2) 1.0 (0.8, 1.2) 1.0 (0.9, 1.3) 0.81 0.60 
 Model 3 1.0 (ref) 1.0 (0.8, 1.2) 1.0 (0.8, 1.1) 1.0 (0.9, 1.2) 0.84 0.68 
DHA + EPA N 10,372 9,007 9,514 9,452   
 JPE n (%) 506 (4.9%) 446 (5.0%) 546 (5.7%) 573 (6.1%)   
 Model 1 1.0 (ref) 0.9 (0.8, 1.1) 0.9 (0.7, 1.1) 0.9 (0.8, 1.1) 0.64 0.49 
 Model 2 1.0 (ref) 1.0 (0.8, 1.1) 0.9 (0.8, 1.1) 1.0 (0.8, 1.2) 0.80 0.94 
 Model 3 1.0 (ref) 1.0 (0.8, 1.1) 0.9 (0.8, 1.1) 1.0 (0.8, 1.2) 0.80 0.87 
ALA N 9,872 9,566 9,615 9,292   
 JPE n (%) 484 (4.9%) 500 (5.2%) 508 (5.3%) 579 (6.2%)   
 Model 1 1.0 (ref) 1.0 (0.8, 1.1) 0.9 (0.8, 1.1) 0.9 (0.8, 1.1) 0.79 0.53 
 Model 2 1.0 (ref) 1.0 (0.9, 1.2) 1.0 (0.9, 1.2) 1.1 (0.9, 1.3) 0.86 0.40 
 Model 3 1.0 (ref) 1.0 (0.8, 1.2) 1.0 (0.8, 1.2) 1.1 (0.9, 1.3) 0.92 0.50 
JPE: J-point elevation 
P Model: p value for the exposure term 
P Trend: p value for exposure modeled linearly using the median values in each category 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables (hypertension, HDL, HDL, triglycerides) 
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Table 4-8. Associations of seafood consumption (in servings/week) with J-point height (in millivolts) in ARIC participants (n=12,611), 1987-1998. Millivolt 
deltas and 95% confidence intervals from generalized estimating equations. 
  
Zero 
Servings/Week 
Less Than 1 
Servings/Week 
One to Two 
Servings/Week 
Two or More 
Servings/Week P Model  P Trend 
Total Seafood Total N (all Visits) 3,213 5,355 17,574 12,203   
 J-Point Ht Mean (Std) 53.2 (33.6) 52.6 (34.0) 55.0 (35.8) 56.3 (36.8)   
 Model 2b 0.0 (ref) -0.1 (-2.0, 1.8) 0.0 (-1.7, 1.7) -0.8 (-2.6, 1.0) 0.47 0.20 
 Model 4b 0.0 (ref) 0.0 (-1.8, 1.9) 0.2 (-1.4, 1.9) -0.7 (-2.4, 1.1) 0.44 0.21 
 Model 5b 0.0 (ref) 0.0 (-1.8, 1.9) 0.2 (-1.5, 1.8) -0.7 (-2.5, 1.1) 0.42 0.18 
Total Fish Total N (all Visits) 4,070 6,436 17,926 159 (9,913)   
 J-Point Ht Mean (Std) 53.4 (33.7) 53.1 (34.2) 55.3 (36.0) 56.2 (37.0)   
 Model 2b 0.0 (ref) 0.2 (-1.5, 1.9) -0.1 (-1.6, 1.5) -0.6 (-2.4, 1.2) 0.74 0.29 
 Model 4b 0.0 (ref) 0.3 (-1.4, 2.0) 0.1 (-1.4, 1.7) -0.3 (-2.1, 1.4) 0.82 0.42 
 Model 5b 0.0 (ref) 0.3 (-1.4, 1.9) 0.1 (-1.5, 1.6) -0.4 (-2.2, 1.3) 0.79 0.37 
Omega-3 Rich Fish Total N (all Visits) 8,524 10,018 14,208 5,595   
 J-Point Ht Mean (Std) 55.8 (36.3) 54.3 (35.7) 55.4 (35.7) 53.6 (35.1)   
 Model 1 0.0 (ref) 0.4 (-0.9, 1.7) 0.6 (-0.7, 1.8) -0.6 (-2.2, 1.0) 0.39 0.30 
 Model 2 0.0 (ref) 0.6 (-0.7, 1.9) 0.8 (-0.5, 2.1) -0.2 (-1.8, 1.4) 0.38 0.52 
 Model 3 0.0 (ref) 0.5 (-0.8, 1.8) 0.7 (-0.5, 2.0) -0.3 (-1.9, 1.3) 0.38 0.45 
Ht: height 
Std: standard deviation 
P Model: p value for the exposure term 
P Trend: p value for exposure modeled linearly using the median values in each category 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables (hypertension, HDL, LDL, triglycerides) 
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Table 4-9. Associations of fatty acid intake (in quartiles) with J-point height (in millivolts) in ARIC participants (n=12,611), 1987-1998. Millivolt deltas and 
95% confidence intervals from generalized estimating equations. 
  Q1 Q2 Q3 Q4 P Model  P Trend 
ALA + DHA + EPA Total N (all Visits) 9,701 9,795 9,459 9,390   
 J-Point Ht Mean (Std) 52.8 (34.5) 54.4 (35.2) 55.4 (36.1) 57.3 (37.0)   
 Model 1 0.0 (ref) -0.5 (-1.8, 0.7) -0.9 (-2.2, 0.4) -1.0 (-2.3, 0.4) 0.47 0.15 
 Model 2 0.0 (ref) -0.1 (-1.3, 1.2) -0.2 (-1.4, 1.1) -0.2 (-1.6, 1.1) 0.99 0.69 
 Model 3 0.0 (ref) -0.2 (-1.4, 1.1) -0.3 (-1.6, 1.0) -0.4 (-1.7, 1.0) 0.96 0.58 
DHA + EPA Total N (all Visits) 10,372 9,007 9,514 9,452   
 J-Point Ht Mean (Std) 53.2 (34.9) 54.8 (35.1) 55.9 (36.3) 56.0 (36.6)   
 Model 1 0.0 (ref) -0.2 (-1.5, 1.0) 0.3 (-1.1, 1.6) -0.9 (-2.3, 0.5) 0.30 0.20 
 Model 2 0.0 (ref) 0.3 (-1.0, 1.5) 0.2 (-1.1, 1.5) -1.0 (-2.4, 0.4) 0.21 0.10 
 Model 3 0.0 (ref) 0.3 (-1.0, 1.5) 0.2 (-1.1, 1.5) -0.9 (-2.3, 0.4) 0.24 0.12 
ALA Total N (all Visits) 9,872 9,566 9,615 9,292   
 J-Point Ht Mean (Std) 53.4 (34.9) 54.3 (35.1) 54.8 (36.3) 57.5 (36.6)   
 Model 1 0.0 (ref) -0.3 (-1.6, 0.9) -0.7 (-2.0, 0.5) -0.6 (-1.9, 0.6) 0.67 0.27 
 Model 2 0.0 (ref) 0.2 (-1.0, 1.5) 0.3 (-1.0, 1.6) 0.6 (-0.8, 2.0) 0.88 0.49 
 Model 3 0.0 (ref) 0.2 (-1.1, 1.4) 0.2 (-1.1, 1.5) 0.5 (-0.9, 1.9) 0.93 0.62 
Ht: height 
Std: standard deviation 
P Model: p value for the exposure term 
P Trend: p value for exposure modeled linearly using the median values in each category 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables (hypertension, HDL, LDL, triglycerides) 
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5 MANUSCRIPT 3: BIOSTATISTICAL METHODS TO ADDRESS 
DIETARY EXPOSURE MEASUREMENT ERROR (IN 
FULFILLMENT OF THE BIOSTATISTICS MINOR)  
5.1 SYNOPSIS 
Background: A common issue in studies with a dietary exposure is measurement error in 
self-reported intake.  The true (unknown) exposure value can be treated as a missing 
value problem, and it can be imputed using multiple imputation for measurement error 
(MIME).  We expand on this idea using Multiple Imputation by Chained Equations 
(MICE). 
Methods: We utilized data from the Atherosclerosis in Communities (ARIC) study, a 
prospective cohort of adults recruited from four field centers in the United States.  One 
field center collected plasma fatty acid biomarker values from participants, and these 
data were used to augment self-report dietary data obtained via food frequency 
questionnaire.  We imputed biomarker values using MICE to investigate the associations 
of biomarker measures of the omega-3 polyunsaturated fatty acids alpha linoleic acid 
(ALA), docosahexaenoic acid (DHA) + eicosapentaenoic acid (EPA), and ALA+DHA+EPA 
with prolonged QT, HbA1c, and incident type 2 diabetes (T2D).  We also qualitatively 
compared associations in the full cohort – imputed and observed plasma values – to 
associations obtained using observed plasma values only.   
Results: In both the full cohort and the observed plasma populations, none of the 
exposures were significantly associated with our outcomes of interest.  Point estimates 
in both populations were similar across three different covariate-adjustment models, 
and confidence intervals were narrower for associations from the full cohort population 
than those from the observed plasma population. 
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Conclusions: Using MICE to augment self-report dietary data with biomarker data did 
not fundamentally change the associations between exposure and outcome, but it did 
increase precision. 
5.2 INTRODUCTION 
Measurement error in dietary exposures is a significant challenge for nutritional 
epidemiological studies [199] and understanding the direction and magnitude of the 
error is necessary for accurate interpretation of nutritional epidemiology study results 
[200].  Different dietary assessment methods can have varying levels of measurement 
error [169]; this manuscript will focus on food frequency questionnaire (FFQ)-derived 
measures and biomarker measures of dietary intake of omega-3 polyunsaturated fatty 
acids (PUFAs). 
FFQs are relatively inexpensive ways to obtain dietary data from a large group of 
subjects without a high participant burden [169].  Some epidemiologists view FFQs as a 
way to qualitatively rank subjects’ dietary intake from low to high and/or to 
quantitatively estimate subjects’ absolute nutrient intakes [169].  However, many 
commentaries have been written regarding the fallibility of the data obtained from FFQs 
[201-203].  Key in those commentaries is evidence suggesting that data from FFQs are 
imprecise and subject to measurement error.   
Biomarker values are another measure of dietary intake. These are objective 
measures that indicate how much of the nutrient was absorbed (bioavailability), and 
may be a good measure of usual intake provided between-season variability in an 
individual’s intake is not large [169]. Given the potential biases that can result from 
measurement error in the exposure variable, several techniques have been developed 
to augment FFQ data using biomarker data [108, 114, 121, 122, 204-220].  For this 
manuscript, we used biomarker data collected from participants in the Minnesota (MN) 
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field center of the Atherosclerosis Risk in Communities (ARIC) Study to address potential 
measurement error in omega-3 PUFA intake as measured via FFQ.     
Specifically, we expanded upon the premise embodied in Multiple Imputation for 
Measurement Error (MIME) and imputed biomarker data for non-MN ARIC participants 
using Multiple Imputation by Chained Equations (MICE) [221-223].  We then 
investigated the associations of plasma ALA, DHA+EPA, and ALA+DHA+EPA with three 
outcomes previously analyzed with respect to their associations with FFQ exposures: (1) 
prolonged QTc, (2) HbA1c, and (3) incident type 2 diabetes (T2D).  Finally, we compared 
the measures of association in the full cohort (imputed + observed biomarker data) with 
those in the MN field center (observed biomarker data). 
The remainder of this manuscript is divided into four parts.  Part 1 introduces the 
ARIC study, our research questions of interest, and we describe the methods that are 
independent of multiple imputation.  In Part 2, we define MIME and MICE and describe 
the methods specific to the multiple imputation process.  Part 3 describes how we 
analyzed the post-imputation data and compared the results from our two populations 
of interest: results derived using observed plasma values from MN participants versus 
results derived from the full cohort (observed and imputed plasma exposure values).  
We conclude in Part 4 by describing our results and offering discussion points and 
overall conclusions. 
5.3 PART 1 – THE ASSOCIATION OF OMEGA-3 PUFA WITH 
PROLONGED QTC, HBA1C, AND INCIDENT TYPE 2 DIABETES 
5.3.1 BACKGROUND 
5.3.1.1 Omega-3 PUFA and ECG 
Predictors of SCD 
Intake of omega-3 PUFAs has been associated with lower incidence of sudden 
cardiac death (SCD) [46, 51, 194, 195].  ECG predictors of SCD include prolonged QT 
interval [96-99, 142], and prolonged QT interval may be the mechanism underlying the 
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association observed between intake of omega-3 PUFAs and SCD.  We previously 
investigated whether FFQ-measured consumption of seafood, the fish-derived omega-3 
PUFAs DHA and EPA, and the vegetable-derived omega-3 PUFA ALA were associated 
with heart rate-corrected QT interval (QTc) in the ARIC study.  In this manuscript, we 
addressed potential FFQ measurement error by utilizing a biomarker sub-study to 
augment our ALA, DHA+EPA, and ALA+DHA+EPA exposure estimates.  These updated 
exposures were used to reevaluate the association of omega-3 PUFA with prolonged 
QTc. 
5.3.1.2 Omega-3 PUFA and Markers of 
Glucose Homeostasis 
Studies investigating seafood intake and intake of fish-derived omega-3 PUFAs 
with markers of glucose homeostasis have been mixed with some reporting favorable  
[86], adverse  [85-88], and null [85, 86] associations, depending on study population and 
exposure definition. Studies investigating intake of the vegetable-derived ALA have been 
similarly mixed with both favorable [85] and null [86] results.  Given the inconsistent 
nature of the previous literature, we previously tested the associations among FFQ-
obtained intakes of seafood, DHA + EPA, and ALA with glycemia outcomes in the ARIC 
study.  In this manuscript, we addressed potential FFQ measurement error by utilizing a 
biomarker sub-study to augment our ALA, DHA+EPA, and ALA+DHA+EPA exposure 
estimates.  These updated exposures were used to reevaluate the association of omega-
3 PUFA with HbA1c and Incident T2D. 
5.3.2 METHODS 
5.3.2.1 Study Population 
The ARIC study has been described previously [155]. Briefly, it is a prospective 
study of cardiovascular disease including 15,792 men and women 45–64 years of age at 
baseline (visit 1). Participants were recruited from four US communities using 
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probability sampling techniques. The communities and racial composition were: 
predominately white subjects from suburbs of Minneapolis, Minnesota, and Washington 
County, Maryland; black subjects from Jackson, Mississippi; and white and black 
subjects from Forsyth County, North Carolina. 
For the analyses described in this manuscript, there were two sets of 
inclusion/exclusion criteria.  The first set included criteria that were specific to the 
outcome of interest and the study design used in investigating that outcome.  These are 
described later in this section (Part 1).  The second set of inclusion/exclusion criteria are 
specific to the imputation methodology.  These are described in Part 2. 
5.3.2.2 Exposures: Measures of Dietary 
Omega-3 PUFA intake 
Although our exposure of interest was circulating concentrations of omega-3 
PUFA biomarkers, we will briefly revisit the FFQ measures of omega-3 PUFA before 
describing the biomarker exposures. 
5.3.2.2.1 Food Frequency Questionnaire 
Participants’ usual dietary intake was assessed at visit 1 using an interviewer-
administered, 66-item FFQ. The FFQ was a based on the instrument developed by 
Willett et al. [167], with three principal modifications: (1) Data regarding alcohol 
consumption were obtained using a separate, more detailed instrument; (2) Several 
food items were added (e.g., donuts, biscuits, and cornbread); and (3) Some items were 
split into detailed subcategories – notably a single item on fish consumption was 
separated into three specific fish items. 
Daily intake of macro- and micronutrients was calculated via the FFQ by 
multiplying the nutrient content of each food by the frequency of daily consumption 
and then summing the results [124]. This process yielded daily intake of nutrients 
expressed as grams per day. Three different classifications of omega-3 fatty acids were 
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investigated in prior analyses: (1) vegetable-derived ALA, (2) fish-derived DHA+EPA; and 
(3) total omega-3 PUFA ALA+DHA+EPA. 
5.3.2.2.2 Biomarker Measures of Plasma Fatty Acids 
Blood samples were obtained from MN field participants at visit 1 (n= 3,757) and 
plasma fatty acids were measured in cholesterol esters and phospholipids using gas 
chromatography [126].  The fatty acid profile of cholesterol esters reflects medium-term 
(weeks) dietary intake of fatty acids while phospholipids reflect intake over a slightly 
longer duration (weeks to months) [127].  Phospholipid measurements were used for 
the present analysis.  Previous analyses in ARIC have shown that correlation coefficients 
for FFQ values compared to plasma phospholipid values are r=0.15 (ALA), r=0.20 (EPA), 
and r=0.42 (DHA) [126]. 
Biomarker values of omega-3 PUFA were expressed as percentage of total fatty 
acids.  We considered three exposure categories: ALA, DHA+EPA, and ALA+DHA+EPA.  
Each of these three exposures was categorized into quartiles. 
5.3.2.3 Outcomes: ECG Predictors of 
Sudden Cardiac Death and 
Markers of Glucose Homeostasis 
5.3.2.3.1 Prolonged QTc 
At visit 1, a standard, resting, supine 12-lead ECG was obtained for each subject 
using MAC PC personal cardiography equipment (Marquette Electronics, Inc., 
Milwaukee, WI). We defined prolonged QT as a heart rate-corrected (QTc) value of 460 
ms or longer in women and 450 ms or longer in men [138].  
5.3.2.3.2 HbA1c 
HbA1c was measured from whole blood samples using high-performance liquid 
chromatography.  The blood was collected during visit 2 (1990-92) and stored at -70 °C 
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for 14-18 years until HbA1c measurements could be obtained.  Selvin et al. give a 
detailed description of the HbA1c measurement process [158].  
5.3.2.3.3 Incident Type 2 Diabetes 
Diabetes was defined as (1) self-report of physician-diagnosed diabetes; (2) self-
reported use of diabetes medication in the past two weeks; (3) fasting glucose level ≥ 
7.0 mmol/liter (126 mg/dl); or (4) non-fasting glucose level > 11.1 mmol/liter (200 
mg/dl).   
5.3.2.4 Covariates: Potential 
Confounders 
All potential confounders were measured at visit 1.  Variables of interest 
included sociodemographic variables (age, sex, race, and education), lifestyle variables 
(physical activity, smoking status, drinking status, and drinking amount), dietary 
variables (trans fatty acids, saturated fatty acids, dietary fiber), and clinical variables 
(body mass index (BMI), hypertension, LDL, HDL, triglycerides).   
Several variables were obtained via self-report.  Age, sex, and race were 
obtained at visit 1 and confirmed at subsequent visits.  Participants’ smoking status and 
education level were obtained via self-report and categorized.  Education level was 
categorized based on years of education: basic (less than high school graduate), 
intermediate (high school graduate, no college), and advanced (at least some college). 
Smoking status had three categories: current smokers, former smokers (more than 100 
cigarettes in the past), and never smokers. 
Physical activity, alcohol intake, and dietary intake were measured using 
validated instruments.  Physical activity was measured using the Baecke questionnaire 
[144]. The questionnaire translated into three indexes ranging from 1 (low) to 5 (high) 
for physical activity at work, during leisure time, and in sports. The three physical 
activity scores were summed and then translated into tertiles of physical activity (low, 
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medium, and high).  Alcohol intake and amount (grams/day) was measured via an 
interviewer-administered questionnaire.  Dietary intake of trans fatty acids, saturated 
fatty acids, and dietary fiber were obtained with the same methodology used to 
translate FFQ responses into grams of omega-3 PUFA per day. 
Finally, the remaining variables were measured by trained technicians.  Weight 
and height were measured with the participant wearing light clothes. BMI was 
calculated as weight (kilograms) divided by height squared (meters2).  Technicians also 
obtained three blood pressure measurements with a random-zero sphygmomanometer 
and the mean of the last two measurements was used.  Hypertension was defined as a 
systolic blood pressure above 140 mmHg, a diastolic above 90 mmHg, or self-reported 
use of antihypertensive medication.  Participants with missing hypertension values were 
imputed as not having hypertension (no disease).  For metrics requiring phlebotomy, 
blood was drawn after a minimum 8-hour fasting period with minimal trauma from an 
antecubital vein [146]. Plasma total cholesterol and triglycerides were measured by 
enzymatic methods [132], and LDL cholesterol was calculated using the Friedewald 
formula [147]. HDL cholesterol was measured after dextran-magnesium precipitation of 
non-HDL lipoproteins [132].  
5.3.2.5 Statistical Analysis 
The statistical methods used were dependent on the study design used to 
investigate the relationship between the exposure and the outcome of interest.  
Outcome-specific study populations, study designs, and statistical methods are 
described below.  Figure 5-1 represents this pictorially.  All analyses were limited to 
white participants – additional details regarding rationale are in Part 2. 
5.3.2.5.1 Prolonged QTc 
Analyses investigating this outcome utilized data from a cross-sectional study 
design using data from visit 1.  Participants were excluded if they were non-white and if 
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they had prevalent cardiovascular disease (CVD) – defined as coronary heart disease 
(CHD), heart failure (HF), or stroke – as prevalent conditions influence how patients 
have their comorbidities managed, diagnosed and treated.  If a participant was missing 
data on CVD prevalence, it was assumed that the participant did not have prevalent 
CVD.  We excluded participants who self-reported use of antiarrhythmic medications 
and those whose duration of the QRS complex was ≥120 ms, as those individuals have 
major conduction defects that make the interpretation of primary repolarization 
abnormalities inappropriate [197]. 
Data were analyzed using logistic regression – prolonged QTc was the outcome 
of interest and quartiles of plasma ALA, DHA+EPA, and ALA+DHA+EPA were the 
exposures, with the lowest quartile as the reference category.  Three covariate-
adjustment models were tested.  Model 1 included age, sex, and education level.  Model 
2 was Model 1 plus BMI, physical activity, smoking status, drinking status and amount, 
and the dietary variables trans fatty acids, saturated fatty acids, and dietary fiber.  
Model 3 was Model 2 plus the clinical covariates: hypertension, LDL, HDL, and 
triglycerides. 
5.3.2.5.2 Hemoglobin A1c 
Analyses investigating this outcome utilized data from a modified cross-sectional 
study design, with exposures and potential confounders measured at visit 1 and the 
outcome measured at visit 2.  Our exclusion criteria were non-white race and CVD.  We 
excluded those participants who reported diagnoses of CHD, HF, or stroke at either visit 
1 or 2 – not only because their clinical treatment may differ from those who do not have 
those conditions, but because incident disease between visits 1 and 2 may have led to 
changes in the exposure and covariate behaviors reported at visit 1.  Finally, we 
restricted our analysis to diabetic participants as previous analyses suggested this 
population was most likely to show differences in HbA1c levels across different strata of 
omega-3 PUFA intake. 
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For those participants who reported taking anti-hyperglycemic medications, we 
applied a correction factor using the approach described in Tobin et al. [159] and used in 
other studies with glycemia outcomes [160, 161].  Specifically, for medicated 
participants, we added a constant of 1 percentage point to HbA1c values.  These 
constants were based on pharmaceutical studies, systematic reviews, and meta-
analyses of the effect of medication on glycemia lab values [162-166]. 
Data were analyzed using linear regression – HbA1c was the outcome of interest 
and quartiles of plasma ALA, DHA+EPA, and ALA+DHA+EPA were the exposures, with the 
lowest quartile as the reference category.  The same three covariate-adjustment models 
were tested: Model 1 (sociodemographic variables), Model 2 (Model 1 + lifestyle and 
dietary variables), and Model 3 (Model 2 + clinical variables).   
5.3.2.5.3 Incident Type 2 Diabetes 
This was a prospective study design, with exposures and potential confounders 
measured at visit 1 and the outcome of interest being time to incident T2D or censoring.  
Our inclusion/exclusion criteria were similar to the other two outcomes with respect to 
race and CVD.  Assignment of variables followed the algorithm depicted in Figure 5-2, 
with participants censored if lost to follow-up, experienced incident CVD, or reached 
visit 4 without developing T2D. 
Data were analyzed using Cox proportional hazards regression.  Exposures were 
quartiles of plasma ALA, DHA+EPA, and ALA+DHA+EPA, with the lowest quartile as the 
reference category.  The same three covariate-adjustment models were tested: Model 1 
(sociodemographic variables), Model 2 (Model 1 + lifestyle and dietary variables), and 
Model 3 (Model 2 + clinical variables).  We tested for violations of the proportional 
hazards assumption using a log(time)*exposure interaction term in our model and an α 
of 0.10 (Ho=no violation). 
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5.4 PART 2 – MULTIPLE IMPUTATION METHODS 
As previously mentioned, this section will describe our imputation process.  Here 
we present an overview of multiple imputation followed by our imputation-specific 
methods. 
5.4.1 OVERVIEW 
When investigating the associations between dietary exposures and an outcome 
of interest, the investigators attempt to quantify subjects’ true intake.  Researchers 
must consider participant burden and expense along with measurement error and 
accuracy.  FFQs are inexpensive and have low participant burden [169], but their output 
can have measurement error [198]. 
Our paradigm can be described as follows: consumption of omega-3 PUFA and 
other foods, behaviors (smoking, exercise), and biological factors (race, sex) influence 
how dietary omega-3 PUFA are digested and absorbed into circulating concentrations of 
biomarker omega-3 PUFA.  Data exist for diet, behaviors, and biological factors in the 
full ARIC cohort.  Data exist for biomarkers in the MN sub-study.  We can use the MN 
data to establish the relationship of diet and other variables with plasma values of 
omega-3 PUFA. 
This is not without precedent.  Several approaches exist to leverage biomarker 
data to address measurement error [108, 114, 121, 122, 209].  One such approach is 
multiple imputation for measurement error or MIME – a technique first proposed by 
Rubin in 1987 [216, 224] that treats measurement error as a missing data problem 
where the “true” value is missing.  We expand on this premise, but instead of imputing 
corrected FFQ values using data from a validation study, we impute plasma biomarker 
values utilizing the validation sub-study and FFQ data. 
The multiple imputation process can be summarized as three steps.  The first is 
that missing values are replaced with a simulated value to create a complete dataset.  
This process is repeated until there are m datasets.  After the imputation process is 
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finished, step two is to analyze each of the m complete datasets separately using 
standard methods – these are the methods that were described in Part 1.  As an 
example, for our HbA1c outcome, each dataset was analyzed using linear regression 
with the imputed exposure values and relevant covariates.  Each of the m-sets of 
analyses result in m-sets of regression results.   Finally, step three combines the m-sets 
of regression data into a single result using “Rubin’s Rules” – simplistically they are 
“averaged” to get an overall beta coefficient and standard error [220, 225, 226]. 
5.4.2 METHODS 
Our overall manuscript methods can be simplistically described in three steps: 
impute missing values, analyze the data for our two populations of interest (full cohort 
and MN only), compare the population-specific results.  This section describes the 
imputation process – specifically the inclusion/exclusion criteria, imputation method 
used, variables used in the imputation, and model specifications.  All statistical analyses 
were performed with SAS (version 9.4, Enterprise guide 7.1, SAS Institute Inc., Cary, NC, 
USA). 
5.4.2.1 Inclusion and Exclusion Criteria 
As previously mentioned, there were two sets of inclusion/exclusion criteria: 
those specific to imputation, and those specific to our outcomes (e.g., diabetics only for 
HbA1c analyses).  Here we will describe our imputation inclusion/exclusion criteria. 
We could not eliminate the possibility that race could be a confounder or an 
effect modifier in the relationship between dietary intake of omega-3 fatty acids and 
biomarker measures of omega-3 fatty acids. There is evidence that the translation of 
FFQ responses into nutrients can vary by race [227].  Additionally, race can be 
associated with FFQ exposure through dietary patterns and cooking methods and affect 
biomarker concentrations through potential genetic differences in converting dietary 
PUFA to plasma PUFA [228].  Because MN field center participants were overwhelmingly 
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white, we could not include race in our imputation model.  Consequently, we limited 
our analyses to white participants at the MN and other field centers. 
Additionally, we excluded those participants who did not fill out an FFQ (n=12), 
whose FFQ responses were not translatable into nutrient intakes (n=207), and those 
who had implausible responses on their FFQ (n=47; 43 males with values below 700 
kcal/day and 4 females with values above 3500 kcal/day).  The improbable calorie cut-
points (males: >4500, <700; females: >3500, <500) represent the 1st and 99th sex-specific 
percentiles of all ARIC FFQ responses [156].  Because we hypothesized biomarker 
imputation would depend on dietary intakes, we did not want implausible data to skew 
our results. 
5.4.2.2 Multiple Imputation by Chained 
Equations 
Step 1 in the imputation process is to replace missing values with a simulated 
value. We calculated our simulated values via MICE [221-223] , also known as fully 
conditional specification [212, 223].  Azur et al.[221] describes the process in five steps: 
1. Impute a placeholder value for all the missing values in your dataset.  For 
example, a random sample of observed values from your validation study. 
2. Select a single variable, and set all placeholder values for that variable back to 
missing. 
3. Regress the variable of interest on the variables of the imputation model (e.g., 
biomarker values of ALA regressed on all other variables in the dataset) 
4. Replace the missing values from step 2 with predictions from step 3.  This is like 
step 1 above except, instead of placeholders, we are imputing predicted values 
based on regression. 
5. Complete this process (steps 2-4) for all variables with missing values 
   129 
 
A cycle is defined completing these steps for all variables with missing values.  
For subsequent cycles, steps 2 through 5 are repeated.  Typically at least 10 cycles are 
performed [229] and, once a predetermined number of cycles are complete, the final 
iteration is output.  This output is an imputed dataset.  This process is repeated until m 
imputed datasets are output. 
5.4.2.3 Selecting Imputation Model 
Parameters  
Here we describe how we selected our variables, regression techniques, cycles to 
run before outputting an imputed dataset, and total number of imputed datasets. 
5.4.2.3.1 Variable Selection  
We had FFQ data on all ARIC participants and biomarker measures of plasma 
fatty acids for MN field center participants.  We wanted to address FFQ measurement 
error by utilizing the biomarker values – specifically, using the MN biomarker sub-study 
to elucidate the relationship between FFQ-derived intake of omega-3 PUFA and plasma 
measures of omega-3 PUFA – and then use these findings to impute plasma measures 
for the rest of the ARIC cohort. 
As previously stated, variables with missing values are imputed by regressing 
their observed values (dependent variable) against a set of related variables 
(independent variables) [221-223].  Given our theoretical paradigm (biomarkers are a 
function of dietary intake), our imputation model for our exposure variables (plasma 
biomarkers) must at a minimum include their FFQ-derived analogs. 
For the full imputation model, we selected our variables based on two criteria 
adapted from Azur et al. [221]: (1) the imputation model should be more general than 
the models used in post-imputation analyses; and (2) impute variables at lowest level 
possible. 
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For #1, a “more general” imputation model means that the imputation model 
should include all covariates used in the post-imputation analyses [221] along with post-
imputation outcomes [217, 230].  If interaction terms will be used in post-imputation 
regressions, then those terms should be in the imputation model as well [221].  
Variables that predict missingness should also be included in the model [217].  In 
general, increasing the number of variables in the imputation model does not 
deleteriously influence precision or bias [221, 231], but failing to include important 
variables can [217, 230]. 
For #2, to impute variables at the lowest level possible means that if a 
continuous variable was categorized, we included its continuous form in the imputation 
model and re-categorized it post-imputation [221, 232].  Similarly, if a variable was a 
function of other variables (e.g., x = f(a, b, c) ) then we included a, b, and c in the 
imputation model and generated x post-imputation. 
In addition to our exposures (and dietary analogs), outcomes, potential 
confounders, and variables used for inclusion/exclusion, we included other variables in 
the imputation model that could have predicted omega-3 PUFA intake.  These included 
fish consumption in servings/week as measured via FFQ (tuna, dark fish, other fish, and 
shellfish) and dietary intake of omega-6 PUFA in grams/day as these fatty acids 
influence the bioavailability of dietary omega-3 PUFAs [233]. 
The “more general” approach for selecting covariates relies on including 
interaction terms if necessary [221].  We did not include interaction terms in our 
imputation model for two reasons.  The first is because previous analyses did not show 
evidence of interaction by sex for the association of omega-3 PUFAs and HbA1c, 
prolonged QTc, or time to incident T2D.  The second is that the MN data did not suggest 
there were differences by sex for dietary intake of omega-3 PUFAs and plasma levels 
after adjusting for total caloric intake (data not shown). 
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Figure 5-3 lists the variables that were part of our imputation model along with 
the regression method used for imputation.  
5.4.2.3.2 Regression Method  
To justify our selection of regression method (linear, logistic, or discriminant 
analysis), we will first provide some theoretical details.  There are two components to 
multiple imputation: the model (variables) and the distribution assumptions.  That is, 
imputation is a function of our data Y and distributions theta: f(Y|ϴ) [212, 
234].  Imputing a missing value is a random draw of the set of all imputed values from 
the posterior predictive distribution of the missing data: f(Ymiss|Yobs|ϴ) where ϴ is the 
vector of parameters or functions of these that uniquely define the predictive 
distribution [212].  When software performs the imputation using MICE, part of the 
process is deriving the posterior predictive distribution f(Ymiss|Yobs|ϴ) [212, 226, 234]. 
Continuous variables with missing data use linear regression derive the posterior 
predictive distribution, and categorical variables can use logistic regression or 
discriminant analysis [212, 234].  For categorical variables, we tried logistic regression 
first as it makes the fewest assumptions about model parameters [234].  However, 
sometimes maximum likelihood estimation failed to estimate a posterior predictive 
distribution without augmenting the data [235].  An alternative to augmenting data is to 
use discriminant analysis instead of logistic regression – discriminant analysis  also 
estimates categorical outcomes, but assumes covariates are approximately multivariate 
normal and the within-group covariance matrices are approximately equal [234].  We 
did not test these assumptions, but relied on our ample sample size [171]. 
Finally, regardless of regression method, all regressions were set to have a 
minimum value of zero by using the minimum option in SAS PROC MI.  Although setting 
a minimum value can introduce bias if the data are skewed [236], post-imputation 
rounding of values also introduces bias [236].  Since all plasma values were biologically 
constrained from 0 to 100 (as a percentage of total fatty acids), we set the minimum 
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value as zero.  In a sensitivity analysis, we considered how many negative values were 
imputed if we did not include the minimum option.  Six (out of 49) variables had 
negative values (across all imputations) and the percentages of negative values were all 
less than 0.1% except for the physical activity via work variable, which had 2.3% 
negative values. 
5.4.2.3.3 Cycles and Datasets 
As previously mentioned, typically at least 10 MICE cycles (burn-ins) are 
performed before outputting an imputed dataset [229].  We used 40 burn-in iterations.  
Theoretically, five imputed datasets (m=5) are sufficient for the imputation 
technique [210, 218, 237].  However, using a large number of imputed datasets (m>20) 
provides a greater ability to reduce sampling variability from the imputation process and 
better confidence interval coverage [214, 217, 218].  Table 5-1 shows the relative 
efficiency given percentage of missingness as derived using the equation  
where RE is relative efficiency,  is the percentage of missing data, and m is the number 
of datasets [211].   
Because we imputed biomarker values for all white ARIC participants who were 
not part of the biomarker subsample, we had a high proportion of missingness 
(approximately 2,500 MN participants among approximately 9,500 white participants is 
roughly 75% missingness).  We used m=40 imputations for our analysis. 
5.5 PART 3 – POST IMPUTATION 
Here we describe how we utilized the imputed data to investigate the 
associations between omega-3 biomarker exposures and our outcomes of interest, and 
how we compared results from our two populations of interest (full cohort and MN-
only). 

RE  (1

m
)1
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5.5.1 POST-IMPUTATION ANALYSES 
Our imputation process generated m=40 datasets where all missing values were 
imputed.  Using these data, we considered our two populations.  For simplicity, we will 
use the term “imputed” for the full cohort even though those data contain both 
imputed and observed plasma values.  Similarly, we will use “observed” for the MN 
participants with observed plasma values, even though some covariates had missing 
values imputed. 
Each of the two populations were analyzed as described in Part 1.  That is, each 
of the m datasets had outcome-specific inclusion/exclusion criteria applied and were 
analyzed using the outcome-specific statistical methods.  The m sets of results were 
combined into a single set of regression results using Rubin’s rules [220, 225, 226] via 
SAS PROC MIANALYZE. 
5.5.2 COMPARING RESULTS  
All exposures of interest were categorized into quartiles with the lowest quartile 
as the reference category.  Thus, for any given exposure, we had six beta estimates and 
six standard errors – three for the full cohort (imputed) results (Q2 vs. Q1, Q3 vs. Q1, 
and Q4 vs. Q1) and three for the MN population (observed) results. 
We considered if our full cohort (imputed) results were qualitatively different 
from the observed (MN field center) results.  That is, if imputing missing plasma values 
fundamentally changed the measures of association compared to results obtained using 
observed plasma values.  We did this by comparing the beta coefficients and their 
confidence intervals for the imputed and observed populations. 
5.6 RESULTS 
In this section, we will describe the results from the imputation process first, 
followed by the results from regressions involving the three outcomes of interest.  For 
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each outcome, we report and compare the imputed (full cohort) results and the 
observed (MN-specific) results. 
5.6.1 IMPUTATION RESULTS 
Our goal was to impute plasma values for the white, non-MN participants and 
impute any missing covariates in the full cohort.  There were 11,478 white participants 
at visit 1.  Of those, n=266 were excluded for missing or implausible FFQ results.  Data 
from the remaining n=11,212 participants were available for the multiple imputation 
procedure. Table 5-2 lists variables that had missing values prior to the imputation 
process and the relative efficiency after 40 imputations.  Table 5-3 shows the baseline 
characteristics post-imputation for the MN field center participants, non-MN field 
center participants, and the full cohort.  Counts were calculated by averaging across the 
m=40 imputations.  In general, Minnesotans were more highly educated and exercised 
more.  A greater proportion of Minnesotans were current alcohol drinkers, but fewer 
were current smokers. 
5.6.2 POST IMPUTATION REGRESSION 
RESULTS:  PROLONGED QTC. 
For the prolonged QTc analysis we excluded those with prevalent CVD, those 
who used antiarrhythmic medications, and those whose QRS duration was greater than 
120 ms.  Figure 5-4 shows the inclusion/exclusion results for the prolonged QTc analysis.  
Average counts across the 40 imputations were n=8,791 full cohort; n=3,061 MN only. 
5.6.2.1 ALA, DHA+EPA, ALA+DHA+EPA 
and Prolonged QTc 
In both the full cohort and the MN-only analyses, quartiles of plasma ALA, 
DHA+EPA, or ALA+DHA+EPA were not associated with prolonged QTc.  See tables 5-4, 5-
5, and 5-6 and figures 5-5, 5-6, and 5-7. 
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5.6.2.2 Full Cohort vs. Minnesota-Only:  
Prolonged QTc 
Results for the imputed exposures (full cohort) analyses were similar to those for 
the observed exposures (MN-only).  There were no instances where the point estimate 
in one population suggested lower odds but the other population suggested higher 
odds.  Furthermore, the point estimate for one population was always within the 95% 
confidence interval for the point estimate of the other population.  Finally, the 
confidence intervals for the MN analyses were always wider than those for the full 
cohort analyses. Figure 5-8 shows all nine analyses. 
5.6.3 POST IMPUTATION REGRESSION 
RESULTS:  HBA1C. 
Analyses investigating the HbA1c outcome were limited to those with T2D at visit 
2.  Additionally, the exclusion criteria for the HbA1c outcome was prevalent CVD at visit 
1 or visit 2.  Figure 5-4 shows the inclusion/exclusion criteria.  Final counts were n=1,019 
for the full cohort; and n=299 for the MN population. 
5.6.3.1 ALA, DHA+EPA, ALA+DHA+EPA 
and HbA1c 
In both the full cohort and the MN-only analyses, there was no association of 
quartiles of plasma ALA with HbA1c.  See Table 5-7 and Figure 5-9.  
In both the full cohort and the MN-only analyses, there was a suggestion that 
higher concentrations of DHA+EPA and of ALA+DHA+EPA are associated with lower 
HbA1c in those with T2D, although the association was not statistically significant 
(ALA+DHA+EPA Q4 vs. Q1 percentage point difference (95% CI); Model 3; full cohort: -
0.4 (-1.0, 0.2); MN-only: -0.6 (-1.3, 0.2)).  See tables 5-8 and 5-9 and figures 5-10 and 5-
11. 
   136 
 
5.6.3.2 Full Cohort vs. Minnesota-Only:  
HbA1c 
Results for the imputed exposures (full cohort) analyses were similar to those for 
the observed exposures (MN-only).  There were only two instances where the point 
estimate in one population suggested lower HbA1c values with higher concentrations of 
omega-3 PUFAs and the other population suggested higher HbA1c with higher 
concentrations (Q4 vs. Q1, ALA, Model 3; Q2 vs. Q1, ALA+DHA+EPA, Model 1).  
Regardless, the point estimate for one population was always within the 95% 
confidence interval for the point estimate of the other population.  Finally, the 
confidence intervals for the MN analyses were always wider than those for the full 
cohort analyses.  Figure 5-12 shows all nine analyses. 
5.6.4 POST IMPUTATION REGRESSION 
RESULTS:  INCIDENT T2D. 
Our exclusion criteria for incident T2D analysis were prevalent CVD or T2D at 
visit 1.  Figure 5-4 shows the inclusion/exclusion criteria for the incident T2D analysis.  
Final counts were n=8,638 full cohort; n=3,131 MN only.  In all analyses, the 
proportional hazards assumption was not violated (data not shown). 
5.6.4.1 ALA, DHA+EPA, ALA+DHA+EPA 
and Incident T2D 
In both the full cohort and the MN-only analyses, there was an association of 
quartiles of plasma ALA with incident T2D, with higher circulating concentrations 
associated with lower risk (Q4 vs. Q1 HR (95% CI), Model 1; full cohort: 0.6 (0.5, 0.9); 
MN-only: 0.6 (0.4, 0.9)), although this association disappeared after adjustment (Q4 vs. 
Q1 HR (95% CI), Model 3; full cohort: 0.8 (0.6, 1.1); MN-only: 0.9 (0.6, 1.3)).  See Table 5-
10 and Figure 5-13.  
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In both the full cohort and the MN-only analyses, there was no association of 
DHA+EPA or ALA+DHA+EPA with incident T2D. See tables 5-11 and 5-12 and figures 5-14 
and 5-15. 
5.6.4.2 Full Cohort vs. Minnesota-Only:  
Incident T2D 
Results for the imputed exposures (full cohort) analyses were similar to those for 
the observed exposures (MN-only).  There were no instances where the point estimate 
in one population suggested lower incidence of T2D in those with higher concentrations 
of omega-3 PUFAs and the other population suggested higher incidence, although there 
were multiple instances where one hazard ratio rounded to 1.0 and the other did not.  
Furthermore, the point estimate for one population was always within the 95% 
confidence interval for the point estimate of the other population.  Finally, the 
confidence intervals for the MN analyses were always wider than those for the full 
cohort analyses.  Figure 5-16 shows all nine analyses. 
5.7 DISCUSSION 
In this population-based study of middle aged adults, our investigation of the 
relationship among plasma omega-3 PUFA observed in MN participants suggested that 
higher circulating concentrations of ALA may be associated with lower incidence of T2D.  
The data also suggested that circulating concentrations of DHA+EPA in those with T2D 
may be associated with lower HbA1c.  Using the MN data to impute plasma values for 
other white participants at other field centers yielded similar results, and the standard 
errors were lower for the full cohort analyses compared to the MN-only analyses as can 
be seen by the narrower confidence intervals. 
Our plasma-exposure results were different from the FFQ results for some 
exposures and outcomes.  Specifically, higher intake of ALA (grams/day) was associated 
with higher incidence of T2D in Manuscript 1 results (HR 4.0, 95% CI: 1.7, 9.6, comparing 
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extreme quartiles) whereas there was a nonsignificant trend in the plasma analysis 
towards lower incidence of T2D with higher levels of circulating ALA.  Similarly, the 
HbA1c results from Manuscript 1 indicated that higher versus lower intakes of omega-3 
PUFAs, especially ALA, were associated with approximately 1 percentage point higher 
HbA1c values in those with T2D.  In contrast, plasma analyses suggested no relationship 
between circulating concentrations of ALA and HbA1c, and further suggested a non-
significant association of DHA+EPA and ALA+DHA+EPA with HbA1c, with higher 
concentrations non-significantly associated with lower HbA1c values. 
These differences could be due to measurement error in FFQ data that was 
corrected using biomarker data.  However, other plausible explanations exist.  Disease 
status (T2D) could limit the absorption of omega-3 PUFAs, so higher plasma levels could 
be an indicator for less disease (and thus result in a favorable association).  There could 
also be unmeasured confounding – dietary variables that influence the bioavailability of 
omega-3 PUFAs that that were not included in our imputation model, or geographically 
differences in the omega-3 content of foods in MN compared to other areas of the 
United States.  Finally, there was evidence of effect modification by race in the 
relationship of dietary intake of fish and seafood with HbA1c values, with whites 
showing null-to-favorable associations with seafood exposures.  Thus, differences could 
be due to limiting analyses to whites only. 
The approach used in this study was motivated by MIME, where we sought to 
address dietary measurement error by utilizing a plasma biomarker sub-study.  Other 
researchers have combined biomarker data with FFQ data where participants had both 
measures [121, 128] but, to our knowledge, ours was the first to utilize multiple 
imputation in harnessing the relationship between dietary intake and circulating 
biomarker values and expanding the analysis beyond those participants in the sub-
study.   
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In our own analysis, our comparison of the observed and imputed results is akin 
to comparing a complete case analysis (observed MN results) to imputed results (full 
cohort).  A minor difference is that our observed MN results had observed plasma 
values, but missing covariate values were imputed using MICE.   
Our results are similar to other studies comparing multiple imputation results to 
complete case analysis where point estimates were similar and confidence 
intervals/standard errors were more narrow/smaller [238, 239].  In a case-control study 
of diet and breast cancer, multiple imputation had similar point estimates and smaller 
standard errors compared to complete case analysis, but imputation also revealed 
associations between other covariates and breast cancer that the complete case 
analysis did not [240].  
One study did not perform a complete case analysis, but their design does 
demonstrate the viability of imputing a large number of missing values and obtaining an 
unbiased measure of association [241].  This study utilized an existing case-cohort 
design with waist circumference data available for the entire cohort.  The authors 
simulated a multiple imputation analysis by deleting waist circumference values for all 
participants except those the comparison sample.  This resulted in approximately 90% 
missing values for the exposure of interest.  In their analysis, the association of waist 
circumference with incident T2D using imputed data was similar to the association 
calculated using full cohort data, demonstrating that multiple imputation can provide 
unbiased estimates of association when compared to those obtained with observed 
values [241]. 
In general, multiple imputation is more efficient than complete case analysis 
when data are missing completely at random and is less biased when data are MAR [14].  
Other missing data mechanisms can lead to increased bias with multiple imputation, 
and merely comparing standard errors is insufficient because that does not account for 
bias – standard errors may be smaller because the estimate was biased towards the null 
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[14].  In general, methodologists suggest that multiple imputation and complete case 
analysis offer a tradeoff between bias and precision [114, 213] and that the increase in 
precision is reduced as the size of the validation sample increases [242].   
5.8 CONCLUSION 
While our results were predominately null, the similarity of our results between 
the observed and the imputed populations and the narrower confidence intervals in the 
imputed full cohort results suggest we gained efficiency/precision through imputation.  
Utilizing biomarker data in conjunction with self-report dietary data could be an 
important tool in investigating diet/disease relationships.  
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5.9 FIGURES 
 
Figure 5-1. Study design depiction with variable temporality, ARIC, 1987-1998 
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Figure 5-2. Assignment of outcome and time to event data for incident T2D analysis, ARIC, 1987-1998. 
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Figure 5-3. Variables and regression techniques used in multiple imputation model, ARIC, 1987-1998. 
 
 
 
 
Figure 5-4. Inclusion/Exclusion criteria, ARIC, 1987-1998. 
  
Post-Imputation Exposures Outcome or Used in Derivation of Outcome
Plasma ALA Age Saturated Fatty Acids g/day Heart Rate
Plasma DHA Sex
D
Diastolic Blood Pressure QT duration
Plasma EPA Education Level
LR
Systolic Blood Pressure HbA1c
Dietary Predictors of Plasma Omega-3 PUFA BMI Hypertension
LR Antihyperglycemic medications at Visit 2D
ALA grams/day Indices from Baecke (Work, Sport, Leisure) HDL Time to event
EPA grams/day Smoking status (current, former, never)
LR
LDL Censored/T2D
D
DHA grams/day Drinking status (current, former, never)
D
Triglycerides Inclusion Exclusion Criteria
Fish servings/week (tuna, dark, other, shell)* Drinking amount g/day QRS duration
TCAL per day Type 2 Diabetes at Visit 2
D
Trans fatty acids g/day Anti-arrhythmic medications
LR
Dietary Fiber g/day Other Relevant Variables
D Modeled using Discriminant Function *Each parenthetical is a separate continuous variable Fasting Blood Glucose, T2D
D
LR Modeled using Logistic Regression Unlabeled variables used linear regression.  Variables Visit 1 unless noted. Antihyperglycemic medications
D
Omega-6 fatty acids grams/day 
(octadecadienoic acid, eicosatetraenoic acid, 
and docosapentaenoic acid)*
Post-Imputation Model Covariates
Visit 1 Participants (MN, NC, MD) 11,212 3,861 Visit 1 Participants (MN Only)
With T2D @ Visit 2 1,342 377 With T2D @ Visit 2
Prolonged QTc
QRS>120 420 150 QRS>120
anti-arrhythmic Rx 1,593 533 anti-arrhythmic Rx
V1 Prevalent CVD 1,086 323 V1 Prevalent CVD
Prol QTc (all exclusions) 2,421 800 Prol QTc (all exclusions)
Total N 8,791 3,061 Total N
HbA1c
V1 Prevalent CVD 273 67 V1 Prevalent CVD
V2 Prevalent CVD 196 46 V2 Prevalent CVD
HbA1c - T2D only (all exclusions) 323 78 HbA1c - T2D only (all exclusions)
Total N 1,019 299 Total N
Incident T2D
Exclusions for Prevalant Disease 2,574 730 Exclusions for Prevalent Disease
Total N 8,638 3,131 Total N
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Figure 5-5. Odds ratios for prolonged QTc by quartiles of ALA; fully adjusted model; multiple imputation 
vs. observed. 
 
 
Figure 5-6. Odds ratios for prolonged QTc by quartiles of DHA+EPA; fully adjusted model; multiple 
imputation vs. observed plasma values, ARIC, 1987-1989. 
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Figure 5-7. Odds ratios for prolonged QTc by quartiles of ALA+DHA+EPA; fully adjusted model; multiple 
imputation vs. observed plasma values, ARIC, 1987-1989. 
 
 
 
Figure 5-8. Odds ratios for prolonged QTc by quartiles of ALA, DHA+EPA, and ALA+DHA+EPA; all 
covariate adjustment models; multiple imputation vs. observed plasma values, ARIC, 1987-1989. 
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Figure 5-9. Deltas in HbA1c by quartiles of ALA; fully adjusted model; multiple imputation vs. observed 
plasma values, ARIC, 1987-1993. 
 
 
Figure 5-10. Deltas in HbA1c by quartiles of DHA+EPA; fully adjusted model; multiple imputation vs. 
observed plasma values, ARIC, 1987-1993. 
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Figure 5-11. Deltas in HbA1c by quartiles of ALA+DHA+EPA; fully adjusted model; multiple imputation 
vs. observed plasma values, ARIC, 1987-1993. 
 
 
Figure 5-12. Percentage point deltas in HbA1c QTc by quartiles of ALA, DHA+EPA, and ALA+DHA+EPA; all 
covariate adjustment models; multiple imputation vs. observed plasma values, ARIC, 1987-1993.  
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Figure 5-13. Hazard ratios for incident T2D by quartiles of ALA; fully adjusted model; multiple 
imputation vs. observed plasma values, ARIC, 1987-1998. 
 
 
Figure 5-14. Hazard ratios for incident T2D by quartiles of DHA+EPA; fully adjusted model; multiple 
imputation vs. observed plasma values, ARIC, 1987-1998. 
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Figure 5-15. Hazard ratios for incident T2D by quartiles of ALA+DHA+EPA; fully adjusted model; multiple 
imputation vs. observed plasma values, ARIC, 1987-1998. 
 
 
 
Figure 5-16. Hazard ratios for incident T2D by quartiles of ALA, DHA+EPA, and ALA+DHA+EPA; all 
covariate adjustment models; multiple imputation vs. observed plasma values, ARIC, 1987-1993.  
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5.10 TABLES 
Table 5-1. Relative Efficiency of Multiple Imputation Datasets (m) Given Percentage of Missingness (λ). 
[18] 
 
λ 
M 25% 50% 75% 90% 
3 0.92 0.86 0.80 0.77 
5 0.95 0.91 0.87 0.85 
10 0.98 0.95 0.93 0.92 
20 0.99 0.98 0.96 0.96 
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Table 5-2. Pre- and post-imputation characteristics for variables with missing values in white ARIC 
participants (n=11,212), 1987-1998. 
Variable Number 
Observed 
Values 
Number 
Missing 
Values 
% 
Missing 
Variable Category Relative 
Efficiency 
Plasma ALA 3,861 7,351 65.6% Exposure 97.9% 
Plasma DHA 3,861 7,351 65.6% Exposure 98.1% 
Plasma EPA 3,861 7,351 65.6% Exposure 98.2% 
HbA1c 10,338 874 7.8% Outcome 99.9% 
Antihyperglycemic Rx at Visit 2 10,497 715 6.4% Outcome 99.8%* 
QT Duration 11,094 118 1.1% Outcome 100.0% 
Heart Rate 11,094 118 1.1% Outcome 100.0% 
LDL 11,001 211 1.9% Confounder 99.9% 
Sport Physical Activity 11,179 33 0.3% Confounder 100.0% 
HDL 11,188 24 0.2% Confounder 100.0% 
Triglycerides 11,188 24 0.2% Confounder 100.0% 
Alcohol Intake 11,196 16 0.1% Confounder 100.0% 
Education Level 11,199 13 0.1% Confounder 100.0%* 
Drinking Status 11,202 10 0.1% Confounder 100.0%* 
Leisure Physical Activity 11,204 8 0.1% Confounder 100.0% 
BMI 11,204 8 0.1% Confounder 100.0% 
Work Physical Activity 11,205 7 0.1% Confounder 100.0% 
Smoking Status 11,205 7 0.1% Confounder 100.0%* 
Diastolic Blood Pressure 11,208 4 0.0% Confounder 100.0% 
Systolic Blood Pressure 11,208 4 0.0% Confounder 100.0% 
T2D (Visit 2) 10,476 736 6.6% Inclusion/Exclusion 99.8%* 
Fasting Blood Glucose (Visit 2) 10,486 726 6.5% Related Variable 99.9% 
QRS Duration 11,091 121 1.1% Inclusion/Exclusion 100.0% 
T2D (Visit 1) 11,187 25 0.2% Related Variable 100.0%* 
Fasting Blood Glucose (Visit 1) 11,200 12 0.1% Related Variable 100.0% 
*Calculated using (1+(% missing/40))-1 
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Table 5-3. Baseline characteristics of ARIC participants (n=11,212) by field center, 1987–1989. Values 
correspond to mean N (%) or Mean (min, max), m=40 imputations. 
 
 Non-MN MN Full Cohort 
N  7,351 3,861 11,212 
Sociodemographic Variable    
 Age (years) 54.6 (44, 66) 54.0 (44, 65) 54.4 (44, 66) 
 Male 3,428 (49.9%) 1,855 (50.0%) 5,283 (49.9%) 
 Education    
 Basic 1,673 (22.8%) 239 (6.2%) 1,913 (17.1%) 
 Intermediate 3,267 (44.4%) 1,812 (46.9%) 5,079 (45.3%) 
 Advanced 2,410 (32.8%) 1,810 (46.9%) 4,221 (37.6%) 
Lifestyle Variables    
 BMI 27.0 (14, 56) 27.1 (14, 51) 27.0 (14, 56) 
 Physical Activity^    
 Low 2,817 (38.3%) 1,156 (29.9%) 3,973 (35.4%) 
 Medium 2,345 (31.9%) 1,314 (34.0%) 3,659 (32.6%) 
 High 2,189 (29.8%) 1,391 (36.0%) 3,580 (31.9%) 
 Current Smokers 1,907 (25.9%) 862 (22.3%) 2,769 (24.7%) 
 Current Alcohol Drinkers 4,061 (55.2%) 3,213 (83.2%) 7,274 (64.9%) 
Dietary Covariates    
 Total Energy Intake (kcal/day) 1,644 (501, 4,179) 1,640 (508, 4,176) 1,642 (501, 4,179) 
 Dietary Fiber (g/day) 18.4 (1, 82) 16.3 (2, 73) 17.7 (1, 82) 
 Saturated Fats (g/day) 22.4 (1, 82) 22.9 (3, 90) 22.6 (1, 90) 
 Trans Fats (g/day) 2.9 (0, 17) 3.2 (0, 17) 3.0 (0, 17) 
Clinical Covariates    
 Hypertension 2,061 (44.9%) 976 (43.5%) 3,037 (44.4%) 
 Systolic Blood Pressure 118.3 (61, 208) 118.8 (61, 198) 118.5 (61, 208) 
 Diastolic Blood Pressure 70.4 (12, 130) 73.7 (42, 116) 71.5 (12, 130) 
 High Density Lipoprotein 49.6 (4, 135) 52.1 (12, 143) 50.5 (4, 143) 
 Low Density Lipoprotein 138.7 (1, 505) 137.2 (4, 452) 138.2 (1, 505) 
 Triglycerides 142.3 (1, 1876) 129.6 (4, 1599) 137.9 (1, 1876) 
Nutrient Intake (g/day)    
 Alpha-linolenic acid (ALA) 0.7 (0, 3) 0.7 (0, 3) 0.7 (0, 3) 
 Docosahexaenoic acid (DHA) 0.2 (0, 4) 0.2 (0, 2) 0.2 (0, 4) 
 Eicosapentaenoic acid (EPA) 0.1 (0, 2) 0.1 (0, 1) 0.1 (0, 2) 
^Work+Leisure+Sport Averaged and Divided into Low/Medium/High   
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Table 5-4. Association of plasma quartiles of ALA with prolonged QTc, ARIC, 1987-1989.  Odds ratios and 
95% confidence intervals. 
   Q1 Q2 Q3 Q4 
Fu
ll 
C
o
h
o
rt
  
(I
m
p
u
te
d
) 
ALA FA% mean (min, max) 0.1 (0.0, 0.1) 0.1 (0.1, 0.1) 0.2 (0.1, 0.2) 0.2 (0.2, 0.4) 
 Total N 2,277 2,123 2,208 2,184 
 Prolonged QTc (%) 19 (0.8%) 19 (0.9%) 16 (0.7%) 17 (0.8%) 
 Model 1 1.0 (ref) 1.0 (0.5, 2.2) 0.8 (0.3, 2.1) 0.8 (0.3, 1.9) 
 Model 2 1.0 (ref) 1.1 (0.5, 2.2) 0.8 (0.3, 2.1) 0.8 (0.3, 2.0) 
 Model 3 1.0 (ref) 1.1 (0.5, 2.3) 0.8 (0.3, 2.2) 0.9 (0.4, 2.2) 
M
in
n
es
o
ta
 O
n
ly
 
(O
b
se
rv
ed
) 
ALA FA% mean (min, max) 0.1 (0.0, 0.1) 0.1 (0.1, 0.1) 0.2 (0.2, 0.2) 0.2 (0.2, 0.4) 
 Total N 900 779 658 725 
 Prolonged QTc (%) 6 (0.7%) 7 (0.9%) 2 (0.3%) 5 (0.7%) 
 Model 1 1.0 (ref) 1.3 (0.4, 3.9) 0.4 (0.1, 1.9) 0.8 (0.2, 2.7) 
 Model 2 1.0 (ref) 1.4 (0.4, 4.3) 0.4 (0.1, 2.1) 0.9 (0.3, 3.2) 
 Model 3 1.0 (ref) 1.4 (0.5, 4.5) 0.4 (0.1, 2.1) 0.9 (0.2, 3.3) 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy 
intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and 
amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables 
(hypertension, HDL, LDL, triglycerides) 
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Table 5-5. Association of plasma quartiles of DHA+EPA with prolonged QTc, ARIC, 1987-1989.  Odds 
ratios and 95% confidence intervals. 
   Q1 Q2 Q3 Q4 
Fu
ll 
C
o
h
o
rt
 (
im
p
) 
DHA + EPA FA% mean (min, max) 2.3 (0.3, 2.8) 3.1 (2.8, 3.4) 3.7 (3.4, 4.1) 4.9 (4.1, 14.0) 
 Total N 2,199 2,197 2,197 2,198 
 Prolonged QTc (%) 20 (0.9%) 15 (0.7%) 15 (0.7%) 21 (0.9%) 
 Model 1 1.0 (ref) 0.7 (0.3, 1.7) 0.7 (0.3, 1.7) 0.9 (0.4, 2.1) 
 Model 2 1.0 (ref) 0.7 (0.3, 1.8) 0.7 (0.3, 1.8) 1.0 (0.4, 2.3) 
 Model 3 1.0 (ref) 0.7 (0.3, 1.8) 0.7 (0.3, 1.8) 0.9 (0.4, 2.3) 
M
in
n
es
o
ta
 O
n
ly
 (
o
b
s)
 
DHA + EPA FA% mean (min, max) 2.4 (0.7, 2.8) 3.1 (2.8, 3.4) 3.7 (3.4, 4.1) 5.1 (4.1, 12.2) 
 Total N 869 943 704 545 
 Prolonged QTc (%) 8 (0.9%) 6 (0.6%) 2 (0.3%) 4 (0.7%) 
 Model 1 1.0 (ref) 0.6 (0.2, 1.8) 0.3 (0.1, 1.2) 0.7 (0.2, 2.3) 
 Model 2 1.0 (ref) 0.6 (0.2, 1.9) 0.2 (0.1, 1.2) 0.7 (0.2, 2.4) 
 Model 3 1.0 (ref) 0.6 (0.2, 1.9) 0.3 (0.1, 1.3) 0.7 (0.2, 2.5) 
obs: observed; imp: imputed 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy 
intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and 
amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables 
(hypertension, HDL, LDL, triglycerides) 
 
  
   155 
 
Table 5-6. Association of plasma quartiles of ALA+DHA+EPA with prolonged QTc, ARIC, 1987-1989.  
Odds ratios and 95% confidence intervals. 
   Q1 Q2 Q3 Q4 
Fu
ll 
C
o
h
o
rt
 (
im
p
) 
ALA + DHA FA% mean (min, max) 2.4 (0.4, 2.9) 3.2 (2.9, 3.5) 3.9 (3.5, 4.2) 5.0 (4.2, 14.1) 
 + EPA Total N 2,199 2,198 2,197 2,197 
 Prolonged QTc (%) 20 (0.9%) 15 (0.7%) 16 (0.7%) 21 (0.9%) 
 Model 1 1.0 (ref) 0.7 (0.3, 1.6) 0.7 (0.3, 1.7) 0.9 (0.4, 2.0) 
 Model 2 1.0 (ref) 0.7 (0.3, 1.7) 0.8 (0.3, 1.9) 0.9 (0.4, 2.3) 
 Model 3 1.0 (ref) 0.7 (0.3, 1.7) 0.8 (0.3, 1.9) 0.9 (0.4, 2.3) 
M
in
n
es
o
ta
 O
n
ly
 (
o
b
s)
 
ALA + DHA FA% mean (min, max) 2.5 (0.9, 2.9) 3.2 (2.9, 3.5) 3.8 (3.5, 4.2) 5.2 (4.3, 12.3) 
 + EPA Total N 869 939 710 544 
 Prolonged QTc (%) 8 (0.9%) 5 (0.5%) 3 (0.4%) 4 (0.7%) 
 Model 1 1.0 (ref) 0.5 (0.2, 1.6) 0.3 (0.1, 1.4) 0.7 (0.2, 2.2) 
 Model 2 1.0 (ref) 0.5 (0.2, 1.7) 0.3 (0.1, 1.4) 0.7 (0.2, 2.4) 
 Model 3 1.0 (ref) 0.5 (0.2, 1.7) 0.4 (0.1, 1.5) 0.7 (0.2, 2.6) 
obs: observed; imp: imputed 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy 
intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and 
amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables 
(hypertension, HDL, LDL, triglycerides) 
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Table 5-7. Association of plasma quartiles of ALA with HbA1c, ARIC, 1987-1993.  Percentage point deltas 
and 95% confidence intervals. 
   Q1 Q2 Q3 Q4 
Fu
ll 
C
o
h
o
rt
 (
im
p
) 
ALA FA% mean (min, max) 0.1 (0.0, 0.1) 0.1 (0.1, 0.1) 0.2 (0.1, 0.2) 0.2 (0.2, 0.3) 
 Total N 331 266 230 192 
 HbA1c Mean (Std) 7.6 (2.0) 7.6 (2.1) 7.7 (2.1) 7.7 (2.2) 
 Model 1 1.0 (ref) 0.0 (-0.5, 0.4) 0.0 (-0.5, 0.5) -0.1 (-0.6, 0.5) 
 Model 2 1.0 (ref) 0.0 (-0.4, 0.4) 0.0 (-0.5, 0.4) -0.1 (-0.6, 0.5) 
 Model 3 1.0 (ref) 0.0 (-0.5, 0.4) 0.0 (-0.4, 0.5) 0.0 (-0.6, 0.5) 
M
in
n
es
o
ta
 O
n
ly
 (
o
b
s)
 
ALA FA% mean (min, max) 0.1 (0.0, 0.1) 0.1 (0.1, 0.1) 0.2 (0.2, 0.2) 0.2 (0.2, 0.3) 
 Total N 116 87 49 47 
 HbA1c Mean (Std) 7.4 (2.0) 7.5 (2.2) 7.6 (2.2) 7.3 (2.2) 
 Model 1 1.0 (ref) 0.1 (-0.5, 0.6) 0.0 (-0.7, 0.7) -0.3 (-1.1, 0.4) 
 Model 2 1.0 (ref) 0.1 (-0.5, 0.7) 0.1 (-0.6, 0.8) -0.3 (-1.0, 0.5) 
 Model 3 1.0 (ref) 0.0 (-0.6, 0.6) 0.1 (-0.6, 0.9) -0.2 (-1.0, 0.5) 
obs: observed; imp: imputed 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy 
intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and 
amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables 
(hypertension, HDL, LDL, triglycerides) 
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Table 5-8. Association of plasma quartiles of DHA+EPA with HbA1c, ARIC, 1987-1993.  Percentage point 
deltas and 95% confidence intervals. 
   Q1 Q2 Q3 Q4 
Fu
ll 
C
o
h
o
rt
 (
im
p
) 
 DHA FA% mean (min, max) 2.3 (0.6, 2.8) 3.1 (2.8, 3.4) 3.7 (3.4, 4.1) 4.9 (4.1, 10.0) 
 + EPA Total N 237 247 259 276 
 HbA1c Mean (Std) 7.8 (2.3) 7.8 (2.1) 7.5 (1.9) 7.5 (1.9) 
 Model 1 1.0 (ref) 0.0 (-0.5, 0.5) -0.3 (-0.8, 0.3) -0.3 (-0.9, 0.3) 
 Model 2 1.0 (ref) 0.0 (-0.6, 0.5) -0.3 (-0.9, 0.2) -0.4 (-1.0, 0.2) 
 Model 3 1.0 (ref) -0.1 (-0.6, 0.4) -0.3 (-0.8, 0.2) -0.4 (-1.0, 0.2) 
M
in
n
es
o
ta
 O
n
ly
 (
o
b
s)
 
 DHA FA% mean (min, max) 2.4 (1.7, 2.8) 3.1 (2.8, 3.4) 3.7 (3.4, 4.1) 5.1 (4.1, 10.0) 
 + EPA Total N 80 94 72 52 
 HbA1c Mean (Std) 7.6 (2.5) 7.9 (2.2) 7.1 (1.6) 7.0 (1.9) 
 Model 1 1.0 (ref) 0.3 (-0.4, 0.9) -0.5 (-1.2, 0.2) -0.5 (-1.2, 0.2) 
 Model 2 1.0 (ref) 0.1 (-0.6, 0.7) -0.6 (-1.3, 0.1) -0.6 (-1.4, 0.1) 
 Model 3 1.0 (ref) -0.1 (-0.7, 0.6) -0.6 (-1.3, 0.1) -0.6 (-1.3, 0.2) 
obs: observed; imp: imputed 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy 
intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and 
amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables 
(hypertension, HDL, LDL, triglycerides) 
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Table 5-9. Association of plasma quartiles of ALA+DHA+EPA with HbA1c, ARIC, 1987-1993.  Percentage 
point deltas and 95% confidence intervals. 
   Q1 Q2 Q3 Q4 
Fu
ll 
C
o
h
o
rt
 (
im
p
) 
 ALA FA% mean (min, max) 2.4 (0.7, 2.9) 3.2 (2.9, 3.5) 3.9 (3.5, 4.2) 5.0 (4.3, 10.2) 
 + DHA Total N 242 246 259 273 
 + EPA HbA1c Mean (Std) 7.8 (2.3) 7.8 (2.1) 7.5 (1.9) 7.5 (1.9) 
 Model 1 1.0 (ref) -0.1 (-0.6, 0.5) -0.3 (-0.9, 0.2) -0.4 (-0.9, 0.2) 
 Model 2 1.0 (ref) -0.1 (-0.6, 0.4) -0.4 (-0.9, 0.2) -0.5 (-1.1, 0.1) 
 Model 3 1.0 (ref) -0.1 (-0.6, 0.4) -0.4 (-0.9, 0.2) -0.4 (-1.0, 0.2) 
M
in
n
es
o
ta
 O
n
ly
 (
o
b
s)
 
 ALA FA% mean (min, max) 2.5 (1.8, 2.9) 3.2 (2.9, 3.5) 3.9 (3.5, 4.2) 5.3 (4.3, 10.2) 
 + DHA Total N 84 91 73 51 
 + EPA HbA1c Mean (Std) 7.7 (2.5) 7.8 (2.1) 7.0 (1.6) 7.1 (1.9) 
 Model 1 1.0 (ref) 0.1 (-0.5, 0.8) -0.7 (-1.3, 0.0) -0.6 (-1.3, 0.2) 
 Model 2 1.0 (ref) -0.1 (-0.8, 0.6) -0.8 (-1.5, -0.1) -0.7 (-1.4, 0.1) 
 Model 3 1.0 (ref) -0.2 (-0.8, 0.5) -0.7 (-1.4, 0.0) -0.6 (-1.3, 0.2) 
obs: observed; imp: imputed 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy 
intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and 
amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables 
(hypertension, HDL, LDL, triglycerides) 
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Table 5-10. Association of plasma quartiles of ALA with incident T2D, ARIC, 1987-1998.  Hazard Ratios 
and 95% confidence intervals. 
   Q1 Q2 Q3 Q4 
Fu
ll 
C
o
h
o
rt
 (
im
p
) 
ALA FA% mean (min, max) 0.1 (0.0, 0.1) 0.1 (0.1, 0.1) 0.2 (0.1, 0.2) 0.2 (0.2, 0.4) 
 Total N 2,199 2,120 2,189 2,130 
 Incident T2D (%) 243 (11.0%) 208 (9.8%) 165 (7.5%) 140 (6.6%) 
 Model 1 1.0 (ref) 0.9 (0.7, 1.2) 0.7 (0.5, 1.0) 0.6 (0.5, 0.9) 
 Model 2 1.0 (ref) 1.0 (0.7, 1.2) 0.8 (0.6, 1.0) 0.7 (0.5, 1.0) 
 Model 3 1.0 (ref) 1.0 (0.8, 1.3) 0.8 (0.6, 1.1) 0.8 (0.6, 1.1) 
M
in
n
es
o
ta
 O
n
ly
 (
o
b
s)
 
ALA FA% mean (min, max) 0.1 (0.0, 0.1) 0.1 (0.1, 0.1) 0.2 (0.2, 0.2) 0.2 (0.2, 0.4) 
 Total N 902 787 709 733 
 Incident T2D (%) 89 (9.9%) 74 (9.4%) 36 (5.0%) 41 (5.6%) 
 Model 1 1.0 (ref) 1.0 (0.7, 1.3) 0.6 (0.4, 0.8) 0.6 (0.4, 0.9) 
 Model 2 1.0 (ref) 1.2 (0.9, 1.6) 0.7 (0.4, 1.0) 0.7 (0.5, 1.1) 
 Model 3 1.0 (ref) 1.2 (0.9, 1.7) 0.7 (0.4, 1.0) 0.9 (0.6, 1.3) 
obs: observed; imp: imputed 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy 
intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and 
amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables 
(hypertension, HDL, LDL, triglycerides) 
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Table 5-11. Association of plasma quartiles of DHA+EPA with incident T2D, ARIC, 1987-1998.  Hazard 
Ratios and 95% confidence intervals. 
   Q1 Q2 Q3 Q4 
Fu
ll 
C
o
h
o
rt
 (
im
p
) 
 DHA FA% mean (min, max) 2.3 (0.3, 2.8) 3.1 (2.8, 3.4) 3.7 (3.4, 4.1) 4.9 (4.1, 14.0) 
 + EPA Total N 2,161 2,159 2,159 2,158 
 Incident T2D (%) 189 (8.7%) 187 (8.7%) 188 (8.7%) 191 (8.9%) 
 Model 1 1.0 (ref) 1.0 (0.8, 1.3) 1.0 (0.8, 1.4) 1.1 (0.8, 1.5) 
 Model 2 1.0 (ref) 1.0 (0.8, 1.4) 1.1 (0.8, 1.4) 1.2 (0.8, 1.6) 
 Model 3 1.0 (ref) 1.0 (0.8, 1.3) 1.0 (0.8, 1.4) 1.1 (0.8, 1.6) 
M
in
n
es
o
ta
 O
n
ly
 (
o
b
s)
 
 DHA FA% mean (min, max) 2.4 (0.7, 2.8) 3.1 (2.8, 3.4) 3.7 (3.4, 4.1) 5.0 (4.1, 12.2) 
 + EPA Total N 890 950 718 573 
 Incident T2D (%) 67 (7.5%) 74 (7.8%) 55 (7.7%) 44 (7.6%) 
 Model 1 1.0 (ref) 1.1 (0.8, 1.5) 1.1 (0.8, 1.6) 1.1 (0.7, 1.6) 
 Model 2 1.0 (ref) 1.0 (0.7, 1.4) 1.0 (0.7, 1.5) 1.2 (0.8, 1.8) 
 Model 3 1.0 (ref) 1.0 (0.7, 1.4) 0.9 (0.7, 1.4) 1.1 (0.7, 1.7) 
obs: observed; imp: imputed 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy 
intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and 
amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables 
(hypertension, HDL, LDL, triglycerides) 
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Table 5-12. Association of plasma quartiles of ALA+DHA+EPA with incident T2D, ARIC, 1987-1998.  
Hazard Ratios and 95% confidence intervals. 
   Q1 Q2 Q3 Q4 
Fu
ll 
C
o
h
o
rt
 (
im
p
) 
 ALA FA% mean (min, max) 2.4 (0.4, 2.9) 3.2 (2.9, 3.5) 3.9 (3.5, 4.2) 5.0 (4.2, 14.1) 
 + DHA Total N 2,161 2,160 2,159 2,158 
 + EPA Incident T2D (%) 186 (8.8%) 188 (8.7%) 188 (8.7%) 189 (8.7%) 
 Model 1 1.0 (ref) 1.0 (0.8, 1.3) 1.0 (0.8, 1.3) 1.1 (0.8, 1.4) 
 Model 2 1.0 (ref) 1.0 (0.8, 1.3) 1.1 (0.8, 1.4) 1.1 (0.8, 1.6) 
 Model 3 1.0 (ref) 1.0 (0.8, 1.3) 1.0 (0.8, 1.4) 1.1 (0.8, 1.6) 
M
in
n
es
o
ta
 O
n
ly
 (
o
b
s)
 
 ALA FA% mean (min, max) 2.5 (0.9, 2.9) 3.2 (2.9, 3.5) 3.8 (3.5, 4.2) 5.2 (4.3, 12.3) 
 + DHA Total N 892 945 725 569 
 + EPA Incident T2D (%) 67 (7.6%) 73 (7.7%) 56 (7.8%) 43 (7.3%) 
 Model 1 1.0 (ref) 1.1 (0.8, 1.5) 1.1 (0.8, 1.6) 1.1 (0.7, 1.6) 
 Model 2 1.0 (ref) 1.0 (0.7, 1.4) 1.0 (0.7, 1.5) 1.2 (0.8, 1.7) 
 Model 3 1.0 (ref) 0.9 (0.7, 1.3) 1.0 (0.7, 1.4) 1.1 (0.7, 1.7) 
obs: observed; imp: imputed 
Model 1 adjusted for age, sex, sociodemographic variables (race, center, education), and total energy 
intake. 
Model 2 further adjusted for lifestyle variables (BMI, physical activity, smoking status, drinking status and 
amount) 
Model 3 further adjusted for dietary variables (trans fats, saturated fat, dietary fiber) and clinical variables 
(hypertension, HDL, LDL, triglycerides) 
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6 CONCLUSION 
Currently, both the American Heart Association (AHA) and the American 
Diabetes Association (ADA) recommend at least two servings of oily fish a week to 
promote cardiovascular health [3, 4, 243]. However, results from observational studies 
have been mixed with respect to the associations of fish and omega-3 PUFAs with 
certain cardiovascular and glycemia outcomes.  Specifically, the mechanism through 
which fish intake affects risk of SCD has yet to be elucidated, and associations of omega-
3 PUFAs and fish with markers of glucose homeostasis have been mixed [73, 85-88, 174, 
244-247].  
The original research described in this dissertation examined the relationship 
among dietary intake of fish, fish-derived omega-3 PUFAs DHA and EPA, and the 
vegetable-derived omega-3 PUFA ALA with ECG predictors of SCD and measures of 
glycemia in a population-based cohort of middle aged adults. 
Data from the first manuscript suggest that dietary intake of fish and omega-3 
PUFAs may adversely affect glycemic control among those with diabetes.  Furthermore, 
results suggested the deleterious associations were differential across race and sex.   
Results from the second manuscript did not provide compelling evidence of a 
relationship between intake of fish or fish-derived omega-3 PUFAs (DHA+EPA) with J-
point height or QT interval duration.  We did find higher intakes of ALA were associated 
with shorter QT interval duration, but this finding should be interpreted with caution 
given the large number of models investigated in that study. 
The results from the first two manuscripts were derived using exposure data 
collected via FFQ.  Because data collected using FFQs are subject to measurement error 
[201-203], whereas biomarker values offer an objective measure of nutrient absorption 
(bioavailability) that can be a proxy for usual intake [169], we reanalyzed our data for 
select outcomes using plasma phospholipid values of DHA, EPA, and ALA obtained at 
visit 1 from MN field center participants.  Associations among plasma omega-3 PUFAs 
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and prolonged QTc, HbA1c, and incident T2D in MN participants were null.  Imputing 
biomarker values for white participants at other field centers using MICE increased our 
precision, but did not change the magnitude of association for these outcomes. 
Taken together, the results presented in this dissertation suggest that neither 
fish nor the fish-derived omega-3 PUFAs DHA+EPA reduces SCD risk through changes in 
J-point height or QT interval duration; higher intake of ALA may be associated with more 
favorable (shorter) QT interval durations.  Data do suggest that intake of fish and of the 
omega-3 PUFAs DHA, EPA, and ALA may adversely affect glycemic control in those with 
diabetes, especially in black participants and female participants.   
To place these results into a context, a recent position statement by the AHA 
considered the evidence for the role of fish-derived omega-3 fatty acids supplements in 
primary/secondary prevention of CVD in various populations [74].  Supplementation 
was recommended for secondary prevention of CHD and SCD among those with 
prevalent CHD [74].  With respect to CVD mortality prevention in those with diabetes or 
pre-diabetes, the evidence indicated no benefit and the position was that treatment 
was not indicated [74]. While this suggests a tentative consensus that high doses of 
omega-3 PUFAs (as supplements) are beneficial for prevention of SCD, the benefits of 
supplementation in diabetes is attenuated by detrimental effects on glucose control. 
It should be noted that these recommendations are for supplements, and that 
dietary intake of foods rich in omega-3 PUFAs may confer benefits beyond their 
nutrients, like displacing foods higher in saturated and trans fatty acids [3].  Regardless, 
the AHA and ADA continue to recommend at least two servings of oily fish per week. 
The data and overall study design utilized in this dissertation have many 
strengths.  The ARIC study is a population-based prospective study with multiple visits 
over several years.  Participants were varied in their medical history and outcomes, and 
retention was high during follow-up.  Data were available for several clinical covariates, 
and these data were refreshed over time.  Dietary data were collected more than once, 
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and the FFQ was modified from its original version to add more questions about seafood 
intake.  Additionally, biomarker values for circulating concentrations of omega-3 fatty 
acids were available for a subpopulation. 
However, the analyses presented in this dissertation are not without limitations.  
Data were not available on food preparation technique, which can influence the 
nutritional composition of the foods consumed.  Additionally, the FFQ was worded such 
that baked fish sticks, deep fried fish sticks, and poached cod are all equivalent.  As such, 
there may be significant misclassification bias of dietary intake, even if FFQ questions 
were answered without error.  We attempted to address this limitation by utilizing 
plasma fatty acid measures in Manuscript 3, but bioavailability and absorption of 
nutrients into circulating concentrations of biomarkers is not a perfect proxy for dietary 
intake of whole foods, and it is influenced by many factors – not all of them measurable.   
A commentary published in 2015 by Subar et al. sought to address the criticism 
of nutritional epidemiology studies that rely on self-reported dietary data [248].  There 
were seven recommendations, and the first was to continue to collect self-reported 
dietary data as they are an invaluable resource.  The authors also implored researchers 
to acknowledge the limitations of self-reported dietary data when presenting and 
interpreting results derived from them, and offered techniques for addressing 
measurement error.  It is this last point that resonates the most.  Dietary data are 
difficult to measure in a free-living population.  Methods that do not place a high 
burden on participants are key in recruiting and maintain a diverse set of individuals 
willing to participate in long-term cohort studies.  FFQs augmented with 24-hour recalls, 
3-day food records, and other gold standard self-report instruments can help mitigate 
measurement error, especially when combined with sophisticated statistical methods 
like multiple imputation.  Equal weight should be given to studies utilizing biomarkers 
and other objective measures of dietary intake, so that we can triangulate exposure 
status and address the criticism levied against nutritional epidemiological studies. 
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Additional research incorporating the suggestions made by Subar et al. may help 
elucidate the relationship of dietary intake of fish with markers of glucose homeostasis, 
and determine if revisions should be made in dietary guidelines recommending regular 
consumption of oily fish by those with diabetes. 
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